Gene	Variant	Disease	Drug	EvidenceLevel	Effect	PubMedID	Source
KDR	p.A1065T	Angiosarcoma	Sorafenib,Sunitinib	D	Sensitivity/Response	19723655	CiViC
KRAS	p.A146P	Colorectal Cancer	Cetuximab	B	Resistance	19603018	CiViC
KRAS	p.A146T	Colorectal Cancer	Dactolisib,Selumetinib	D	Sensitivity/Response	22392911	CiViC
KRAS	p.A146T	Colorectal Cancer	Cetuximab	D	Resistance	20570890	CiViC
KRAS	p.A146T	Colorectal Cancer	FOLFOX-4 Regimen,Cetuximab	B	Resistance	25666295	CiViC
KRAS	p.A146V	Lung Non-small Cell Carcinoma	Abemaciclib	C	Sensitivity/Response	24836576	CiViC
KRAS	p.A146V	Colorectal Cancer	Selumetinib,Dactolisib	D	Sensitivity/Response	22392911	CiViC
PRPS1	p.A190T	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	25962120	CiViC
PRPS1	p.A190T	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Lometrexol	D	Sensitivity/Response	25962120	CiViC
MTOR	p.A2034V	Breast Cancer	Sirolimus	D	Resistance	27279227	CiViC
ATM	p.A2062V	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
PML	p.A216V	Acute Promyelocytic Leukemia	Tretinoin	C	Resistance	21613260	CiViC
PML	p.A216V	Acute Promyelocytic Leukemia	Arsenic Trioxide	B	Resistance	26537301	CiViC
MTHFR	p.A222V	Stomach Cancer	Fluorouracil	B	Sensitivity/Response	18704422	CiViC
MTHFR	p.A222V	Rectum Cancer	Fluorouracil	B	Sensitivity/Response	26693073	CiViC
EGFR	p.A289V	Malignant Glioma	Erlotinib	D	Sensitivity/Response	17177598	CiViC
ABL1	p.A397P	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
KIT	p.A502_Y503insAY	Gastrointestinal Stromal Tumor	Sunitinib	D	Sensitivity/Response	25239608	CiViC
EGFR	p.A763_Y764insFQEA	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	24353160	CiViC
EGFR	p.A767_V769dupASV	Lung Adenocarcinoma	Erlotinib	C	Resistance	24353160	CiViC
KIT	p.A829P	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	D	Resistance	25239608	CiViC
EGFR	p.A864T	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	19147750	CiViC
TP53	ALTERATION	Ovarian Cancer	Cisplatin,Carboplatin	B	Resistance	11595686	CiViC
BRAF	AMPLIFICATION	Colorectal Cancer	Selumetinib	E	Resistance	21098728	CiViC
ALK	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	22277784	CiViC
AURKA	AMPLIFICATION	Esophagus Adenocarcinoma	Cisplatin,Alisertib	E	Sensitivity/Response	22302096	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Sensitivity/Response	11248153	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Sensitivity/Response	15911866	CiViC
BIRC7	AMPLIFICATION	Colon Cancer	Cisplatin	D	Resistance	23188704	CiViC
FGFR1	AMPLIFICATION	Lung Squamous Cell Carcinoma	PD173074	D	Sensitivity/Response	21160078	CiViC
FGFR1	AMPLIFICATION	Lung Non-small Cell Carcinoma	PD173074	D	Sensitivity/Response	21666749	CiViC
MET	AMPLIFICATION	Gastric Adenocarcinoma	Onartuzumab	C	Sensitivity/Response	22389872	CiViC
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Gefitinib	D	Resistance	17463250	CiViC
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	21623265	CiViC
MYCN	AMPLIFICATION	Neuroblastoma	FACT Complex-targeting Curaxin CBL0137	D	Sensitivity/Response	26537256	CiViC
PIK3CA	AMPLIFICATION	Epithelial Ovarian Cancer	Pictilisib	C	Sensitivity/Response	25370471	CiViC
ERBB2	AMPLIFICATION	Breast Cancer	AKTi-1/2	D	Sensitivity/Response	18725974	CiViC
ERBB2	AMPLIFICATION	Breast Cancer	Neratinib	B	Sensitivity/Response	20142587	CiViC
ALK	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	22235099	CiViC
ALK	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	23344087	CiViC
MAPK1	AMPLIFICATION	Lung Non-small Cell Carcinoma	WZ4002	D	Resistance	22961667	CiViC
NOTCH1	AMPLIFICATION	Colorectal Cancer	NOTCH1 Antibody (PF-06293622)	D	Sensitivity/Response	26152787	CiViC
MET	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	26724472	CiViC
EGFR	AMPLIFICATION	Colorectal Cancer	Panitumumab,Cetuximab	B	Sensitivity/Response	24653627	CiViC
RSF1	AMPLIFICATION	Breast Cancer	Tamoxifen	B	Resistance	24367492	CiViC
ERBB2	AMPLIFICATION	Uterine Corpus Endometrial Carcinoma	Afatinib	D	Sensitivity/Response	25268372	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Lapatinib,Trastuzumab	B	Sensitivity/Response	25537159	CiViC
TOP1	AMPLIFICATION	Colorectal Cancer	Irinotecan	B	Sensitivity/Response	24256029	CiViC
MET	AMPLIFICATION	Lung Squamous Cell Carcinoma	Crizotinib	C	Sensitivity/Response	24192513	CiViC
TYMS	AMPLIFICATION	Lung Adenocarcinoma	Pemetrexed	B	Resistance	23645741	CiViC
EGFR	AMPLIFICATION	Colorectal Cancer	Cetuximab	B	Sensitivity/Response	18794099	CiViC
EGFR	AMPLIFICATION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	B	Sensitivity/Response	20826716	CiViC
ABCC3	AMPLIFICATION	Breast Cancer	Monomethyl Auristatin E,Paclitaxel	D	Resistance	18593940	CiViC
ASNS	AMPLIFICATION	Ovarian Cancer	Asparaginase	D	Resistance	17088436	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib	B	Sensitivity/Response	22418700	CiViC
ERBB2	AMPLIFICATION	Pancreatic Adenocarcinoma	Afatinib	D	Sensitivity/Response	26668065	CiViC
ERBB2	AMPLIFICATION	Breast Cancer	Trastuzumab,Lapatinib	D	Sensitivity/Response	16091755	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	B	Sensitivity/Response	22493419	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	B	Sensitivity/Response	20124187	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib	B	Sensitivity/Response	22418700	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib	B	Sensitivity/Response	26596672	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Trastuzumab	B	Sensitivity/Response	25370464	CiViC
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab	B	Sensitivity/Response	20728210	CiViC
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Lapatinib	B	Sensitivity/Response	24868024	CiViC
ERBB2	AMPLIFICATION	Lung Small Cell Carcinoma	Irinotecan,Trastuzumab	C	Sensitivity/Response	25601188	CiViC
ERBB2	AMPLIFICATION	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine	D	Sensitivity/Response	24898067	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pertuzumab,Trastuzumab,Docetaxel	B	Sensitivity/Response	25693012	CiViC
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	26729443	CiViC
ERBB2	AMPLIFICATION	Endometrial Serous Adenocarcinoma	Trastuzumab	C	Sensitivity/Response	18555254	CiViC
FGFR1	AMPLIFICATION	Breast Cancer	Afimoxifene	D	Resistance	20179196	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Neratinib,Trastuzumab	A	Sensitivity/Response	26874901	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	A	Sensitivity/Response	16236737	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Capecitabine,Lapatinib	B	Sensitivity/Response	17192538	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Capecitabine	B	Sensitivity/Response	19289619	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	24793816	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	23020162	CiViC
FGFR1	AMPLIFICATION	Ewing Sarcoma Of Bone	Ponatinib	D	Sensitivity/Response	26179511	CiViC
CDK4	AMPLIFICATION	Liposarcoma	Palbociclib	B	Sensitivity/Response	23569312	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pictilisib	D	Sensitivity/Response	22802530	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	A66	D	Sensitivity/Response	22802530	CiViC
MET	AMPLIFICATION	Lung Adenocarcinoma	Gefitinib,Erlotinib	C	Resistance	23470965	CiViC
ERBB2	AMPLIFICATION	Lung Adenocarcinoma	Erlotinib,Gefitinib	C	Resistance	23470965	CiViC
PIK3CA	AMPLIFICATION	Stomach Carcinoma	Alpelisib	D	Sensitivity/Response	24608574	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	23382472	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pertuzumab,Docetaxel,Trastuzumab	B	Sensitivity/Response	22149875	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	B	Sensitivity/Response	22257673	CiViC
RICTOR	AMPLIFICATION	Lung Adenocarcinoma	Sapanisertib,MTOR Kinase Inhibitor CC-223	C	Sensitivity/Response	26370156	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pilaralisib,Trastuzumab	D	Sensitivity/Response	23204226	CiViC
PIK3CA	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	Taselisib	D	Sensitivity/Response	26589432	CiViC
KIT	AMPLIFICATION	Mucosal Melanoma	Imatinib	B	Resistance	23775962	CiViC
CCND1	AMPLIFICATION	Skin Melanoma	Carboplatin,Paclitaxel,Sorafenib	B	Sensitivity/Response	26307133	CiViC
RAF1	AMPLIFICATION	Skin Melanoma	Carboplatin,Paclitaxel,Sorafenib	B	Sensitivity/Response	26307133	CiViC
KRAS	AMPLIFICATION	Skin Melanoma	Carboplatin,Docetaxel,Sorafenib	B	Sensitivity/Response	26307133	CiViC
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab	A	Sensitivity/Response	20728210	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Palbociclib,Trastuzumab	D	Sensitivity/Response	19874578	CiViC
CCND1	AMPLIFICATION	Breast Cancer	Palbociclib	D	Sensitivity/Response	19874578	CiViC
MET	AMPLIFICATION	Glioblastoma Multiforme	Crizotinib	C	Sensitivity/Response	22162573	CiViC
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	D	Sensitivity/Response	21716144	CiViC
MET	AMPLIFICATION	Colorectal Cancer	Crizotinib,Vemurafenib	C	Sensitivity/Response	27325282	CiViC
FGFR1	AMPLIFICATION	Breast Cancer	Dovitinib	B	Sensitivity/Response	23658459	CiViC
FGFR2	AMPLIFICATION	Breast Cancer	Dovitinib	B	Sensitivity/Response	23658459	CiViC
FGF3	AMPLIFICATION	Breast Cancer	Dovitinib	B	Sensitivity/Response	23658459	CiViC
ERBB2	AMPLIFICATION	Breast Cancer	MTOR Kinase Inhibitor PP242	D	Sensitivity/Response	21358673	CiViC
AKT2	AMPLIFICATION	Lung Adenocarcinoma	Everolimus,Vandetanib	C	Sensitivity/Response	25982012	CiViC
CCNE1	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Palbociclib	D	Resistance	27020857	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab	B	Resistance	22586653	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab	B	Resistance	22586653	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Panitumumab,Cetuximab	B	Resistance	23348520	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Trastuzumab,Lapatinib	B	Sensitivity/Response	27108243	CiViC
MET	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	25922291	CiViC
ERBB2	AMPLIFICATION	Scrotum Paget's Disease	Trastuzumab	C	Sensitivity/Response	25692060	CiViC
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	27664533	CiViC
MET	AMPLIFICATION	Cancer	Crizotinib	C	Sensitivity/Response	25232318	CiViC
CCNE1	AMPLIFICATION	Ovarian Serous Cystadenocarcinoma	Dinaciclib,Akt Inhibitor MK2206	D	Sensitivity/Response	27663592	CiViC
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	21172893	CiViC
FGFR1	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Ponatinib	D	Sensitivity/Response	22238366	CiViC
PDGFRA	AMPLIFICATION	Lung Non-small Cell Carcinoma	Sunitinib	D	Sensitivity/Response	19366796	CiViC
FGFR1	AMPLIFICATION	Lung Squamous Cell Carcinoma	Infigratinib	B	Sensitivity/Response	27870574	CiViC
MET	AMPLIFICATION	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	D	Resistance	23729478	CiViC
MET	AMPLIFICATION	Colorectal Cancer	Cetuximab,Crizotinib	D	Sensitivity/Response	23729478	CiViC
FGFR2	AMPLIFICATION	Stomach Carcinoma	FGFR Inhibitor AZD4547	B	Sensitivity/Response	27179038	CiViC
FGFR1	AMPLIFICATION	Breast Cancer	FGFR Inhibitor AZD4547	C	Sensitivity/Response	27179038	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab	B	Resistance	28223103	CiViC
BRAF	AMPLIFICATION	Colorectal Cancer	Panitumumab,Dabrafenib	C	Resistance	25673644	CiViC
NTRK1	AMPLIFICATION	Cancer	Entrectinib	B	Resistance	28183697	CiViC
NTRK3	AMPLIFICATION	Cancer	Entrectinib	B	Resistance	28183697	CiViC
EGFR	AMPLIFICATION	Lung Non-small Cell Carcinoma	Osimertinib,Rociletinib	D	Resistance	28202511	CiViC
FGFR1	AMPLIFICATION	Lung Non-small Cell Carcinoma	Dovitinib	B	Sensitivity/Response	27315356	CiViC
CDK4	AMPLIFICATION	Liposarcoma	Palbociclib	B	Sensitivity/Response	27124835	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Trastuzumab,Pertuzumab	B	Sensitivity/Response	29320312	CiViC
ERBB2	AMPLIFICATION	Bladder Carcinoma	Trastuzumab,Pertuzumab	B	Sensitivity/Response	29320312	CiViC
ERBB2	AMPLIFICATION	Biliary Tract Cancer	Trastuzumab,Pertuzumab	B	Sensitivity/Response	29320312	CiViC
ERBB2	AMPLIFICATION	Salivary Gland Carcinoma	Trastuzumab,Pertuzumab	B	Sensitivity/Response	29320312	CiViC
ERBB2	AMPLIFICATION	Pancreatic Cancer	Trastuzumab,Pertuzumab	B	Sensitivity/Response	29320312	CiViC
TLK2	AMPLIFICATION	Breast Cancer	Go6983,GF109203X	D	Sensitivity/Response	27694828	CiViC
BRAF	AMPLIFICATION	Melanoma	Dabrafenib,Vemurafenib	B	Resistance	24265155	CiViC
PIK3CA	AMPLIFICATION	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
KRAS	AMPLIFICATION	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
FGFR1	AMPLIFICATION	Breast Cancer	Pazopanib	C	Sensitivity/Response	29223982	CiViC
ERBB2	AMPLIFICATION	Colorectal Cancer	Pertuzumab,Trastuzumab	B	Sensitivity/Response	30857956	CiViC
ERBB2	AMPLIFICATION	Cholangiocarcinoma	Trastuzumab,Pertuzumab	C	Sensitivity/Response	31453370	CiViC
ERBB2	AMPLIFICATION	Stomach Cancer	Trastuzumab Deruxtecan	B	Sensitivity/Response	31047804	CiViC
BRAF	AMPLIFICATION	Melanoma	Trametinib,Dabrafenib	B	Resistance	25452114	CiViC
FGFR1	AMPLIFICATION	Adenosquamous Cell Lung Carcinoma	Pazopanib	C	Sensitivity/Response	24302556	CiViC
ALK	p.C1156Y	Lung Non-small Cell Carcinoma	Ceritinib,Luminespib,Crizotinib	C	Resistance	26698910	CiViC
ALK	p.C1156Y	Lung Non-small Cell Carcinoma	Lorlatinib	C	Sensitivity/Response	26698910	CiViC
ALK	p.C1156Y	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	24675041	CiViC
ALK	p.C1156Y-L1198F	Lung Non-small Cell Carcinoma	Lorlatinib	C	Resistance	26698910	CiViC
ALK	p.C1156Y-L1198F	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	26698910	CiViC
MAP2K1	p.C121S	Melanoma	Vemurafenib	C	Resistance	21383288	CiViC
MTOR	p.C1483Y	T-cell Acute Lymphoblastic Leukemia	Sirolimus	D	Sensitivity/Response	24631838	CiViC
ATM	p.C2488Y	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
POLD1	p.C284Y	Lung Adenocarcinoma	Pembrolizumab	C	Sensitivity/Response	25765070	CiViC
ABL1	p.C475V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
BTK	p.C481S	Chronic Lymphocytic Leukemia	Ibrutinib	B	Resistance	24869598	CiViC
BTK	p.C481S	Chronic Lymphocytic Leukemia	Ibrutinib	B	Resistance	26182309	CiViC
BRCA1	p.C61G	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
RET	p.C634W	Thyroid Gland Medullary Carcinoma	Motesanib	D	Resistance	21422803	CiViC
BRCA1	p.C64Y	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
EGFR	p.C797S	Lung Non-small Cell Carcinoma	Osimertinib	B	Resistance	25939061	CiViC
EGFR	p.C797S	Lung Adenocarcinoma	Osimertinib	C	Resistance	26181354	CiViC
EGFR	p.C797Y	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
KIT	p.C809G	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
ALK	p.CAD-ALK	Colorectal Cancer	Entrectinib	C	Sensitivity/Response	26633560	CiViC
RET	p.CCDC6-RET	Lung Non-small Cell Carcinoma	Nintedanib	C	Sensitivity/Response	26787234	CiViC
RET	p.CCDC6-RET	Colorectal Cancer	Agerafenib	C	Sensitivity/Response	29538669	CiViC
ALK	p.CLTC-ALK	Diffuse Large B-cell Lymphoma	TAE684	D	Sensitivity/Response	21494621	CiViC
ALK	p.CLTC-ALK	Diffuse Large B-cell Lymphoma	Crizotinib	C	Sensitivity/Response	26221234	CiViC
PDGFB	p.COL1A1-PDGFB	Dermatofibrosarcoma Protuberans	Sunitinib	C	Sensitivity/Response	29760553	CiViC
CTLA4	p.CTLA4-CD28	Sezary's Disease	Ipilimumab	C	Sensitivity/Response	25802883	CiViC
BRAF	p.CUX1-BRAF	Pancreatic Cancer	Vemurafenib	C	Sensitivity/Response	29320312	CiViC
MET	p.D1228N	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	27343442	CiViC
MET	p.D1228V	Lung Non-small Cell Carcinoma	Cabozantinib	C	Sensitivity/Response	27694386	CiViC
MET	p.D1228V	Lung Non-small Cell Carcinoma	Savolitinib	C	Resistance	27694386	CiViC
ATM	p.D1682H	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
BRCA1	p.D1692N	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
PRPS1	p.D183E	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	25962120	CiViC
ATM	p.D1930V	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
STK11	p.D194E	Pancreatic Cancer	Everolimus	C	Sensitivity/Response	21189378	CiViC
ABL1	p.D276G	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.D276G	Chronic Myeloid Leukemia	Nilotinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.D276G	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.D276G	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
PIK3CA	p.D350G	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
ABL1	p.D363G	Chronic Myeloid Leukemia	Imatinib	C	Resistance	16775234	CiViC
NT5C2	p.D407A	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	23377281	CiViC
SMO	p.D473H	Brain Medulloblastoma	Vismodegib	C	Resistance	19726788	CiViC
SMO	p.D473H	Basal Cell Carcinoma	Vismodegib	D	Resistance	25759020	CiViC
SMO	p.D473H	Brain Medulloblastoma	Patidegib	D	Sensitivity/Response	22550175	CiViC
ESR1	p.D538G	Breast Cancer	Hormone Therapy	D	Resistance	24185512	CiViC
ESR1	p.D538G	Breast Cancer	Fulvestrant,Tamoxifen	D	Sensitivity/Response	24185510	CiViC
KIT	p.D579DEL	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	14645423	CiViC
KIT	p.D579DEL	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
BRAF	p.D594A	Skin Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib	E	Sensitivity/Response	20141835	CiViC
BRAF	p.D594G	Colorectal Cancer	Irinotecan,Cetuximab	C	Resistance	26989027	CiViC
BRAF	p.D594G	Skin Melanoma	Sorafenib	D	Sensitivity/Response	18794803	CiViC
BRAF	p.D594G	Skin Melanoma	U0126	D	Resistance	18794803	CiViC
BRAF	p.D594G	Cancer	Trametinib	D	Sensitivity/Response	28783719	CiViC
BRAF	p.D594K	Colorectal Cancer	Irinotecan	B	Resistance	19603024	CiViC
BRAF	p.D594K	Colorectal Cancer	Oxaliplatin	B	Resistance	19603024	CiViC
BRAF	p.D594V	Skin Melanoma	Trametinib,Sorafenib	E	Sensitivity/Response	20141835	CiViC
KDR	p.D717V	Angiosarcoma	Sunitinib,Sorafenib	D	Sensitivity/Response	19723655	CiViC
EGFR	p.D761Y	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	C	Resistance	17085664	CiViC
ERBB2	p.D769H	Breast Cancer	Neratinib,Lapatinib	D	Sensitivity/Response	23220880	CiViC
ERBB2	p.D769Y	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
EGFR	p.D770_N771insGL	Lung Adenocarcinoma	Erlotinib	C	Resistance	24353160	CiViC
EGFR	p.D770_N771insGT	Lung Adenocarcinoma	Erlotinib	C	Resistance	23371856	CiViC
EGFR	p.D770_N771insGY	Lung Adenocarcinoma	Erlotinib	C	Resistance	24353160	CiViC
EGFR	p.D770_N771insSVD	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	24353160	CiViC
KIT	p.D816E	Gastrointestinal Stromal Tumor	Sunitinib,Imatinib	D	Resistance	25239608	CiViC
KIT	p.D816H	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
KIT	p.D816V	Systemic Mastocytosis	Midostaurin	B	Sensitivity/Response	27355533	CiViC
KIT	p.D816V	Cancer	Imatinib	D	Resistance	14645423	CiViC
KIT	p.D816V	Cancer	Dasatinib,Imatinib	C	Resistance	25317746	CiViC
KIT	p.D820A	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
KIT	p.D820G	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
KIT	p.D820Y	Melanoma	Imatinib	C	Resistance	21642685	CiViC
KIT	p.D820Y	Melanoma	Sunitinib	D		19035443	CiViC
KIT	p.D820Y	Gastrointestinal Stromal Tumor	Regorafenib	C	Sensitivity/Response	22614970	CiViC
FLT3	p.D835	Acute Myeloid Leukemia	Ponatinib,Quizartinib	D	Resistance	23430109	CiViC
FLT3	p.D835	Acute Myeloid Leukemia	SU5614	D	Resistance	19318574	CiViC
FLT3	p.D835	Acute Myeloid Leukemia	Quizartinib,Sorafenib	B	Resistance	22504184	CiViC
FLT3	p.D835	Acute Myeloid Leukemia	Sorafenib	B	Resistance	22368270	CiViC
FLT3	p.D835H	Acute Myeloid Leukemia	Sorafenib	C	Resistance	23969938	CiViC
FLT3	p.D835H/Y	Acute Myeloid Leukemia	Sorafenib	D	Resistance	23969938	CiViC
FLT3	p.D835V	Acute Myeloid Leukemia	Tandutinib	D	Resistance	15256420	CiViC
FLT3	p.D835V	Acute Myeloid Leukemia	Sunitinib,Cytarabine	D	Sensitivity/Response	15304385	CiViC
FLT3	p.D835V	Acute Myeloid Leukemia	Sunitinib,Daunorubicin	D	Sensitivity/Response	15304385	CiViC
FLT3	p.D835V	Acute Myeloid Leukemia	AS602868,Tyrphostin AG 1296	D	Sensitivity/Response	17330097	CiViC
FLT3	p.D835V	Acute Myeloid Leukemia	Sunitinib	C	Sensitivity/Response	15459012	CiViC
FLT3	p.D835Y	Acute Myeloid Leukemia	Gilteritinib	D	Sensitivity/Response	27908881	CiViC
PDGFRA	p.D842_I843delinsVM	Gastrointestinal Stromal Tumor	Crenolanib	D	Sensitivity/Response	22745105	CiViC
PDGFRA	p.D842I	Gastrointestinal Stromal Tumor	Crenolanib	D	Sensitivity/Response	22745105	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Imatinib	B	Resistance	15928335	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Imatinib	B	Resistance	16954519	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Crenolanib	D	Sensitivity/Response	22745105	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Imatinib	D	Resistance	12949711	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Imatinib	B	Resistance	26130666	CiViC
PDGFRA	p.D842V	Cancer	Imatinib	D	Resistance	14645423	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	14645423	CiViC
PDGFRA	p.D842V	Cancer	Sunitinib	D	Resistance	18955458	CiViC
PDGFRA	p.D842V	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
PDGFRA	p.D842V	Cancer	Imatinib Mesylate	D	Resistance	18955458	CiViC
PDGFRA	p.D842Y	Gastrointestinal Stromal Tumor	Crenolanib	D	Sensitivity/Response	22745105	CiViC
ALK	DEL4-11	Neuroblastoma	Brigatinib	D	Sensitivity/Response	27049722	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Gefitinib	D	Sensitivity/Response	16730237	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	B	Sensitivity/Response	16818686	CiViC
GSTP1	DELETION	Ovarian Carcinoma	Cisplatin,Carboplatin,Paclitaxel	D	Sensitivity/Response	25010864	CiViC
EGFR	DELETION	Epithelial Ovarian Cancer	Cisplatin	D	Resistance	23764753	CiViC
LRP1B	DELETION	Ovarian Cancer	Doxorubicin	D	Resistance	22896685	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	23816960	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	25862853	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	22452895	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Erlotinib	B	Sensitivity/Response	22285168	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	26515464	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	24439929	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	25589191	CiViC
HSPH1	DELETION	Colorectal Cancer	Oxaliplatin,Fluorouracil	B	Sensitivity/Response	24512910	CiViC
PTEN	DELETION	Prostate Cancer	Everolimus	B	Sensitivity/Response	23582881	CiViC
SMAD4	DELETION	Colorectal Cancer	Fluorouracil	B	Resistance	12237773	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	18509184	CiViC
SMARCB1	DELETION	Rhabdoid Cancer	Tazemetostat	D	Sensitivity/Response	23620515	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Gefitinib	B	Sensitivity/Response	22370314	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Erlotinib	A	Sensitivity/Response	24868098	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Afatinib	A	Sensitivity/Response	23982599	CiViC
EGFR	DELETION	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	27566387	CiViC
EGFR	DELETION	Lung Non-small Cell Carcinoma	Dacomitinib,Erlotinib	B	Sensitivity/Response	26768165	CiViC
DPYD	DELETION	Head And Neck Squamous Cell Carcinoma	Leucovorin,Fluorouracil	C	Sensitivity/Response	31871216	CiViC
KIT	DUPLICATION	Malignant Anus Melanoma	Imatinib	C	Sensitivity/Response	18421059	CiViC
BRCA1	p.E1559K	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
MTOR	p.E1799K	Clear Cell Renal Cell Carcinoma	Sirolimus	D	Sensitivity/Response	24631838	CiViC
AKT1	p.E17K	Melanoma	Uprosertib	D	Sensitivity/Response	24735930	CiViC
AKT1	p.E17K	Breast Cancer	Capivasertib	C	Sensitivity/Response	26351323	CiViC
AKT1	p.E17K	Cancer	Capivasertib	B	Sensitivity/Response	28489509	CiViC
AKT1	p.E17K	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
AKT3	p.E17K	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
ALK	p.E2;A20	Lung Non-small Cell Carcinoma	Crizotinib	E	Sensitivity/Response	18927303	CiViC
ALK	p.E20;A20	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	20979469	CiViC
ALK	p.E20;A20	Lung Non-small Cell Carcinoma	Crizotinib	D	Sensitivity/Response	22912387	CiViC
ALK	p.E20;A20	Lung Non-small Cell Carcinoma	Alvespimycin,Crizotinib	D	Sensitivity/Response	22912387	CiViC
ALK	p.E20;A20	Cancer	Crizotinib	C	Sensitivity/Response	25408655	CiViC
ATM	p.E2187*	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
MTOR	p.E2419K	Urothelial Carcinoma	Pazopanib,Everolimus	C	Sensitivity/Response	24625776	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib	D	Resistance	15194504	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib	D	Resistance	15930265	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	19075254	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	22371878	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Dasatinib	C	Reduced Sensitivity	17264298	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.E255K	Acute Lymphoblastic Leukemia	Dasatinib	C	Resistance	16775234	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	D	Resistance	15705718	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	C	Resistance	19652056	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	19075254	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Bosutinib	C	Reduced Sensitivity	22371878	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	C	Resistance	19652056	CiViC
ABL1	p.E255V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.E279K	Chronic Myeloid Leukemia	Axitinib	D	Sensitivity/Response	25686603	CiViC
ABL1	p.E292V	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	16772610	CiViC
MAPK1	p.E322K	Head And Neck Squamous Cell Carcinoma	Erlotinib	C	Sensitivity/Response	26181029	CiViC
ABL1	p.E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
POLD1	p.E374K	Lung Non-small Cell Carcinoma	Pembrolizumab	C	Sensitivity/Response	25765070	CiViC
ERRFI1	p.E384*	Cholangiocarcinoma	Erlotinib	C	Sensitivity/Response	24550739	CiViC
ABL1	p.E453A	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.E459K	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
PIK3CA	p.E542K	Colorectal Cancer	Panitumumab,Cetuximab	B	Resistance	19223544	CiViC
PIK3CA	p.E542K	Breast Cancer	PI3K-alpha Inhibitor MEN1611	D	Sensitivity/Response	21558396	CiViC
PIK3CA	p.E542K	Breast Cancer	Sirolimus	D	Sensitivity/Response	15647370	CiViC
PIK3CA	p.E542K	Head And Neck Squamous Cell Carcinoma	Apitolisib	C	Sensitivity/Response	26787751	CiViC
PIK3CA	p.E542K	Thyroid Cancer	Perifosine,Temsirolimus	D	Sensitivity/Response	19706758	CiViC
PIK3CA	p.E542K	Breast Cancer	Fulvestrant,Alpelisib	A	Sensitivity/Response	31091374	CiViC
PIK3CA	p.E545G	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
PIK3CA	p.E545K	Colorectal Cancer	Panitumumab,Cetuximab	C	Resistance	19223544	CiViC
PIK3CA	p.E545K	Breast Cancer	Pictilisib,Akt Inhibitor MK2206	D	Sensitivity/Response	23888070	CiViC
PIK3CA	p.E545K	Lung Adenocarcinoma	Gefitinib	D	Resistance	16906227	CiViC
PIK3CA	p.E545K	Her2-receptor Positive Breast Cancer	Trastuzumab	D	Resistance	18829560	CiViC
PIK3CA	p.E545K	Cancer	Apitolisib	C	Sensitivity/Response	26787751	CiViC
PIK3CA	p.E545K	Lung Adenocarcinoma	Afatinib,Erlotinib,Gefitinib	B	Resistance	27304188	CiViC
PIK3CA	p.E545K	Breast Cancer	Pictilisib Bismesylate	D	Sensitivity/Response	20453058	CiViC
PIK3CA	p.E545K	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	26920887	CiViC
PIK3CA	p.E545K	Lung Non-small Cell Carcinoma	PI103	D	Sensitivity/Response	19513541	CiViC
PIK3CA	p.E545K	Cervix Carcinoma	Pictilisib	D	Sensitivity/Response	27489350	CiViC
PIK3CA	p.E545K	Cervix Carcinoma	Cisplatin	D	Resistance	27489350	CiViC
PIK3CA	p.E545K	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
ALK	p.E6;A20	Lung Non-small Cell Carcinoma	2,4-pyrimidinediamine	D	Sensitivity/Response	18593892	CiViC
ALK	p.E6;A20	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	20979469	CiViC
ALK	p.E6;A20	Lung Non-small Cell Carcinoma	TAE684	D	Sensitivity/Response	18451166	CiViC
ALK	p.E6;A20	Lung Non-small Cell Carcinoma	Ceritinib	D	Sensitivity/Response	24675041	CiViC
EGFR	p.E734Q	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
EGFR	p.E746_A750del	Bronchiolo-alveolar Adenocarcinoma	Erlotinib	C	Sensitivity/Response	15329413	CiViC
EGFR	p.E746_A750del	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	15329413	CiViC
EGFR	p.E746_T751>I	Lung Adenocarcinoma	Gefitinib	C	Sensitivity/Response	15329413	CiViC
EGFR	p.E746G	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	26773740	CiViC
EGFR	p.E868G	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
ABL1	p.E98G	Chronic Myeloid Leukemia	Imatinib	C	Resistance	16775234	CiViC
ATM	p.F1025L	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
ALK	p.F1174L	Inflammatory Myofibroblastic Tumor	Crizotinib	D	Resistance	21030459	CiViC
ALK	p.F1174L	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	21030459	CiViC
ALK	p.F1174L	Neuroblastoma	Alectinib	D	Sensitivity/Response	21575866	CiViC
ALK	p.F1174L	Neuroblastoma	Crizotinib	D	Sensitivity/Response	21948233	CiViC
ALK	p.F1174L	Neuroblastoma	Crizotinib	D	Resistance	22072639	CiViC
ALK	p.F1174L	Neuroblastoma	TAE684	D	Sensitivity/Response	18923525	CiViC
ALK	p.F1174L	Neuroblastoma	AZD3463	D	Sensitivity/Response	26786851	CiViC
ALK	p.F1174L	Neuroblastoma	Lorlatinib	D	Sensitivity/Response	26554404	CiViC
ALK	p.F1245C	Neuroblastoma	Lorlatinib	D	Sensitivity/Response	26554404	CiViC
ALK	p.F1245C	Neuroblastoma	Crizotinib	C	Resistance	23598171	CiViC
ALK	p.F1245C	Cancer	Crizotinib	D	Resistance	22034911	CiViC
ALK	p.F1245C	Lung Non-small Cell Carcinoma	Ceritinib	C	Sensitivity/Response	26775591	CiViC
ALK	p.F1245C	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	26775591	CiViC
ALK	p.F1245V	Neuroblastoma	Entrectinib	C	Sensitivity/Response	28183697	CiViC
MTOR	p.F2108L	Thyroid Gland Carcinoma	Everolimus	C	Resistance	25295501	CiViC
MTOR	p.F2108L	Breast Cancer	Sirolimus	D	Resistance	27279227	CiViC
ATM	p.F2732V	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
ABL1	p.F311L	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.F317C	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.F317I	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.F317I	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Dasatinib	B	Resistance	18818391	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Ponatinib	D	Sensitivity/Response	24236021	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Ponatinib	B	Sensitivity/Response	25349473	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Bosutinib	C	Reduced Sensitivity	22371878	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Dasatinib	B	Resistance	19779040	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Dasatinib	C	Reduced Sensitivity	17264298	CiViC
ABL1	p.F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.F317R	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.F317S	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.F317V	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.F317V	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.F317V	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	C	Resistance	19652056	CiViC
ABL1	p.F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.F359I	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.F359I	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	19075254	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Dasatinib	C	Reduced Sensitivity	17264298	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Dasatinib	C	Resistance	16775234	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	C	Resistance	19652056	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.F486S	Chronic Myeloid Leukemia	Nilotinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.F486S	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	22371878	CiViC
ABL1	p.F486S	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
JAK2	p.F694L	Pediatric B-cell Acute Lymphoblastic Leukemia	Ruxolitinib	C	Sensitivity/Response	27860260	CiViC
AR	p.F877L	Prostate Cancer	Apalutamide,Enzalutamide	D	Resistance	23779130	CiViC
FGFR2	FUSION	Cholangiocarcinoma	Infigratinib	C	Sensitivity/Response	27870574	CiViC
FGFR2	FUSION	Cancer	Erdafitinib	B	Sensitivity/Response	26324363	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Pemetrexed	B	Sensitivity/Response	21642865	CiViC
NTRK1	FUSIONS	Colorectal Cancer	Larotrectinib	D	Sensitivity/Response	26716414	CiViC
NTRK1	FUSIONS	Lung Adenocarcinoma	Larotrectinib,Lestaurtinib,Crizotinib	D	Sensitivity/Response	24162815	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Ceritinib	B	Sensitivity/Response	26973324	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	A	Sensitivity/Response	20979469	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	A	Sensitivity/Response	23724913	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	A	Sensitivity/Response	25470694	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	24478318	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	27022118	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride	C	Sensitivity/Response	20940188	CiViC
ALK	FUSIONS	Anaplastic Large Cell Lymphoma	Crizotinib	C	Sensitivity/Response	21345110	CiViC
ALK	FUSIONS	Inflammatory Myofibroblastic Tumor	Crizotinib	B	Sensitivity/Response	23598171	CiViC
ALK	FUSIONS	Diffuse Large B-cell Lymphoma	Crizotinib	C	Sensitivity/Response	24330038	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	B	Sensitivity/Response	23639470	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	C	Sensitivity/Response	26938871	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	B	Sensitivity/Response	25153538	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	A	Sensitivity/Response	26708155	CiViC
ALK	FUSIONS	Colorectal Adenocarcinoma	Crizotinib	E	Sensitivity/Response	19737969	CiViC
ALK	FUSIONS	Breast Cancer	Crizotinib	E	Sensitivity/Response	19737969	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	21933749	CiViC
PDGFRB	FUSIONS	Chronic Myeloproliferative Disease	Imatinib	A	Sensitivity/Response	16960151	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	26466010	CiViC
ALK	FUSIONS	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	25922291	CiViC
NTRK1	FUSIONS	Lung Non-small Cell Carcinoma	Entrectinib	C	Sensitivity/Response	26565381	CiViC
NTRK1	FUSIONS	Cancer	Entrectinib	B	Sensitivity/Response	28183697	CiViC
NTRK3	FUSIONS	Cancer	Entrectinib	B	Sensitivity/Response	28183697	CiViC
ALK	FUSIONS	Cancer	Entrectinib	B	Sensitivity/Response	28183697	CiViC
NTRK1	FUSIONS	Cancer	Larotrectinib	C	Sensitivity/Response	26603524	CiViC
NTRK1	FUSIONS	Sarcoma	Larotrectinib	C	Sensitivity/Response	26216294	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Brigatinib	B	Sensitivity/Response	28475456	CiViC
RET	FUSIONS	Lung Non-small Cell Carcinoma	Cabozantinib	B	Sensitivity/Response	27825636	CiViC
RET	FUSIONS	Lung Non-small Cell Carcinoma	Vandetanib	B	Sensitivity/Response	27803005	CiViC
RET	FUSIONS	Lung Non-small Cell Carcinoma	Vandetanib	B	Sensitivity/Response	27825616	CiViC
RET	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	B	Sensitivity/Response	27544060	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	B	Sensitivity/Response	28586279	CiViC
FGFR3	FUSIONS	Adrenal Carcinoma	Erdafitinib	C	Sensitivity/Response	26324363	CiViC
FGFR2	FUSIONS	Cholangiocarcinoma	Infigratinib	B	Sensitivity/Response	29182496	CiViC
ALK	FUSIONS	Anaplastic Thyroid Carcinoma	Crizotinib	C	Sensitivity/Response	24687827	CiViC
ALK	FUSIONS	Vagina Sarcoma	Crizotinib	C	Sensitivity/Response	26942346	CiViC
ALK	FUSIONS	Epithelioid Inflammatory Myofibroblastic Sarcoma	Crizotinib	C	Sensitivity/Response	25028698	CiViC
NRG1	FUSIONS	Pancreatic Adenocarcinoma	Afatinib	C	Sensitivity/Response	29802158	CiViC
NTRK1	FUSIONS	Cancer	Larotrectinib	B	Sensitivity/Response	29466156	CiViC
NTRK3	FUSIONS	Cancer	Larotrectinib	B	Sensitivity/Response	29466156	CiViC
NTRK1	FUSIONS	Cancer	Larotrectinib	B	Sensitivity/Response	29606586	CiViC
ABL2	FUSIONS	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Dasatinib	D	Sensitivity/Response	25207766	CiViC
ALK	FUSIONS	Lung Non-small Cell Carcinoma	Lorlatinib	B	Sensitivity/Response	30413378	CiViC
KRAS	p.G12/G13	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	B	Resistance	15696205	CiViC
KRAS	p.G12/G13	Colorectal Cancer	Chemotherapy,Cetuximab	B	Resistance	20619739	CiViC
KRAS	p.G12/G13	Colorectal Cancer	Cetuximab	D	Resistance	18202412	CiViC
KRAS	p.G12/G13	Pancreatic Adenocarcinoma	Gemcitabine,Trametinib	B	Resistance	24915778	CiViC
KRAS	p.G12/G13	Colorectal Cancer	Cetuximab	B	Resistance	19603024	CiViC
KRAS	p.G12/G13	Colorectal Cancer	Panitumumab,Cetuximab	B	Resistance	19223544	CiViC
ALK	p.G1202R	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	22277784	CiViC
ALK	p.G1202R	Lung Non-small Cell Carcinoma	Ceritinib	D	Resistance	24675041	CiViC
ALK	p.G1202R	Cancer	Alectinib	D	Resistance	25727400	CiViC
ALK	p.G1202R	Cancer	Brigatinib	D	Resistance	25727400	CiViC
ALK	p.G1202R	Lung Non-small Cell Carcinoma	Tanespimycin	D	Sensitivity/Response	22277784	CiViC
ALK	p.G1202R	Lung Adenocarcinoma	Crizotinib	C	Resistance	22277784	CiViC
ALK	p.G1269A	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	22235099	CiViC
ALK	p.G1269A	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	23344087	CiViC
ALK	p.G1269A	Lung Non-small Cell Carcinoma	Ceritinib	D	Sensitivity/Response	24675041	CiViC
ALK	p.G1269A	Cancer	Brigatinib	D	Sensitivity/Response	25727400	CiViC
ALK	p.G1269A	Cancer	Alectinib	D	Resistance	25727400	CiViC
ALK	p.G1269A	Cancer	Ceritinib	D	Sensitivity/Response	25727400	CiViC
KRAS	p.G12A	Lung Adenocarcinoma	Gefitinib,Erlotinib	B	Resistance	19794967	CiViC
KRAS	p.G12A	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12A	Lung Cancer	Gefitinib	B	Resistance	17409929	CiViC
KRAS	p.G12A	Multiple Myeloma	Melphalan	B	Resistance	19284554	CiViC
KRAS	p.G12A	Multiple Myeloma	Melphalan	D	Resistance	11050000	CiViC
KRAS	p.G12A	Multiple Myeloma	Melphalan	D	Resistance	12483530	CiViC
KRAS	p.G12A	Multiple Myeloma	Melphalan	D	Resistance	16497971	CiViC
KRAS	p.G12A	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12A	Colorectal Cancer	Cetuximab,Panitumumab	C	Resistance	19223544	CiViC
KRAS	p.G12C	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	B	Sensitivity/Response	26125448	CiViC
KRAS	p.G12C	Cancer	ARS-853,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	D	Sensitivity/Response	26739882	CiViC
KRAS	p.G12C	Colorectal Cancer	Gefitinib,Erlotinib	B	Resistance	23313110	CiViC
KRAS	p.G12C	Colorectal Cancer	Dactolisib,Selumetinib	D	Sensitivity/Response	22392911	CiViC
KRAS	p.G12C	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12C	Lung Cancer	Gefitinib	B	Resistance	17409929	CiViC
KRAS	p.G12C	Multiple Myeloma	Melphalan	B	Resistance	19284554	CiViC
KRAS	p.G12C	Multiple Myeloma	Melphalan	D	Resistance	11050000	CiViC
KRAS	p.G12C	Multiple Myeloma	Melphalan	D	Resistance	12483530	CiViC
KRAS	p.G12C	Multiple Myeloma	Melphalan	D	Resistance	16497971	CiViC
KRAS	p.G12C	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12D	Lung Non-small Cell Carcinoma	Dactolisib,Selumetinib	D	Sensitivity/Response	19029981	CiViC
KRAS	p.G12D	Pancreatic Carcinoma	Akt Inhibitor MK2206	C	Sensitivity/Response	22025163	CiViC
KRAS	p.G12D	Hairy Cell Leukemia	Vemurafenib	C	Resistance	26352686	CiViC
KRAS	p.G12D	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes	C	Sensitivity/Response	27959684	CiViC
KRAS	p.G12D	Colorectal Cancer	Dactolisib,Selumetinib	D	Sensitivity/Response	22392911	CiViC
KRAS	p.G12D	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12D	Lung Cancer	Gefitinib	B	Resistance	17409929	CiViC
KRAS	p.G12D	Multiple Myeloma	Melphalan	B	Resistance	19284554	CiViC
KRAS	p.G12D	Multiple Myeloma	Melphalan	D	Resistance	11050000	CiViC
KRAS	p.G12D	Multiple Myeloma	Melphalan	D	Resistance	12483530	CiViC
KRAS	p.G12D	Multiple Myeloma	Melphalan	D	Resistance	16497971	CiViC
NRAS	p.G12D	Colorectal Cancer	Cetuximab	B	Resistance	25666295	CiViC
KRAS	p.G12D	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12D	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
KRAS	p.G12D	Ovarian Cancer	Cetuximab	D	Resistance	22246397	CiViC
KRAS	p.G12D	Colorectal Cancer	Cetuximab,Panitumumab	C	Resistance	19223544	CiViC
KRAS	p.G12R	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12R	Colorectal Cancer	Cetuximab	D	Resistance	22722830	CiViC
KRAS	p.G12R	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12S	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12S	Lung Cancer	Gefitinib	B	Resistance	17409929	CiViC
KRAS	p.G12S	Multiple Myeloma	Melphalan	B	Resistance	19284554	CiViC
KRAS	p.G12S	Multiple Myeloma	Melphalan	D	Resistance	11050000	CiViC
KRAS	p.G12S	Multiple Myeloma	Melphalan	D	Resistance	12483530	CiViC
KRAS	p.G12S	Multiple Myeloma	Melphalan	D	Resistance	16497971	CiViC
KRAS	p.G12S	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12S	Colorectal Cancer	Panitumumab,Cetuximab	C	Resistance	19223544	CiViC
KRAS	p.G12V	Colorectal Cancer	Cetuximab	D	Resistance	20978259	CiViC
KRAS	p.G12V	Lung Non-small Cell Carcinoma	Palbociclib	D	Sensitivity/Response	20609353	CiViC
KRAS	p.G12V	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	B	Sensitivity/Response	26125448	CiViC
KRAS	p.G12V	Colorectal Cancer	Selumetinib,Dactolisib	D	Sensitivity/Response	22392911	CiViC
KRAS	p.G12V	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
KRAS	p.G12V	Lung Cancer	Gefitinib	C	Resistance	17409929	CiViC
KRAS	p.G12V	Colorectal Cancer	Regorafenib	D	Resistance	26161928	CiViC
KRAS	p.G12V	Colorectal Cancer	Cetuximab,Panitumumab	C	Resistance	19223544	CiViC
NRAS	p.G13D	Melanoma	Tanespimycin	C	Sensitivity/Response	18375819	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	D	Sensitivity/Response	20978259	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	B	Sensitivity/Response	20978259	CiViC
HRAS	p.G13D	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	C	Resistance	26561417	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	B	Resistance	26371285	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	B	Resistance	26812186	CiViC
KRAS	p.G13D	Colorectal Cancer	Dactolisib,Selumetinib	D	Sensitivity/Response	22392911	CiViC
KRAS	p.G13D	Colorectal Cancer	Panitumumab	C	Resistance	18316791	CiViC
HRAS	p.G13D	Skin Squamous Cell Carcinoma	Vemurafenib	C	Resistance	22256804	CiViC
HRAS	p.G13D	Colorectal Cancer	Cetuximab	D	Resistance	26561417	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	D	Resistance	22722830	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab	B	Resistance	25666295	CiViC
KRAS	p.G13D	Colorectal Cancer	Cetuximab,Panitumumab	C	Resistance	19223544	CiViC
KRAS	p.G13V	Colorectal Cancer	Cetuximab,Panitumumab	C	Resistance	19223544	CiViC
ROS1	p.G2032R	Lung Adenocarcinoma	Crizotinib	C	Resistance	23724914	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Cabozantinib	D	Sensitivity/Response	25351743	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Cabozantinib,Foretinib	D	Sensitivity/Response	26372962	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Brigatinib,Crizotinib,AZD3463,Ceritinib	D	Resistance	26372962	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Lorlatinib	D	Sensitivity/Response	25733882	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	25688157	CiViC
ROS1	p.G2032R	Lung Non-small Cell Carcinoma	Foretinib	D	Sensitivity/Response	25688157	CiViC
ROS1	p.G2032R	Lung Adenocarcinoma	Crizotinib	C	Resistance	23724914	CiViC
ROS1	p.G2101A	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	25688157	CiViC
ROS1	p.G2101A	Lung Non-small Cell Carcinoma	Foretinib	D	Sensitivity/Response	25688157	CiViC
TP53	p.G245S	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	19075254	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Bosutinib	C	Reduced Sensitivity	22371878	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Dasatinib	C	Reduced Sensitivity	17264298	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Imatinib	C	Resistance	22371878	CiViC
ABL1	p.G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	B	Resistance	17264298	CiViC
DDR2	p.G253C	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
ERBB3	p.G284R	Urothelial Carcinoma	Afatinib	B	Sensitivity/Response	27044931	CiViC
ERBB2	p.G309A	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
ABL1	p.G340L	Lung Non-small Cell Carcinoma	Imatinib Mesylate,Dasatinib	D	Sensitivity/Response	26758680	CiViC
ABL1	p.G398R	Chronic Myeloid Leukemia	Nilotinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.G398R	Chronic Myeloid Leukemia	Dasatinib	D	Sensitivity/Response	19075254	CiViC
EGFR	p.G465R	Colorectal Cancer	Futuximab/Modotuximab Mixture	C	Sensitivity/Response	26888827	CiViC
EGFR	p.G465R	Colorectal Cancer	Panitumumab,Cetuximab	C	Resistance	26888827	CiViC
BRAF	p.G466V	Colorectal Cancer	Panitumumab,Irinotecan	D	Sensitivity/Response	28783719	CiViC
BRAF	p.G469	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	B	Sensitivity/Response	31580757	CiViC
BRAF	p.G469E	Skin Melanoma	Sorafenib	D	Sensitivity/Response	18794803	CiViC
BRAF	p.G469E	Skin Melanoma	U0126	D		18794803	CiViC
DDR2	p.G505S	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
BRAF	p.G596C	Lung Non-small Cell Carcinoma	Dabrafenib,Trametinib	D	Sensitivity/Response	27577079	CiViC
NTRK3	p.G623R	Breast Cancer	Entrectinib	C	Resistance	26884591	CiViC
NTRK1	p.G667C	Colorectal Adenocarcinoma	Entrectinib	C	Resistance	26546295	CiViC
EGFR	p.G719	Lung Adenocarcinoma	Erlotinib	B	Sensitivity/Response	26773740	CiViC
EGFR	p.G719	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	21531810	CiViC
EGFR	p.G719A	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	20038723	CiViC
EGFR	p.G719D	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	C	Sensitivity/Response	21531810	CiViC
EGFR	p.G719S	Lung Non-small Cell Carcinoma	Gefitinib	D	Sensitivity/Response	15118125	CiViC
EGFR	p.G719S	Colorectal Cancer	Cetuximab	D	Sensitivity/Response	24894453	CiViC
EGFR	p.G719S	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	26124334	CiViC
EGFR	p.G719S	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	19147750	CiViC
EGFR	p.G724S	Colorectal Cancer	Cetuximab	D	Sensitivity/Response	24894453	CiViC
DDR2	p.G774V	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
ERBB2	p.G776L	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	22325357	CiViC
ERBB2	p.G778_P780DUP	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	22325357	CiViC
ERBB2	p.G778_P780DUP	Lung Non-small Cell Carcinoma	Dacomitinib	C	Sensitivity/Response	25899785	CiViC
PDGFRA	p.G853D	Melanoma	Crenolanib,Imatinib	D	Sensitivity/Response	24132921	CiViC
EGFR	p.Gain-of-function	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	15118073	CiViC
ROS1	p.GOPC-ROS1	Glioblastoma Multiforme	Lorlatinib	D	Sensitivity/Response	30171048	CiViC
PIK3CA	p.H1047R	Breast Cancer	PI3K-alpha Inhibitor MEN1611	D	Sensitivity/Response	21558396	CiViC
PIK3CA	p.H1047R	Colorectal Cancer	Panitumumab,Cetuximab	C	Resistance	19223544	CiViC
PIK3CA	p.H1047R	Head And Neck Cancer	Dactolisib	D	Sensitivity/Response	25855885	CiViC
PIK3CA	p.H1047R	Head And Neck Cancer	Dactolisib	D	Sensitivity/Response	23619167	CiViC
PIK3CA	p.H1047R	Head And Neck Cancer	Dactolisib,Cetuximab	D	Sensitivity/Response	23619167	CiViC
PIK3CA	p.H1047R	Head And Neck Cancer	Alpelisib	D	Sensitivity/Response	25550549	CiViC
PIK3CA	p.H1047R	Lung Adenocarcinoma	Dactolisib	D	Sensitivity/Response	19029981	CiViC
PIK3CA	p.H1047R	Head And Neck Squamous Cell Carcinoma	Taselisib	D	Sensitivity/Response	26589432	CiViC
PIK3CA	p.H1047R	Her2-receptor Positive Breast Cancer	Capivasertib,Trastuzumab	D	Sensitivity/Response	22294718	CiViC
PIK3CA	p.H1047R	Her2-receptor Positive Breast Cancer	Capivasertib,Lapatinib	D	Sensitivity/Response	22294718	CiViC
PIK3CA	p.H1047R	Her2-receptor Positive Breast Cancer	Everolimus,Fulvestrant	C	Sensitivity/Response	27445490	CiViC
PIK3CA	p.H1047R	Thyroid Cancer	Perifosine,Temsirolimus	D	Sensitivity/Response	19706758	CiViC
PIK3CA	p.H1047R	Breast Cancer	Trastuzumab	D	Resistance	20453058	CiViC
PIK3CA	p.H1047R	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	26920887	CiViC
PIK3CA	p.H1047R	Colorectal Cancer	Vemurafenib	D	Resistance	22180495	CiViC
PIK3CA	p.H1047R	Colorectal Cancer	Akt Inhibitor MK2206,Vemurafenib	D	Sensitivity/Response	22180495	CiViC
MTOR	p.H1968Y	Melanoma	Capivasertib,PI3K/BET Inhibitor LY294002	D	Sensitivity/Response	26490311	CiViC
ABL1	p.H396P	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	22371878	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
EGFR	p.H773_V774insH	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	24353160	CiViC
EGFR	p.H773_V774insNPH	Lung Adenocarcinoma	Erlotinib	C	Resistance	24353160	CiViC
PDGFRA	p.H845Y	Melanoma	Crenolanib,Imatinib	D	Sensitivity/Response	24132921	CiViC
ERBB2	p.H878Y	Hepatocellular Carcinoma	Lapatinib	D	Sensitivity/Response	22046346	CiViC
GSTP1	p.I105V	Colorectal Cancer	FOLFOX Regimen	B	Sensitivity/Response	19922504	CiViC
ABCB1	p.I1145I	Lung Non-small Cell Carcinoma	Cisplatin,Carboplatin	B	Sensitivity/Response	22296372	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Alectinib	C	Resistance	25228534	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Ceritinib	C	Sensitivity/Response	25228534	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	TAE684	D	Sensitivity/Response	25228534	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	25228534	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Ceritinib	D	Sensitivity/Response	24675041	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Alectinib	C	Resistance	25736571	CiViC
ALK	p.I1171	Lung Non-small Cell Carcinoma	Ceritinib	C	Sensitivity/Response	25736571	CiViC
ALK	p.I1171N	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	C	Resistance	25393796	CiViC
ALK	p.I1171S	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	C	Resistance	25393796	CiViC
DDR2	p.I638F	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
PDGFRA	p.I843DEL	Gastrointestinal Stromal Tumor	Crenolanib	D	Sensitivity/Response	22745105	CiViC
PDGFRA	p.I843DEL	Gastrointestinal Stromal Tumor	Imatinib	D	Sensitivity/Response	14645423	CiViC
EGFR	INSERTION	Lung Adenocarcinoma	Afatinib	B	Resistance	26051236	CiViC
EGFR	INSERTION	Lung Adenocarcinoma	Erlotinib	C	Resistance	22895145	CiViC
NF2	p.K159FS*16	Breast Cancer	Temsirolimus	C	Sensitivity/Response	25878190	CiViC
PRPS1	p.K176N	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	25962120	CiViC
H3-3A	p.K27M	Glioma	Akt/ERK Inhibitor ONC201	B	Sensitivity/Response	172409	CiViC
ATM	p.K293*	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
BRCA2	p.K3226*	Glioblastoma Multiforme	Olaparib,Temozolomide	C	Sensitivity/Response	31619547	CiViC
NT5C2	p.K359Q	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	23377281	CiViC
EGFR	p.K467T	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	D	Sensitivity/Response	26888827	CiViC
EGFR	p.K467T	Colorectal Cancer	Cetuximab	D	Resistance	26888827	CiViC
BRAF	p.K483M	Skin Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib	E	Sensitivity/Response	20141835	CiViC
KIT	p.K484_G487DEL	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	18955451	CiViC
KIT	p.K550_K558del	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.K550_W557del	Gastrointestinal Stromal Tumor	Sunitinib,Ponatinib,Regorafenib,Imatinib	D	Sensitivity/Response	25239608	CiViC
KIT	p.K558_V559del	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.K558NP	Gastrointestinal Stromal Tumor	Sunitinib,Ponatinib,Regorafenib,Imatinib	D	Sensitivity/Response	25239608	CiViC
MAP2K1	p.K57N	Lung Adenocarcinoma	Selumetinib	D	Sensitivity/Response	18632602	CiViC
BRAF	p.K601E	Skin Melanoma	Trametinib,Vemurafenib	D	Sensitivity/Response	22798288	CiViC
KIT	p.K642E	Mucosal Melanoma	Imatinib	C	Sensitivity/Response	18510589	CiViC
KIT	p.K642E	Melanoma	Dasatinib	C	Sensitivity/Response	21523734	CiViC
KIT	p.K642E	Gastrointestinal Stromal Tumor	Ponatinib,Sunitinib	D	Sensitivity/Response	25239608	CiViC
SF3B1	p.K666N	Breast Cancer	Spliceostatin A	D	Sensitivity/Response	25424858	CiViC
SF3B1	p.K700E	Breast Cancer	Spliceostatin A	D	Sensitivity/Response	25424858	CiViC
PMS2	p.K706FS*19	Glioblastoma Multiforme	Nivolumab	C	Sensitivity/Response	27001570	CiViC
ERCC2	p.K751Q	Osteosarcoma	Cisplatin	B	Resistance	19434073	CiViC
ERCC2	p.K751Q	Lung Non-small Cell Carcinoma	Carboplatin,Paclitaxel	B	Sensitivity/Response	19470925	CiViC
EGFR	p.K757R	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	26773740	CiViC
BRAF	p.KIAA1549-BRAF	Skin Melanoma	Trametinib	C	Sensitivity/Response	26072686	CiViC
BRAF	p.KIAA1549-BRAF	Sarcoma	Temsirolimus,Bevacizumab,Sorafenib	C	Sensitivity/Response	24422672	CiViC
RET	p.KIF5B-RET	Lung Adenocarcinoma	Vandetanib	C	Sensitivity/Response	23584301	CiViC
RET	p.KIF5B-RET	Lung Adenocarcinoma	Vandetanib,Everolimus	C	Sensitivity/Response	25982012	CiViC
ALK	p.L1152R	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	21791641	CiViC
ALK	p.L1196M	Lung Non-small Cell Carcinoma	Alectinib	D	Sensitivity/Response	21575866	CiViC
ALK	p.L1196M	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	20979473	CiViC
ALK	p.L1196M	Lung Non-small Cell Carcinoma	Crizotinib	B	Resistance	20979473	CiViC
ALK	p.L1196M	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	22277784	CiViC
ALK	p.L1196M	Lung Non-small Cell Carcinoma	Ceritinib	D	Sensitivity/Response	24675041	CiViC
RAD50	p.L1237F	Ureter Small Cell Carcinoma	Checkpoint Kinase Inhibitor AZD7762,Irinotecan	C	Sensitivity/Response	24934408	CiViC
PRPS1	p.L191F	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	25962120	CiViC
PRPS1	p.L191F	Childhood B-cell Acute Lymphoblastic Leukemia	Cytarabine	D	Sensitivity/Response	25962120	CiViC
ROS1	p.L2026M	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	25733882	CiViC
ROS1	p.L2026M	Lung Non-small Cell Carcinoma	Lorlatinib	D	Sensitivity/Response	25733882	CiViC
ROS1	p.L2026M	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	25688157	CiViC
ROS1	p.L2026M	Lung Non-small Cell Carcinoma	Foretinib	D	Sensitivity/Response	25688157	CiViC
ROS1	p.L2155S	Lung Non-small Cell Carcinoma	Foretinib,TAE684,Crizotinib	D	Resistance	25688157	CiViC
PML	p.L218P	Acute Promyelocytic Leukemia	Tretinoin	C	Resistance	21613260	CiViC
DDR2	p.L239R	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
ATM	p.L2427P	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
ABL1	p.L248R	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	D	Resistance	15705718	CiViC
ABL1	p.L248R	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.L248R	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.L248V	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.L248V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib,Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.L248V	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.L248V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.L248V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
MYD88	p.L265P	Waldenström's Macroglobulinemia	Ibrutinib	B	Sensitivity/Response	25853747	CiViC
MYD88	p.L265P	Waldenström's Macroglobulinemia	IMG-2005-5,IRAK-1/4 Inhibitor	D	Sensitivity/Response	22931316	CiViC
ABL1	p.L384M	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.L384M	Chronic Myeloid Leukemia	Dasatinib	C	Resistance	19779040	CiViC
ABL1	p.L387F	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.L387F	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	22371878	CiViC
ABL1	p.L387F	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
SMO	p.L412F	Basal Cell Carcinoma	Vismodegib	D	Resistance	25759020	CiViC
SMO	p.L412F	Basal Cell Carcinoma	Vismodegib	C	Resistance	26822128	CiViC
BRAF	p.L505H	Melanoma	Vemurafenib	D	Resistance	24112705	CiViC
BRAF	p.L505H	Melanoma	Vemurafenib	B	Resistance	25515853	CiViC
ESR1	p.L536Q	Breast Cancer	Hormone Therapy	D	Resistance	24185512	CiViC
ESR1	p.L536Q	Breast Cancer	Fulvestrant,Tamoxifen	D	Sensitivity/Response	24185510	CiViC
KIT	p.L576P	Melanoma	Nilotinib,Imatinib,Sorafenib	D	Resistance	19671763	CiViC
KIT	p.L576P	Melanoma	Dasatinib	D	Sensitivity/Response	19671763	CiViC
KIT	p.L576P	Lung Non-small Cell Carcinoma	Dasatinib,Nilotinib,Imatinib	D	Sensitivity/Response	17372901	CiViC
KIT	p.L576P	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.L576P	Cancer	Dasatinib,Imatinib	D	Sensitivity/Response	25317746	CiViC
BRAF	p.L597Q	Skin Melanoma	Vemurafenib,Trametinib	D	Sensitivity/Response	22798288	CiViC
BRAF	p.L597Q	Skin Melanoma	Trametinib	C	Sensitivity/Response	24933606	CiViC
BRAF	p.L597R	Melanoma	Vemurafenib	C	Sensitivity/Response	23715574	CiViC
BRAF	p.L597R	Skin Melanoma	Vemurafenib,Trametinib	D	Sensitivity/Response	22798288	CiViC
BRAF	p.L597S	Skin Melanoma	Trametinib,Vemurafenib	D	Sensitivity/Response	22798288	CiViC
BRAF	p.L597S	Skin Melanoma	MEK Inhibitor TAK-733	C	Sensitivity/Response	22798288	CiViC
BRAF	p.L597V	Skin Melanoma	Trametinib	C	Sensitivity/Response	22805292	CiViC
DDR2	p.L63V	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	22328973	CiViC
EGFR	p.L747_P753delinsS	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	19147750	CiViC
EGFR	p.L747_S752delinsQ	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	15329413	CiViC
ERBB2	p.L755S	Breast Cancer	Lapatinib	D	Resistance	23220880	CiViC
ERBB2	p.L755S	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
ERBB2	p.L755S	Colon Cancer	Trastuzumab,Lapatinib,Neratinib	D	Sensitivity/Response	26243863	CiViC
ERBB2	p.L755W	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
EGFR	p.L838P	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	21531810	CiViC
EGFR	p.L838V	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	19147750	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	B	Sensitivity/Response	24736073	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	B	Sensitivity/Response	24457318	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib	D	Sensitivity/Response	15118125	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	23816960	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	22452895	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	B	Sensitivity/Response	22285168	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	26515464	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Afatinib	B	Sensitivity/Response	24439929	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	18509184	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	24755888	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	20038723	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Gefitinib	C	Sensitivity/Response	15329413	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Gefitinib	D	Sensitivity/Response	24893891	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Lapatinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Dacomitinib	D	Sensitivity/Response	18089823	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Neratinib	D	Sensitivity/Response	16818618	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Canertinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	C	Sensitivity/Response	15329413	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Gefitinib	B	Sensitivity/Response	22370314	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	A	Sensitivity/Response	24868098	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Afatinib	A	Sensitivity/Response	23982599	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Erlotinib	B	Sensitivity/Response	22285168	CiViC
EGFR	p.L858R	Cancer	Multikinase Inhibitor AEE788,Erlotinib,Gefitinib	D	Sensitivity/Response	19147750	CiViC
EGFR	p.L858R	Cancer	Erlotinib	D	Sensitivity/Response	17877814	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	21132006	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	24353160	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	27612423	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Crizotinib	C	Resistance	22235099	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	27032107	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Erlotinib	D	Sensitivity/Response	27102076	CiViC
EGFR	p.L858R	Lung Adenocarcinoma	Cetuximab	D	Sensitivity/Response	27102076	CiViC
EGFR	p.L858R	Malignant Glioma	Erlotinib	D	Sensitivity/Response	17177598	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	21531810	CiViC
EGFR	p.L858R	Lung Non-small Cell Carcinoma	Dacomitinib	B	Sensitivity/Response	26768165	CiViC
EGFR	p.L861	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	21531810	CiViC
EGFR	p.L861Q	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	21531810	CiViC
EGFR	p.L861Q	Malignant Glioma	Erlotinib	D	Sensitivity/Response	17177598	CiViC
EGFR	p.L861R	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	21531810	CiViC
ERBB2	p.L866M	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	D	Sensitivity/Response	26243863	CiViC
PTCH1	LOH	Brain Medulloblastoma	Vismodegib	B	Sensitivity/Response	26169613	CiViC
CCND3	LOSS	T-cell Lymphoblastic Leukemia/lymphoma	Palbociclib	D	Sensitivity/Response	23079656	CiViC
PTEN	LOSS	Colorectal Cancer	Cetuximab	B	Resistance	21163703	CiViC
PTEN	LOSS	Prostate Cancer	Temsirolimus	D	Sensitivity/Response	11504908	CiViC
PTEN	LOSS	Bladder Carcinoma	Everolimus	B	Resistance	23989949	CiViC
PTEN	LOSS	Breast Cancer	Trastuzumab	B	Resistance	24387334	CiViC
PTEN	LOSS	Melanoma	Uprosertib	D	Sensitivity/Response	24735930	CiViC
PTEN	LOSS	Breast Cancer	PI3Kbeta Inhibitor AZD8186	D	Sensitivity/Response	25398829	CiViC
PTEN	LOSS	Cancer	Carboplatin,Buparlisib,Paclitaxel	B	Sensitivity/Response	25672916	CiViC
PTEN	LOSS	Breast Cancer	Alpelisib	D	Resistance	25409150	CiViC
PTEN	LOSS	Gastric Adenocarcinoma	Lapatinib,Trastuzumab	B	Resistance	25300346	CiViC
MRE11	LOSS	Endometrial Cancer	Talazoparib	D	Sensitivity/Response	24927325	CiViC
PTEN	LOSS	Pancreatic Carcinoma	Akt Inhibitor MK2206	C	Sensitivity/Response	22025163	CiViC
VHL	LOSS	Renal Carcinoma	Temsirolimus	D	Sensitivity/Response	16341243	CiViC
STK11	LOSS	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	D	Resistance	22425996	CiViC
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Everolimus	B	Sensitivity/Response	27091708	CiViC
CDKN2A	LOSS	Skin Melanoma	Alvocidib	D	Sensitivity/Response	12777976	CiViC
CDKN2A	LOSS	Renal Cell Carcinoma	Palbociclib	D	Sensitivity/Response	23898052	CiViC
CDKN2B	LOSS	Renal Cell Carcinoma	Palbociclib	D	Sensitivity/Response	23898052	CiViC
CDKN2A	LOSS	Skin Melanoma	Palbociclib	D	Sensitivity/Response	24495407	CiViC
CDKN2A	LOSS	Ovarian Cancer	Palbociclib	D	Sensitivity/Response	21278246	CiViC
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	D	Resistance	17936563	CiViC
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Resistance	20813970	CiViC
PTEN	LOSS	Her2-receptor Positive Breast Cancer	PI3K/BET Inhibitor LY294002,Trastuzumab	D	Sensitivity/Response	15324695	CiViC
PTEN	LOSS	Ovarian Cancer	Cisplatin	D	Resistance	15790433	CiViC
PTEN	LOSS	Stomach Carcinoma	Chemotherapy	B	Resistance	15900596	CiViC
PTEN	LOSS	Stomach Cancer	Capivasertib,Docetaxel	D	Sensitivity/Response	24088382	CiViC
PTEN	LOSS	Cancer	Capivasertib	D	Sensitivity/Response	22294718	CiViC
PTEN	LOSS	Endometrial Cancer	Temsirolimus	D	Sensitivity/Response	23674493	CiViC
STK11	LOSS	Peutz-Jeghers Syndrome	Sirolimus	D	Sensitivity/Response	18281551	CiViC
STK11	LOSS	Peutz-Jeghers Syndrome	Sirolimus	D	Sensitivity/Response	19541609	CiViC
SOX10	LOSS	Melanoma	Vemurafenib	D	Resistance	24670642	CiViC
NF2	LOSS	Thyroid Gland Carcinoma	Selumetinib	D	Sensitivity/Response	26359368	CiViC
NF1	LOSS	Malignant Peripheral Nerve Sheath Tumor	JQ1 Compound	D	Sensitivity/Response	24373973	CiViC
CDKN2A	LOSS	Her2-receptor Negative Breast Cancer	Palbociclib,Letrozole	C	Sensitivity/Response	26715889	CiViC
MSH2	LOSS	Urothelial Carcinoma	Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680	C	Sensitivity/Response	26674132	CiViC
MSH6	LOSS	Urothelial Carcinoma	Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab	C	Sensitivity/Response	26674132	CiViC
CDKN2A	LOSS	Ewing Sarcoma	Linsitinib,Palbociclib	D	Sensitivity/Response	27286459	CiViC
CDKN2B	LOSS	Ewing Sarcoma	Palbociclib,Linsitinib	D	Sensitivity/Response	27286459	CiViC
CDKN2A	LOSS	Dermatofibrosarcoma Protuberans	Palbociclib	D	Sensitivity/Response	25852058	CiViC
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Resistance	21594665	CiViC
PTEN	LOSS	Breast Cancer	Trastuzumab	B	Resistance	21594665	CiViC
ASS1	LOSS	Sarcoma	Pegargiminase,Chloroquine	D	Sensitivity/Response	27735949	CiViC
ASS1	LOSS	Ovarian Cancer	Platinum Compound	D	Resistance	19533750	CiViC
PTEN	LOSS	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
PTEN	LOSS	Colorectal Cancer	Cetuximab,Panitumumab	B	Resistance	19223544	CiViC
BRCA1	p.M1I	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA2	p.M1I	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA2	p.M1R	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA1	p.M1V	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
MTOR	p.M2327I	Breast Cancer	MTOR Kinase Inhibitor AZD8055	D	Resistance	27279227	CiViC
TP53	p.M237I	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
ABL1	p.M244V	Chronic Myeloid Leukemia	Imatinib	C	Sensitivity/Response	15930265	CiViC
ABL1	p.M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.M244V	Chronic Myeloid Leukemia	Imatinib	C	Resistance	16775234	CiViC
ABL1	p.M343T	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Imatinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Imatinib	C	Sensitivity/Response	15930265	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Nilotinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Bosutinib	C	Reduced Sensitivity	22371878	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Dasatinib	C	Reduced Sensitivity	17264298	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
KIT	p.M541L	Chronic Leukemia	Imatinib	C	Sensitivity/Response	25015329	CiViC
RB1	p.M695FS*26	Estrogen-receptor Positive Breast Cancer	Palbociclib	D	Resistance	27020857	CiViC
EGFR	p.M766_A767insAI	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	24353160	CiViC
ERBB2	p.M774DELINSWLV	Lung Non-small Cell Carcinoma	Dacomitinib	C	Sensitivity/Response	25899785	CiViC
RET	p.M918T	Thyroid Gland Medullary Carcinoma	Motesanib	D	Resistance	21422803	CiViC
RET	p.M918T	Thyroid Gland Medullary Carcinoma	JAK2 Inhibitor AZD1480	D	Sensitivity/Response	23056499	CiViC
RET	p.M918T	Thyroid Gland Medullary Carcinoma	Sorafenib	B	Sensitivity/Response	20368568	CiViC
RET	p.M918T	Thyroid Gland Medullary Carcinoma	Cabozantinib	B	Sensitivity/Response	27525386	CiViC
KIT	MUTATION	Melanoma	Imatinib	B	Sensitivity/Response	23775962	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Tretinoin	B	Resistance	19965647	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab	B	Resistance	20619739	CiViC
WT1	MUTATION	Acute Myeloid Leukemia	Cytarabine,Daunorubicin	B	Resistance	18591546	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Tretinoin	B	Sensitivity/Response	19059939	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Daunorubicin	B	Sensitivity/Response	22417203	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Valproic Acid	B	Sensitivity/Response	24797300	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Tretinoin,NSC348884	D	Sensitivity/Response	21719597	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Anti-CD33,Anti-CD123	E	Sensitivity/Response	24927407	CiViC
NPM1	MUTATION	Acute Myeloid Leukemia	Anti-CD33	E	Sensitivity/Response	24927407	CiViC
FLT3	MUTATION	Acute Myeloid Leukemia	Sorafenib	B	Resistance	22368270	CiViC
FLT3	MUTATION	Acute Myeloid Leukemia	Sorafenib	B	Resistance	18230792	CiViC
KRAS	MUTATION	Colorectal Cancer	Cetuximab	B	Resistance	16618717	CiViC
RUNX1	MUTATION	Acute Myeloid Leukemia	Cytarabine	B	Resistance	21343560	CiViC
APC	MUTATION	Colon Carcinoma	JW55	D	Sensitivity/Response	22440753	CiViC
APC	MUTATION	Colorectal Cancer	G007-LK	D	Sensitivity/Response	23539443	CiViC
ATM	MUTATION	Glioblastoma Multiforme	Temozolomide	D	Sensitivity/Response	23960094	CiViC
ATM	MUTATION	Melanoma	Temozolomide	D	Sensitivity/Response	23960094	CiViC
ATM	MUTATION	Hematologic Cancer	Olaparib	D	Sensitivity/Response	20739657	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	B	Sensitivity/Response	14645423	CiViC
HRAS	MUTATION	Cancer	Binimetinib,MTOR Kinase Inhibitor AZD8055,Selumetinib,MEK Inhibitor PD0325901,Everolimus	D	Sensitivity/Response	26544513	CiViC
MTOR	MUTATION	Bladder Carcinoma	Pazopanib,Everolimus	C	Sensitivity/Response	24625776	CiViC
FBXW7	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	B	Resistance	26508446	CiViC
SMAD4	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	B	Resistance	26508446	CiViC
MET	MUTATION	Cancer	Crizotinib	D	Sensitivity/Response	26547802	CiViC
RIT1	MUTATION	Lung Adenocarcinoma	Pictilisib,Selumetinib	D	Sensitivity/Response	24469055	CiViC
SMO	MUTATION	Basal Cell Carcinoma	Vismodegib	B	Resistance	25759020	CiViC
SMO	MUTATION	Basal Cell Carcinoma	PSI,Arsenic Trioxide	D	Sensitivity/Response	25759020	CiViC
PTCH1	MUTATION	Brain Medulloblastoma	Sonidegib	B	Sensitivity/Response	24651015	CiViC
ERBB4	MUTATION	Melanoma	Lapatinib	D	Sensitivity/Response	19718025	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Cabozantinib	D	Sensitivity/Response	25242168	CiViC
MET	MUTATION	Papillary Renal Cell Carcinoma	Foretinib	B	Sensitivity/Response	23213094	CiViC
MET	MUTATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	25971939	CiViC
PTPRD	MUTATION	Head And Neck Carcinoma	JSI-124	D	Sensitivity/Response	26267899	CiViC
KRAS	MUTATION	Ovarian Cancer	Decitabine	D	Sensitivity/Response	25968887	CiViC
TP53	MUTATION	Gastric Adenocarcinoma	Chemotherapy	B	Sensitivity/Response	24740294	CiViC
TP53	MUTATION	Breast Cancer	Doxorubicin	D	Sensitivity/Response	22698404	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	B	Resistance	23435830	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Pictilisib,Imatinib	D	Sensitivity/Response	23231951	CiViC
KRAS	MUTATION	Cancer	Trametinib	D	Sensitivity/Response	22169769	CiViC
BRAF	MUTATION	Cancer	Trametinib	D	Sensitivity/Response	22169769	CiViC
KRAS	MUTATION	Colorectal Cancer	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	D	Sensitivity/Response	21890455	CiViC
KRAS	MUTATION	Colorectal Cancer	Dasatinib,Cetuximab	D	Sensitivity/Response	20956938	CiViC
ERBB2	MUTATION	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	22325357	CiViC
KRAS	MUTATION	Colorectal Cancer	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	D	Sensitivity/Response	25199829	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	D	Sensitivity/Response	25199829	CiViC
KRAS	MUTATION	Colorectal Cancer	Trametinib,Afatinib	D	Sensitivity/Response	24685132	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Afatinib,Trametinib	D	Sensitivity/Response	24685132	CiViC
KRAS	MUTATION	Colorectal Cancer	Cetuximab	A	Resistance	18946061	CiViC
NRAS	MUTATION	Melanoma	MEK Inhibitor RO4987655	B	Sensitivity/Response	24947927	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	B	Sensitivity/Response	23200175	CiViC
KRAS	MUTATION	Pancreatic Adenocarcinoma	SCH772984,PI3Kbeta Inhibitor AZD8186	D	Sensitivity/Response	26725216	CiViC
KRAS	MUTATION	Colorectal Cancer	Teprotumumab,Selumetinib	D	Sensitivity/Response	21985784	CiViC
MRE11	MUTATION	Prostate Cancer	Olaparib	B	Sensitivity/Response	26510020	CiViC
ERBB2	MUTATION	Lung Adenocarcinoma	Trastuzumab	C	Sensitivity/Response	26598547	CiViC
PML	MUTATION	Acute Promyelocytic Leukemia	Tretinoin	B	Resistance	23670176	CiViC
KRAS	MUTATION	Colorectal Cancer	Chemotherapy,Bevacizumab	B	Resistance	23828442	CiViC
KRAS	MUTATION	Cancer	G-573,MEK Inhibitor GDC-0623	D	Sensitivity/Response	23934108	CiViC
TP53	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	D	Sensitivity/Response	22425996	CiViC
TP53	MUTATION	Lung Non-small Cell Carcinoma	Docetaxel	D	Resistance	22425996	CiViC
TP53	MUTATION	Sarcoma	Pazopanib	B	Sensitivity/Response	26646755	CiViC
KRAS	MUTATION	Colorectal Cancer	Ixazomib	D	Resistance	26709701	CiViC
KRAS	MUTATION	Cancer	AZD5438	D	Sensitivity/Response	26881434	CiViC
MET	MUTATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	26729443	CiViC
MET	MUTATION	Lung Adenocarcinoma	Capmatinib	C	Sensitivity/Response	25971938	CiViC
KRAS	MUTATION	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	B	Resistance	27037411	CiViC
GNAQ	MUTATION	Uveal Melanoma	JQ1	D	Sensitivity/Response	26397223	CiViC
GNA11	MUTATION	Uveal Melanoma	JQ1	D	Sensitivity/Response	26397223	CiViC
KRAS	MUTATION	Pancreatic Cancer	Gemcitabine,Erlotinib	B	Resistance	21862683	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Trametinib	B	Sensitivity/Response	22805291	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	B	Sensitivity/Response	16624552	CiViC
KIT	MUTATION	Melanoma	Imatinib	B	Sensitivity/Response	21690468	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Sunitinib	B	Sensitivity/Response	22439647	CiViC
KIT	MUTATION	Melanoma	Sunitinib	C	Sensitivity/Response	22261812	CiViC
NRAS	MUTATION	Skin Melanoma	Docetaxel,Trametinib	B	Sensitivity/Response	25542057	CiViC
GNA11	MUTATION	Uveal Melanoma	Trametinib	C	Sensitivity/Response	22805292	CiViC
GNAQ	MUTATION	Uveal Melanoma	Trametinib	B	Sensitivity/Response	22805292	CiViC
NRAS	MUTATION	Cancer	Trametinib,Metformin	D	Sensitivity/Response	25504439	CiViC
BAP1	MUTATION	Uveal Melanoma	Vorinostat,Trichostatin A,Panobinostat,Valproic Acid	D	Sensitivity/Response	22038994	CiViC
BAP1	MUTATION	Malignant Mesothelioma	Vorinostat,Mocetinostat,MC1568	E	Sensitivity/Response	25970771	CiViC
FGFR2	MUTATION	Endometrial Cancer	Ponatinib	D	Sensitivity/Response	26574622	CiViC
ALK	MUTATION	Lung Non-small Cell Carcinoma	Ceritinib	B	Sensitivity/Response	24670165	CiViC
FLT3	MUTATION	Acute Myeloid Leukemia	Midostaurin	B	Sensitivity/Response	20733134	CiViC
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Everolimus	B	Sensitivity/Response	27091708	CiViC
KRAS	MUTATION	Colorectal Cancer	Irinotecan,Selumetinib	B	Sensitivity/Response	25322874	CiViC
PIK3CA	MUTATION	Head And Neck Cancer	Dactolisib	D	Sensitivity/Response	23619167	CiViC
BRCA1	MUTATION	Cancer	Olaparib	A	Sensitivity/Response	19553641	CiViC
BRCA2	MUTATION	Cancer	Olaparib	A	Sensitivity/Response	19553641	CiViC
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Resistance	17936563	CiViC
PIK3CA	MUTATION	Cancer	Alpelisib	D	Sensitivity/Response	24608574	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Sunitinib	B	Sensitivity/Response	18955458	CiViC
NRAS	MUTATION	Melanoma	Omipalisib,Trametinib	D	Sensitivity/Response	23431193	CiViC
PTEN	MUTATION	Head And Neck Squamous Cell Carcinoma	Taselisib	D	Resistance	26589432	CiViC
NF1	MUTATION	Skin Melanoma	Vemurafenib	D	Resistance	23171796	CiViC
NF1	MUTATION	Skin Melanoma	Sirolimus,MEK Inhibitor PD0325901	D	Sensitivity/Response	23171796	CiViC
NF1	MUTATION	Skin Melanoma	Vemurafenib	C	Resistance	23288408	CiViC
NF1	MUTATION	Skin Melanoma	VTX-11e,AZ628	D	Sensitivity/Response	23288408	CiViC
NRAS	MUTATION	Skin Melanoma	Binimetinib	B	Sensitivity/Response	23414587	CiViC
NRAS	MUTATION	Skin Melanoma	Amuvatinib	D	Sensitivity/Response	24950457	CiViC
SMO	MUTATION	Basal Cell Carcinoma	Sonidegib,Vismodegib	B	Resistance	26546616	CiViC
TP53	MUTATION	Chronic Lymphocytic Leukemia	Alemtuzumab	B	Sensitivity/Response	14726385	CiViC
PIK3CA	MUTATION	Head And Neck Squamous Cell Carcinoma	Taselisib,Radiation Therapy	D	Sensitivity/Response	26589432	CiViC
PTEN	MUTATION	Cancer	Ipatasertib	D	Sensitivity/Response	23287563	CiViC
PIK3CA	MUTATION	Stomach Cancer	Capivasertib	D	Sensitivity/Response	24088382	CiViC
PIK3CA	MUTATION	Cancer	Capivasertib	D	Sensitivity/Response	22294718	CiViC
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Capivasertib	D	Sensitivity/Response	22294718	CiViC
NRAS	MUTATION	Melanoma	Binimetinib	D	Sensitivity/Response	24588908	CiViC
AR	MUTATION	Prostate Cancer	Flutamide,Nilutamide,Cyproterone Acetate,Bicalutamide	B	Resistance	26000489	CiViC
PTEN	MUTATION	Prostate Cancer	Alpelisib,Enzalutamide,PI3Kbeta Inhibitor AZD8186	D	Sensitivity/Response	25544636	CiViC
BRCA1	MUTATION	Ovarian Carcinoma	Platinum Compound	B	Sensitivity/Response	24240112	CiViC
BRCA2	MUTATION	Ovarian Carcinoma	Platinum Compound	B	Sensitivity/Response	24240112	CiViC
BRCA1	MUTATION	Ovarian Carcinoma	Platinum Compound	B	Sensitivity/Response	24240112	CiViC
BRCA2	MUTATION	Ovarian Carcinoma	Platinum Compound	B	Sensitivity/Response	24240112	CiViC
DNMT3A	MUTATION	Acute Myeloid Leukemia	Decitabine	B	Sensitivity/Response	22124213	CiViC
PIK3CA	MUTATION	Breast Cancer	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	D	Sensitivity/Response	25002028	CiViC
PIK3CA	MUTATION	Breast Cancer	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	D	Sensitivity/Response	25002028	CiViC
PIK3CA	MUTATION	Breast Cancer	Everolimus,MTOR Kinase Inhibitor PP242	D	Sensitivity/Response	21358673	CiViC
PIK3R1	MUTATION	Breast Cancer	MTOR Kinase Inhibitor PP242	D	Sensitivity/Response	21358673	CiViC
PIK3CA	MUTATION	Endometrial Cancer	Pictilisib	D	Sensitivity/Response	23674493	CiViC
FBXW7	MUTATION	Cancer	MTOR Inhibitor	B	Sensitivity/Response	24586741	CiViC
KRAS	MUTATION	Hepatocellular Carcinoma	Refametinib,Sorafenib	B	Sensitivity/Response	25294897	CiViC
MET	MUTATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	26845194	CiViC
NF2	MUTATION	Acoustic Neuroma	Everolimus	B	N/A	25567352	CiViC
BRCA1	MUTATION	Ovarian Cancer	Cediranib,Olaparib	B	Sensitivity/Response	25218906	CiViC
BRCA2	MUTATION	Ovarian Cancer	Cediranib,Olaparib	B	Sensitivity/Response	25218906	CiViC
BRCA1	MUTATION	Triple-receptor Negative Breast Cancer	Cisplatin,Carboplatin	B	Sensitivity/Response	25847936	CiViC
BRCA2	MUTATION	Triple-receptor Negative Breast Cancer	Cisplatin,Carboplatin	B	Sensitivity/Response	25847936	CiViC
ERBB2	MUTATION	Bladder Carcinoma	Platinum Compound	C	Sensitivity/Response	25636205	CiViC
KRAS	MUTATION	Colorectal Cancer	Cetuximab	D	Resistance	22586653	CiViC
NRAS	MUTATION	Colorectal Cancer	Cetuximab	D	Resistance	22586653	CiViC
BRAF	MUTATION	Colorectal Cancer	Cetuximab	D	Resistance	22586653	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab	D	Resistance	22586653	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Afatinib	B	Sensitivity/Response	27083334	CiViC
CRBN	MUTATION	Multiple Myeloma	Lenalidomide,Pomalidomide	C	Resistance	23480694	CiViC
BRCA1	MUTATION	Ovarian Cancer	Olaparib	B	Sensitivity/Response	21862407	CiViC
BRCA2	MUTATION	Ovarian Cancer	Olaparib	B	Sensitivity/Response	21862407	CiViC
BRCA1	MUTATION	Triple-receptor Negative Breast Cancer	Olaparib	B	Resistance	21862407	CiViC
POLE	MUTATION	Glioblastoma Multiforme	Pembrolizumab	C	Sensitivity/Response	27683556	CiViC
POLE	MUTATION	Endometrial Cancer	Pembrolizumab	C	Sensitivity/Response	27159395	CiViC
RB1	MUTATION	Lung Small Cell Carcinoma	Chemotherapy	B	Sensitivity/Response	26802149	CiViC
BRCA1	MUTATION	Ovarian Cancer	Rucaparib	B	Sensitivity/Response	27908594	CiViC
ATM	MUTATION	Mantle Cell Lymphoma	Olaparib	D	Sensitivity/Response	20124459	CiViC
FGFR3	MUTATION	Bladder Carcinoma	Infigratinib	B	Sensitivity/Response	27870574	CiViC
FGFR2	MUTATION	Cholangiocarcinoma	Infigratinib	C	Sensitivity/Response	27870574	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	20022809	CiViC
GNA11	MUTATION	Uveal Melanoma	MEK Inhibitor PD0325901,Sotrastaurin Acetate	D	Sensitivity/Response	24141786	CiViC
GNAQ	MUTATION	Uveal Melanoma	MEK Inhibitor PD0325901,Sotrastaurin Acetate	D	Sensitivity/Response	24141786	CiViC
NF1	MUTATION	Plexiform Neurofibroma	Selumetinib	B	Sensitivity/Response	28029918	CiViC
ATM	MUTATION	Prostate Cancer	Olaparib	C	Sensitivity/Response	26510020	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	21258250	CiViC
PIK3CA	MUTATION	Breast Cancer	Trastuzumab	B	Resistance	21594665	CiViC
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Resistance	21594665	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	19692680	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Afatinib	C	Sensitivity/Response	22452896	CiViC
ATM	MUTATION	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
PIK3CA	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Resistance	21258250	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Resistance	21258250	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	B	Sensitivity/Response	14645423	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	B	Sensitivity/Response	18955451	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	14645423	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Imatinib	B	Reduced Sensitivity	18955451	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	15329413	CiViC
TP53	MUTATION	Breast Cancer	Tamoxifen	B	Resistance	10786679	CiViC
TP53	MUTATION	Breast Cancer	Tamoxifen	C	Resistance	10786679	CiViC
TP53	MUTATION	Stomach Carcinoma	Etoposide,Doxorubicin,Cisplatin	C	Sensitivity/Response	14514923	CiViC
DNMT3A	MUTATION	Cancer	Nivolumab,Pembrolizumab,Atezolizumab	B	Resistance	28351930	CiViC
NRAS	MUTATION	Skin Melanoma	Ribociclib,Binimetinib	B	Sensitivity/Response	26987942	CiViC
IDH1	MUTATION	Brain Glioma	Olaparib	D	Sensitivity/Response	28148839	CiViC
NRAS	MUTATION	Skin Melanoma	Binimetinib	B	Sensitivity/Response	28284557	CiViC
EGFR	MUTATION	Lung Cancer	Gefitinib	B	Sensitivity/Response	17409929	CiViC
TP53	MUTATION	Leukemia	RG7112	B	Resistance	26459177	CiViC
TP53	MUTATION	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	MUTATION	Cancer	Nutlin-3a	D	Resistance	17671205	CiViC
CTNNB1	MUTATION	Melanoma	Anti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal Antibody	D	Resistance	25970248	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	A	Resistance	28492898	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	20038723	CiViC
PIK3CA	MUTATION	Cancer	Capivasertib	B	Sensitivity/Response	28489509	CiViC
GNA11	MUTATION	Uveal Melanoma	Cabozantinib	B	Sensitivity/Response	28103611	CiViC
KRAS	MUTATION	Colorectal Cancer	Chemotherapy,Cetuximab	B	Resistance	20619739	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib	B	Sensitivity/Response	15329413	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib	B	Resistance	21969500	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Sunitinib	B	Resistance	18955458	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	C	Reduced Sensitivity	27371698	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	B	Reduced Sensitivity	22614970	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib	C	Sensitivity/Response	21969500	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	B	Sensitivity/Response	23177515	CiViC
BRAF	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	C	Resistance	22614970	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	B	Sensitivity/Response	23177515	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	B	Sensitivity/Response	22614970	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	21531810	CiViC
MET	MUTATION	Lung Adenocarcinoma	Crizotinib	C	Sensitivity/Response	25769807	CiViC
JAK2	MUTATION	Melanoma	Pembrolizumab	C	Resistance	27433843	CiViC
VHL	MUTATION	Renal Cell Carcinoma	Anti-VEGF Monoclonal Antibody	B	Resistance	28103578	CiViC
IDH2	MUTATION	Acute Myeloid Leukemia	Enasidenib	D	Sensitivity/Response	28193778	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Abemaciclib	B	Sensitivity/Response	27217383	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Pemetrexed,Docetaxel,Trametinib	B	Sensitivity/Response	27876675	CiViC
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Atezolizumab,Nivolumab	B	Sensitivity/Response	28525386	CiViC
KRAS	MUTATION	Colorectal Cancer	Binimetinib,Palbociclib	D	Sensitivity/Response	27167191	CiViC
GNAQ	MUTATION	Uveal Melanoma	Cabozantinib	B	Sensitivity/Response	28103611	CiViC
IDH2	MUTATION	Acute Myeloid Leukemia	Enasidenib	B	Sensitivity/Response	28588020	CiViC
FLT3	MUTATION	Acute Myeloid Leukemia	Midostaurin	A	Sensitivity/Response	28546144	CiViC
VHL	MUTATION	Renal Cell Carcinoma	Everolimus	B	Sensitivity/Response	26951309	CiViC
ERBB2	MUTATION	Breast Cancer	Neratinib	B	Sensitivity/Response	28679771	CiViC
BAP1	MUTATION	Renal Cell Carcinoma	Everolimus,Sunitinib	B	Resistance	27751729	CiViC
NRAS	MUTATION	Colorectal Cancer	Cetuximab,Panitumumab	A	Resistance	28275037	CiViC
KRAS	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	A	Resistance	28275037	CiViC
BRCA1	MUTATION	Breast Cancer	Olaparib	B	Sensitivity/Response	28792849	CiViC
BRCA2	MUTATION	Breast Cancer	Olaparib	B	Sensitivity/Response	28792849	CiViC
BRCA2	MUTATION	Pancreatic Cancer	Olaparib	B	Sensitivity/Response	25366685	CiViC
BRCA1	MUTATION	Pancreatic Cancer	Olaparib	B	Sensitivity/Response	25366685	CiViC
BRCA1	MUTATION	Pancreatic Cancer	Oxaliplatin,Cisplatin	B	Sensitivity/Response	25072261	CiViC
BRCA2	MUTATION	Pancreatic Cancer	Platinum Compound	B	Sensitivity/Response	25072261	CiViC
EGFR	MUTATION	Peritoneal Mesothelioma	Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy	B	Sensitivity/Response	20942962	CiViC
BRCA1	MUTATION	Pancreatic Cancer	Veliparib,Cisplatin,Gemcitabine	B	Sensitivity/Response	29338080	CiViC
BRCA2	MUTATION	Pancreatic Cancer	Gemcitabine,Cisplatin,Veliparib	B	Sensitivity/Response	29338080	CiViC
BRCA2	MUTATION	Pancreatic Cancer	Iniparib	C	Sensitivity/Response	21508395	CiViC
PTCH1	MUTATION	Cancer	Vismodegib	B	Sensitivity/Response	29320312	CiViC
ERBB2	MUTATION	Lung Non-small Cell Carcinoma	Pertuzumab,Trastuzumab	B	Sensitivity/Response	29320312	CiViC
NRAS	MUTATION	Melanoma	Dabrafenib,Vemurafenib	B	Resistance	24265155	CiViC
KRAS	MUTATION	Melanoma	Vemurafenib,Dabrafenib	B	Resistance	24265155	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab	B	Resistance	19603024	CiViC
BRAF	MUTATION	Colorectal Cancer	Oxaliplatin	B	Resistance	19603024	CiViC
BRAF	MUTATION	Colorectal Cancer	Irinotecan	B	Resistance	19603024	CiViC
BRAF	MUTATION	Colorectal Cancer	Bevacizumab	B	Resistance	19603024	CiViC
BRAF	MUTATION	Colorectal Cancer	Cetuximab	B	Resistance	19603024	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab,Panitumumab	B	Resistance	19223544	CiViC
PIK3CA	MUTATION	Colorectal Cancer	Aspirin	B	Sensitivity/Response	23094721	CiViC
KIT	MUTATION	Gastrointestinal Stromal Tumor	Regorafenib	B	Sensitivity/Response	27371698	CiViC
STK11	MUTATION	Lung Adenocarcinoma	Pembrolizumab,Nivolumab,Atezolizumab	B	Resistance	29773717	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib	B	Sensitivity/Response	21783417	CiViC
MET	MUTATION	Lung Non-small Cell Carcinoma	Tepotinib	B	Sensitivity/Response	160289	CiViC
IDH1	MUTATION	Acute Myeloid Leukemia	Ivosidenib	A	Sensitivity/Response	29860938	CiViC
FLT3	MUTATION	Acute Myeloid Leukemia	Gilteritinib	B	Sensitivity/Response	28645776	CiViC
PIK3CA	MUTATION	Breast Cancer	Alpelisib,Fulvestrant	A	Sensitivity/Response	31091374	CiViC
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Dacomitinib	B	Sensitivity/Response	28958502	CiViC
FGFR3	MUTATION	Urothelial Carcinoma	Erdafitinib	A	Sensitivity/Response	31340094	CiViC
NFE2L2	MUTATION	Lung Squamous Cell Carcinoma	Sapanisertib	B	Sensitivity/Response	174406	CiViC
IDH1	MUTATION	Cholangiocarcinoma	Ivosidenib	B	Sensitivity/Response	31300360	CiViC
MET	MUTATION	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	123413	CiViC
MET	MUTATION	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	26892698	CiViC
MET	MUTATION	Histiocytic And Dendritic Cell Cancer	Crizotinib	C	Sensitivity/Response	25971938	CiViC
MET	MUTATION	Cancer	Capmatinib	D	Sensitivity/Response	25971938	CiViC
FGFR2	MUTATION	Cholangiocarcinoma	Infigratinib	B	Sensitivity/Response	29182496	CiViC
FGFR3	MUTATION	Urinary Bladder Cancer	Gemcitabine,Cisplatin	B	Sensitivity/Response	29941343	CiViC
SLCO1B1	p.N130D	Cancer	Methotrexate	B	Adverse Response	23652803	CiViC
PRPS1	p.N144S	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	25962120	CiViC
PRPS1	p.N144S	Childhood B-cell Acute Lymphoblastic Leukemia	Cytarabine	D	Sensitivity/Response	25962120	CiViC
ATM	p.N2875H	Prostate Cancer	Olaparib	C	Sensitivity/Response	26510020	CiViC
ABL1	p.N336S	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
BRAF	p.N486_P490del	Pancreatic Cancer	Trametinib	C	Sensitivity/Response	29903880	CiViC
FGFR1	p.N546K	Ewing Sarcoma Of Bone	Ponatinib	E	Sensitivity/Response	26179511	CiViC
FGFR2	p.N550K	Endometrial Cancer	PD173074	D	Sensitivity/Response	18757403	CiViC
PIK3R2	p.N561D	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
KIT	p.N822K	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
KIT	p.N822K	Gastrointestinal Stromal Tumor	Regorafenib	D	Resistance	25239608	CiViC
KIT	p.N822K	Gastrointestinal Stromal Tumor	Regorafenib	C	Sensitivity/Response	22614970	CiViC
KIT	p.N822K	Acute Myeloid Leukemia	Ponatinib	D	Sensitivity/Response	21482694	CiViC
KIT	p.N822K	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	D	Resistance	25239608	CiViC
EGFR	p.N826S	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	19147750	CiViC
ERBB2	p.N857S	Ovarian Cancer	Lapatinib	D	Sensitivity/Response	22046346	CiViC
IGF2	OVEREXPRESSION	Prostate Cancer	Linsitinib	D	N/A	25670080	CiViC
IGF2	OVEREXPRESSION	Prostate Cancer	Linsitinib,Docetaxel,Cabazitaxel	D	Sensitivity/Response	25670080	CiViC
AURKA	OVEREXPRESSION	Cervical Adenocarcinoma	Paclitaxel	D	Resistance	12559175	CiViC
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	B	Sensitivity/Response	22056021	CiViC
ERBB3	OVEREXPRESSION	Colorectal Cancer	Cetuximab	B	Resistance	25520391	CiViC
NT5E	OVEREXPRESSION	Colorectal Cancer	Cetuximab	B	Sensitivity/Response	25520391	CiViC
MYD88	OVEREXPRESSION	Breast Cancer	Paclitaxel	D	Resistance	26596839	CiViC
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	B	Sensitivity/Response	26439803	CiViC
SYK	OVEREXPRESSION	Ovarian Cancer	Paclitaxel	D	Resistance	26096845	CiViC
PBK	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	D	Resistance	26745678	CiViC
CCND1	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Tamoxifen	B	Resistance	15138475	CiViC
AR	OVEREXPRESSION	Breast Cancer	Dactolisib	D	Sensitivity/Response	24356815	CiViC
AURKA	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin	B	Resistance	25082261	CiViC
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Erlotinib,Bevacizumab	B	Sensitivity/Response	24039832	CiViC
TIMP1	OVEREXPRESSION	Breast Cancer	Fulvestrant	D	Resistance	23881388	CiViC
PTP4A3	OVEREXPRESSION	Colorectal Cancer	Cetuximab	D	Sensitivity/Response	23867504	CiViC
TIMP1	OVEREXPRESSION	Breast Cancer	Paclitaxel	B	Resistance	22544540	CiViC
JAK1	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Enzastaurin	D	Sensitivity/Response	22333600	CiViC
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	B	Sensitivity/Response	16707605	CiViC
DDX43	OVEREXPRESSION	Uveal Melanoma	Selumetinib,Trametinib,MEK Inhibitor PD0325901	D	Resistance	24899684	CiViC
TBK1	OVEREXPRESSION	Melanoma	AZ909,Selumetinib	D	Sensitivity/Response	24962318	CiViC
HAVCR2	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD1 Inhibitor	C	Resistance	26883990	CiViC
HAVCR2	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD1 Inhibitor,Anti-TIM-3 Monoclonal Antibody	D	Sensitivity/Response	26883990	CiViC
ERBB3	OVEREXPRESSION	Cancer	Selumetinib,Afatinib	D	Sensitivity/Response	24685132	CiViC
ERBB3	OVEREXPRESSION	Cancer	HER2 Inhibitor CP-724,714,Gefitinib,Selumetinib	D	Resistance	24685132	CiViC
SIRT1	OVEREXPRESSION	Pancreatic Cancer	Niacinamide	D	Resistance	24088390	CiViC
RB1	OVEREXPRESSION	Pancreatic Adenocarcinoma	Mitomycin,Gemcitabine,Doxorubicin,Fluorouracil	D	Resistance	11792751	CiViC
BIRC5	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Trastuzumab	B	Resistance	23204226	CiViC
RET	OVEREXPRESSION	Papillary Adenocarcinoma	Sunitinib	C	Sensitivity/Response	20696054	CiViC
CDK6	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Fulvestrant	B	Resistance	27252418	CiViC
CDK6	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Palbociclib,Fulvestrant	D	Sensitivity/Response	27252418	CiViC
FLT3	OVEREXPRESSION	Adult B-Lymphoblastic Leukemia	Sunitinib	C	Sensitivity/Response	27181063	CiViC
ESR1	OVEREXPRESSION	Breast Cancer	Palbociclib,Letrozole	B	Sensitivity/Response	25524798	CiViC
CCND1	OVEREXPRESSION	Mantle Cell Lymphoma	Palbociclib	D	Sensitivity/Response	16690963	CiViC
PTGS2	OVEREXPRESSION	Colorectal Cancer	Aspirin	B	Sensitivity/Response	17522398	CiViC
MET	OVEREXPRESSION	Skin Melanoma	Vemurafenib	B	Resistance	26359985	CiViC
MET	OVEREXPRESSION	Uveal Melanoma	Crizotinib	D	Sensitivity/Response	24140933	CiViC
JUN	OVEREXPRESSION	Colorectal Adenocarcinoma	Irbesartan	C	Sensitivity/Response	27022066	CiViC
FOS	OVEREXPRESSION	Colon Adenocarcinoma	Irbesartan	C	Sensitivity/Response	27022066	CiViC
AURKA	OVEREXPRESSION	Ovarian Serous Carcinoma	Platinum Compound	B	Resistance	27209210	CiViC
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib	D	Resistance	27451907	CiViC
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib	B	Resistance	27451907	CiViC
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib,SGK1-Inh	D	Sensitivity/Response	27451907	CiViC
CCNE1	OVEREXPRESSION	Ovarian Cancer	CDK Inhibitor SNS-032	D	Sensitivity/Response	26204491	CiViC
RRM1	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine	D	Resistance	17224927	CiViC
RRM2	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine	D	Resistance	17224927	CiViC
AKT3	OVEREXPRESSION	Breast Cancer	Akt Inhibitor MK2206	D	Resistance	27297869	CiViC
AKT3	OVEREXPRESSION	Triple-receptor Negative Breast Cancer	Pan-AKT Kinase Inhibitor GSK690693	E	Sensitivity/Response	24335962	CiViC
ERBB2	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Lapatinib	C	Sensitivity/Response	28061634	CiViC
TP53	OVEREXPRESSION	Stomach Cancer	Mitomycin,Etoposide,Cisplatin	B	Sensitivity/Response	14514923	CiViC
CTAG1B	OVEREXPRESSION	Multiple Myeloma	Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794	B	Sensitivity/Response	26193344	CiViC
CTAG2	OVEREXPRESSION	Multiple Myeloma	Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794	B	Sensitivity/Response	26193344	CiViC
MERTK	OVEREXPRESSION	Melanoma	UNC1062	D	Sensitivity/Response	23585477	CiViC
MYC	OVEREXPRESSION	Lung Small Cell Carcinoma	Prexasertib,Cisplatin,Olaparib	D	Sensitivity/Response	28490518	CiViC
TP53	OVEREXPRESSION	Ovarian Cancer	Carboplatin,Cisplatin	B	Resistance	11595686	CiViC
MET	OVEREXPRESSION	Uveal Melanoma	Selumetinib,Trametinib	D	Resistance	25952648	CiViC
ERBB2	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	B	Sensitivity/Response	28526536	CiViC
CHEK1	OVEREXPRESSION	Lung Small Cell Carcinoma	Prexasertib,Cisplatin,Olaparib	D	Sensitivity/Response	28490518	CiViC
MYC	OVEREXPRESSION	Multiple Myeloma	JQ-1	D	Sensitivity/Response	21889194	CiViC
ERBB2	OVEREXPRESSION	Salivary Gland Cancer	Paclitaxel,Trastuzumab	C	Sensitivity/Response	23826550	CiViC
ERBB2	OVEREXPRESSION	Salivary Gland Cancer	Capecitabine,Trastuzumab,Zoledronic Acid	C	Sensitivity/Response	20504363	CiViC
AKT3	OVEREXPRESSION	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
PARP1	OVEREXPRESSION	Malignant Peripheral Nerve Sheath Tumor	Olaparib	D	Sensitivity/Response	26650448	CiViC
CDK6	OVEREXPRESSION	Glioblastoma Proneural Subtype	Palbociclib	D	Sensitivity/Response	28903422	CiViC
IL6	OVEREXPRESSION	Rhabdomyosarcoma	Bazedoxifene	D	Resistance	28672024	CiViC
PDGFRA	OVEREXPRESSION	Rhabdomyosarcoma	Sunitinib	D	Sensitivity/Response	19366796	CiViC
PDGFRB	OVEREXPRESSION	Dermatofibrosarcoma Protuberans	Sunitinib	C	Sensitivity/Response	29760553	CiViC
ARID1A	p.P1175FS*5	Ovarian Clear Cell Carcinoma	Dasatinib	D	Sensitivity/Response	27364904	CiViC
MAP2K1	p.P124S	Melanoma	Selumetinib	D	Resistance	19915144	CiViC
NQO1	p.P187S	Lung Cancer	Amrubicin	D	Sensitivity/Response	21964527	CiViC
MTOR	p.P2213S	Melanoma	PI3K/BET Inhibitor LY294002,Capivasertib	D	Sensitivity/Response	26490311	CiViC
RAC1	p.P29S	Melanoma	Vemurafenib,Dabrafenib	D	Resistance	25056119	CiViC
PIK3CA	p.P471L	Merkel Cell Carcinoma	Idelalisib	C	Sensitivity/Response	26466009	CiViC
TP53	p.P47S	Cancer	Cisplatin	E	Resistance	27034505	CiViC
KIT	p.P551_E554delPMYE	Gastrointestinal Stromal Tumor	Ponatinib	D	Sensitivity/Response	25239608	CiViC
PDGFRA	p.P577S	Melanoma	Imatinib,Crenolanib	D	Sensitivity/Response	24132921	CiViC
EGFR	p.P753S	Skin Squamous Cell Carcinoma	Sirolimus,Cetuximab	C	Sensitivity/Response	24934779	CiViC
EGFR	p.P772_H773insYNP	Lung Non-small Cell Carcinoma	Erlotinib	C	Resistance	24353160	CiViC
EGFR	p.P772_V774insPHV	Lung Adenocarcinoma	Erlotinib	C	Resistance	24353160	CiViC
ERBB2	p.P780INS	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
ERBB2	p.P780INS	Lung Adenocarcinoma	Dacomitinib	C	Sensitivity/Response	25899785	CiViC
ABL1	PHOSPHORYLATION	Chronic Myeloid Leukemia	Imatinib	C	Resistance	12623848	CiViC
PRKAA2	PHOSPHORYLATION	Cancer	ACLY SiRNA	E	Sensitivity/Response	23506848	CiViC
EIF4EBP1	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	D	Sensitivity/Response	23340172	CiViC
EGFR	PHOSPHORYLATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	22901364	CiViC
RPS6	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	D	Sensitivity/Response	22343617	CiViC
EIF4EBP1	PHOSPHORYLATION	Colorectal Cancer	MTOR Kinase Inhibitor PP242,Dactolisib,WYE354	D	Resistance	22262166	CiViC
RB1	PHOSPHORYLATION	Breast Cancer	Alpelisib	B	Resistance	25002028	CiViC
TSC2	p.Q1178*	Thyroid Gland Carcinoma	Everolimus	C	Sensitivity/Response	25295501	CiViC
BRCA1	p.Q1467*	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
NRAS	p.Q179X	Colorectal Cancer	Cetuximab	B	Resistance	25666295	CiViC
GNAQ	p.Q209	Uveal Melanoma	Refametinib	C	Sensitivity/Response	23434733	CiViC
GNAQ	p.Q209P	Skin Melanoma	Vemurafenib	C	Resistance	24504448	CiViC
GNAQ	p.Q209P	Skin Melanoma	PLX4720	D	Resistance	24504448	CiViC
KRAS	p.Q22*	Colon Mucinous Adenocarcinoma	Panitumumab	C	Resistance	19661358	CiViC
ABL1	p.Q252H	Chronic Myeloid Leukemia	Imatinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.Q252H	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.Q252H	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.Q252H	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.Q252H	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.Q300R	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
XRCC1	p.Q399R	Cervical Cancer	Carboplatin,Cisplatin	B	Sensitivity/Response	16875718	CiViC
ARID1A	p.Q456*	Ovarian Clear Cell Carcinoma	Dasatinib	D	Sensitivity/Response	27364904	CiViC
JAK1	p.Q503*	Skin Melanoma	Pembrolizumab	C	Resistance	27433843	CiViC
MAP2K1	p.Q56_V60del	Ovarian Serous Carcinoma	Selumetinib	C	Sensitivity/Response	26324360	CiViC
MAP2K1	p.Q56P	Melanoma	Selumetinib	D	Resistance	19915144	CiViC
NRAS	p.Q61	Melanoma	Vemurafenib	B	Resistance	23569304	CiViC
NRAS	p.Q61	Colorectal Cancer	Cetuximab	B	Resistance	20619739	CiViC
NRAS	p.Q61	Skin Melanoma	Binimetinib	B	Sensitivity/Response	23414587	CiViC
NRAS	p.Q61	Skin Melanoma	Selumetinib	C	Sensitivity/Response	18390968	CiViC
KRAS	p.Q61	Colorectal Cancer	Chemotherapy,Cetuximab	B	Resistance	20619739	CiViC
KRAS	p.Q61H	Colorectal Cancer	Chemotherapy,Cetuximab	C	Resistance	20619739	CiViC
KRAS	p.Q61H	Colorectal Cancer	Cetuximab	C	Resistance	22722830	CiViC
NRAS	p.Q61K	Neuroblastoma	Binimetinib,Everolimus	D	Sensitivity/Response	26821351	CiViC
NRAS	p.Q61K	Skin Melanoma	Vemurafenib	D	Resistance	22194965	CiViC
NRAS	p.Q61K	Skin Melanoma	Selumetinib	D	Sensitivity/Response	22194965	CiViC
NRAS	p.Q61K	Colorectal Cancer	Selumetinib,Dactolisib	D	Sensitivity/Response	22392911	CiViC
NRAS	p.Q61K	Lung Non-small Cell Carcinoma	Selumetinib,Trametinib	D	Sensitivity/Response	23515407	CiViC
KRAS	p.Q61K	Colorectal Cancer	Chemotherapy,Cetuximab	C	Resistance	20619739	CiViC
NRAS	p.Q61L	Melanoma	Temozolomide	C	Sensitivity/Response	21576590	CiViC
KRAS	p.Q61L	Colorectal Cancer	Chemotherapy,Cetuximab	C	Resistance	20619739	CiViC
NRAS	p.Q61R	Melanoma	Temozolomide	C	Sensitivity/Response	21576590	CiViC
KRAS	p.Q61R	Colorectal Cancer	Irinotecan,Cetuximab	C	Resistance	20619739	CiViC
AKT1	p.Q79K	Melanoma	Vemurafenib	D	Resistance	24265152	CiViC
AKT1	p.Q79K	Melanoma	Vemurafenib	D	Resistance	24265155	CiViC
AKT1	p.Q79K	Melanoma	Dabrafenib	C	Resistance	24265155	CiViC
MET	p.R1004G	Head And Neck Cancer	Crizotinib	C	Sensitivity/Response	31391294	CiViC
ERBB3	p.R103G	Urothelial Carcinoma	Afatinib	B	Sensitivity/Response	27044931	CiViC
EGFR	p.R108K	Malignant Glioma	Erlotinib	D	Sensitivity/Response	17177598	CiViC
ALK	p.R1275Q	Neuroblastoma	TAE684	D	Sensitivity/Response	18923525	CiViC
ALK	p.R1275Q	Neuroblastoma	TAE684	D	Resistance	18923525	CiViC
ALK	p.R1275Q	Neuroblastoma	Crizotinib	D	Sensitivity/Response	22072639	CiViC
ALK	p.R1275Q	Neuroblastoma	Crizotinib	C	Sensitivity/Response	23598171	CiViC
ALK	p.R1275Q	Neuroblastoma	Crizotinib	C	Sensitivity/Response	23598171	CiViC
ALK	p.R1275Q	Neuroblastoma	Lorlatinib	D	Sensitivity/Response	26554404	CiViC
PTEN	p.R130*	Thyroid Cancer	Perifosine,Temsirolimus	D	Sensitivity/Response	19706758	CiViC
IDH1	p.R132	Malignant Glioma	Bevacizumab,Sunitinib	B	Sensitivity/Response	22199315	CiViC
IDH1	p.R132	Malignant Glioma	Bevacizumab	B	Sensitivity/Response	22199315	CiViC
IDH1	p.R132	Intrahepatic Cholangiocarcinoma	Dasatinib	D	Sensitivity/Response	27231123	CiViC
IDH1	p.R132C	Acute Myeloid Leukemia	GSK321	D	Sensitivity/Response	26436839	CiViC
IDH1	p.R132C	Brain Glioma	Temozolomide	B	Sensitivity/Response	20975057	CiViC
IDH1	p.R132C	Malignant Glioma	AGI-5198	D	Sensitivity/Response	23558169	CiViC
IDH1	p.R132C	Acute Myeloid Leukemia	Ivosidenib	B	Sensitivity/Response	25583779	CiViC
IDH1	p.R132C	Acute Myeloid Leukemia	BPTES	D	Sensitivity/Response	24333121	CiViC
IDH1	p.R132H	Anaplastic Oligodendroglioma	AGI-5198	D	Sensitivity/Response	23558169	CiViC
BRCA1	p.R1443*	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA1	p.R1495M	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
TP53	p.R158H	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R158L	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
PREX2	p.R172I	Melanoma	Vemurafenib	C	Resistance	24265155	CiViC
TP53	p.R175H	Breast Cancer	Doxorubicin	D	Sensitivity/Response	22698404	CiViC
TP53	p.R175H	Stomach Carcinoma	EAP Protocol	C	Sensitivity/Response	14514923	CiViC
TP53	p.R175H	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
XRCC1	p.R194W	Lung Non-small Cell Carcinoma	Docetaxel,Gemcitabine,Vinorelbine	B	Sensitivity/Response	19157633	CiViC
GNAS	p.R201C	Colorectal Cancer	Vemurafenib,Irinotecan,Cetuximab	C	Resistance	27729313	CiViC
GNAS	p.R201H	Follicular Thyroid Carcinoma	Radioactive Iodine	C	Sensitivity/Response	26788326	CiViC
TP53	p.R213P	Stomach Carcinoma	EAP Protocol	C	Sensitivity/Response	14514923	CiViC
PTEN	p.R233*	Breast Cancer	MTOR Inhibitor	D	Sensitivity/Response	20085938	CiViC
BRCA2	p.R2336H	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA2	p.R2336P	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
NT5C2	p.R238W	Childhood Acute Lymphocytic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	23377183	CiViC
TP53	p.R248Q	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R248W	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R249	Breast Cancer	Doxorubicin	B	Sensitivity/Response	9569050	CiViC
TP53	p.R249S	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
CDK4	p.R24C	Skin Melanoma	Palbociclib	D	Sensitivity/Response	24495407	CiViC
TP53	p.R273C	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R273H	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R273H	Osteosarcoma	Doxorubicin,Methotrexate	D	Resistance	17363498	CiViC
TP53	p.R273L	Ovarian Cancer	Cisplatin,Carboplatin	C	Resistance	11595686	CiViC
TP53	p.R280K	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R280T	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.R282L	Stomach Carcinoma	EAP Protocol	C	Sensitivity/Response	14514923	CiViC
ATM	p.R3008C	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
ABL1	p.R351W	Lung Non-small Cell Carcinoma	Dasatinib	D	Sensitivity/Response	26758680	CiViC
ABL1	p.R351W	Lung Non-small Cell Carcinoma	Imatinib	D	Sensitivity/Response	26758680	CiViC
NT5C2	p.R367Q	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	23377281	CiViC
NT5C2	p.R367Q	Childhood Acute Lymphocytic Leukemia	Mercaptopurine,Thioguanine	C	Resistance	23377183	CiViC
NT5C2	p.R367Q	Childhood Acute Lymphocytic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	23377183	CiViC
EGFR	p.R451C	Colorectal Cancer	Panitumumab,Cetuximab,Futuximab/Modotuximab Mixture	D	Sensitivity/Response	26888827	CiViC
ERBB2	p.R678Q	Breast Cancer	Lapatinib,Neratinib	D	Sensitivity/Response	23220880	CiViC
BRCA1	p.R71G	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA1	p.R71K	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
EGFR	p.R776C	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	19147750	CiViC
EGFR	p.R831H	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
PDGFRA	p.R841K	Melanoma	Imatinib,Crenolanib	D	Sensitivity/Response	24132921	CiViC
DNMT3A	p.R882	Acute Myeloid Leukemia	Idarubicin	B	Sensitivity/Response	22081665	CiViC
ERBB2	p.R896C	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
KDR	p.R961W	Colorectal Adenocarcinoma	Regorafenib	C	Sensitivity/Response	27004155	CiViC
PRPS1	p.S103I	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	25962120	CiViC
PRPS1	p.S103N	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	25962120	CiViC
PRPS1	p.S103T	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	25962120	CiViC
ALK	p.S1206Y	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	22277784	CiViC
ALK	p.S1206Y	Cancer	Ceritinib	D	Sensitivity/Response	24675041	CiViC
B2M	p.S14FS	Skin Melanoma	Pembrolizumab	C	Resistance	27433843	CiViC
ARAF	p.S214C	Lung Non-small Cell Carcinoma	Sorafenib	C	Sensitivity/Response	24569458	CiViC
ARAF	p.S214C	Lung Non-small Cell Carcinoma	Sorafenib	D	Sensitivity/Response	24569458	CiViC
ARAF	p.S214C	Lung Non-small Cell Carcinoma	Trametinib	D	Sensitivity/Response	24569458	CiViC
MTOR	p.S2215Y	Endometrial Adenocarcinoma	Sirolimus	D	Sensitivity/Response	24631838	CiViC
FGFR3	p.S249C	Urothelial Carcinoma	Pazopanib	C	Sensitivity/Response	25766722	CiViC
ERBB2	p.S310F/Y	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	D	Sensitivity/Response	26243863	CiViC
NT5C2	p.S445F	Childhood Acute Lymphocytic Leukemia	Thioguanine,Mercaptopurine	D	Resistance	23377183	CiViC
ESR1	p.S463P	Estrogen-receptor Positive Breast Cancer	Aromatase Inhibitor	D	Resistance	24185512	CiViC
ARAF	p.S490T	Colorectal Cancer	Cetuximab,Vemurafenib,Irinotecan	C	Resistance	27729313	CiViC
EGFR	p.S492R	Colorectal Cancer	Cetuximab	C	Resistance	22270724	CiViC
EGFR	p.S492R	Colorectal Cancer	Panitumumab	C	Sensitivity/Response	22270724	CiViC
EGFR	p.S492R	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	D	Sensitivity/Response	26888827	CiViC
EGFR	p.S492R	Colorectal Cancer	Cetuximab	D	Resistance	26888827	CiViC
KIT	p.S628N	Cancer	Imatinib,Dasatinib	D	Sensitivity/Response	25317746	CiViC
JAK1	p.S703I	Hepatocellular Carcinoma	Ruxolitinib	D	Sensitivity/Response	26701727	CiViC
EGFR	p.S720	Lung Adenocarcinoma	Erlotinib	C	Resistance	26773740	CiViC
EGFR	p.S768I	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	25521405	CiViC
EGFR	p.S768I	Lung Adenocarcinoma	Gefitinib	C	Sensitivity/Response	20522446	CiViC
EGFR	p.S768I	Lung Adenocarcinoma	Erlotinib	C	Resistance	22895145	CiViC
EGFR	p.S768I	Lung Adenocarcinoma	Erlotinib	D	Resistance	19147750	CiViC
DDR2	p.S768R	Lung Non-small Cell Carcinoma	Dasatinib,Erlotinib	C	Sensitivity/Response	22328973	CiViC
ABCB1	p.S893T	Ovarian Cancer	Paclitaxel	B	Sensitivity/Response	16467099	CiViC
FLT3	p.T227M	Renal Cell Carcinoma	Sunitinib	B	Adverse Response	19667267	CiViC
EGFR	p.T263P	Malignant Glioma	Erlotinib	D	Sensitivity/Response	17177598	CiViC
ATM	p.T2666A	Chronic Lymphocytic Leukemia	Doxorubicin	D	Resistance	23585524	CiViC
PRPS1	p.T303S	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	D	Resistance	25962120	CiViC
ABL1	p.T315A	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.T315A	Chronic Myeloid Leukemia	Axitinib	D	Sensitivity/Response	25686603	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib	B	Resistance	20537386	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib	D	Resistance	15194504	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Ponatinib	B	Sensitivity/Response	23190221	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Nilotinib	D	Resistance	19075254	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	22371878	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Bosutinib	C	Resistance	21865346	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Dasatinib	B	Resistance	19779040	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Axitinib	C	Sensitivity/Response	25686603	CiViC
ABL1	p.T315I	Acute Lymphoblastic Leukemia	Dasatinib	C	Resistance	17264298	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Dasatinib,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
ABL1	p.T315I	Acute Lymphoblastic Leukemia	Imatinib,Nilotinib,Dasatinib	D	Resistance	25686603	CiViC
ABL1	p.T315I	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib	D	Resistance	25686603	CiViC
ABL1	p.T315V	Chronic Myeloid Leukemia	Axitinib	D	Sensitivity/Response	25686603	CiViC
BTK	p.T316A	Chronic Lymphocytic Leukemia	Ibrutinib	C	Resistance	27626698	CiViC
GNAS	p.T393C	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Resistance	24758907	CiViC
GNAS	p.T393C	Esophageal Cancer	Cisplatin,Fluorouracil	B	Resistance	19274060	CiViC
KIT	p.T417_D419delinsY	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	18955451	CiViC
CSF3R	p.T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	D	Sensitivity/Response	24081659	CiViC
CSF3R	p.T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	C	Sensitivity/Response	25180155	CiViC
KIT	p.T670I	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
KIT	p.T670I	Gastrointestinal Stromal Tumor	Regorafenib	D	Resistance	25239608	CiViC
KIT	p.T670I	Gastrointestinal Stromal Tumor	Imatinib	D	Resistance	25239608	CiViC
PDGFRA	p.T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	C	Resistance	12660384	CiViC
PDGFRA	p.T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib	D	Sensitivity/Response	24407160	CiViC
PDGFRA	p.T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	C	Resistance	21818111	CiViC
EGFR	p.T785A	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Erlotinib	A	Resistance	25668228	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Gefitinib	B	Resistance	15728811	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Dacomitinib	B	Resistance	21430269	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Pemetrexed,Erlotinib	C	Sensitivity/Response	24636847	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Staurosporine	E	Sensitivity/Response	24658966	CiViC
EGFR	p.T790M	Lung Cancer	Multikinase Inhibitor AEE788,Gefitinib	D	Resistance	18227510	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Rociletinib	B	Sensitivity/Response	25923550	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Rociletinib	D	Sensitivity/Response	24065731	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Osimertinib	D	Sensitivity/Response	24893891	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Osimertinib	B	Sensitivity/Response	25923549	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Osimertinib	B	Sensitivity/Response	26720284	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	D	Sensitivity/Response	26515464	CiViC
EGFR	p.T790M	Lung Adenocarcinoma	Gefitinib,Erlotinib	B	Resistance	23470965	CiViC
EGFR	p.T790M	Lung Adenocarcinoma	Osimertinib	C	Sensitivity/Response	26181354	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Osimertinib	A	Sensitivity/Response	26729184	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Erlotinib,Afatinib,Gefitinib	B	Resistance	27304188	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Afatinib	B	Resistance	24035188	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Osimertinib	A	Sensitivity/Response	27959700	CiViC
EGFR	p.T790M	Lung Adenocarcinoma	Osimertinib	C	Sensitivity/Response	26269204	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Gefitinib	C	Resistance	15737014	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Gefitinib	C	Resistance	17020982	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Lapatinib	D	Resistance	18408761	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Dacomitinib	D	Sensitivity/Response	18089823	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Neratinib	D	Sensitivity/Response	16818618	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Afatinib	D	Sensitivity/Response	21732342	CiViC
EGFR	p.T790M	Lung Non-small Cell Carcinoma	Canertinib	D	Sensitivity/Response	18408761	CiViC
EGFR	p.T790M	Cancer	Erlotinib	D		19147750	CiViC
ERBB2	p.T862A	Stomach Carcinoma	Lapatinib	D	Sensitivity/Response	22046346	CiViC
ERBB3	p.V104M	Urothelial Carcinoma	Afatinib	B	Sensitivity/Response	27044931	CiViC
ALK	p.V1180L	Lung Non-small Cell Carcinoma	Alectinib	D	Resistance	25228534	CiViC
ALK	p.V1180L	Lung Non-small Cell Carcinoma	Crizotinib	D	Resistance	25228534	CiViC
ALK	p.V1180L	Lung Non-small Cell Carcinoma	Ceritinib	D	Sensitivity/Response	25228534	CiViC
ALK	p.V1180L	Lung Non-small Cell Carcinoma	TAE684	D	Sensitivity/Response	25228534	CiViC
ALK	p.V1180L	Lung Non-small Cell Carcinoma	Brigatinib	D	Sensitivity/Response	25228534	CiViC
TP53	p.V157F	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
BRCA2	p.V159M	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA2	p.V211I	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
BRCA2	p.V211L	Ovarian Cancer	Rucaparib	C	Sensitivity/Response	27908594	CiViC
ATM	p.V2288FS*1	Prostate Cancer	Olaparib	C	Sensitivity/Response	26510020	CiViC
PTPRD	p.V253I	Ewing Sarcoma Of Bone	Teprotumumab,Cixutumumab	C	Sensitivity/Response	23800680	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Nilotinib	D	Sensitivity/Response	19075254	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Bosutinib	C	Reduced Sensitivity	22371878	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Dasatinib	C	Resistance	19779040	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	15705718	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Dasatinib	D	Resistance	16772610	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Imatinib Mesylate	B	Resistance	22371878	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Axitinib	D	Sensitivity/Response	25686603	CiViC
ABL1	p.V299L	Chronic Myeloid Leukemia	Dasatinib,Ponatinib	D	Sensitivity/Response	25686603	CiViC
PTEN	p.V317FS	Skin Melanoma	MEK Inhibitor CI-1040,Akt Inhibitor MK2206	D	Sensitivity/Response	24504448	CiViC
ABL1	p.V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	17264298	CiViC
KIT	p.V555_V559DEL	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.V559D	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	22114577	CiViC
KIT	p.V559D	Cancer	PD-180970,Sunitinib,Dasatinib,Imatinib,Tandutinib	D	Sensitivity/Response	16046538	CiViC
KIT	p.V559D	Gastrointestinal Stromal Tumor	Ponatinib,Regorafenib,Imatinib	D	Sensitivity/Response	25239608	CiViC
KIT	p.V560_L576DEL	Gastrointestinal Stromal Tumor	Regorafenib	D	Sensitivity/Response	25239608	CiViC
KIT	p.V560D	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.V560D	Gastrointestinal Stromal Tumor	Sunitinib,Regorafenib,Ponatinib,Imatinib	D	Sensitivity/Response	25239608	CiViC
KIT	p.V560D	Cancer	Imatinib Mesylate	D	Sensitivity/Response	18955458	CiViC
KIT	p.V560DEL	Thymic Carcinoma	Imatinib	C	Sensitivity/Response	15201427	CiViC
KIT	p.V560G	Gastrointestinal Stromal Tumor	Ponatinib,Imatinib,Regorafenib	D	Sensitivity/Response	25239608	CiViC
PDGFRA	p.V561A	Gastrointestinal Stromal Tumor	Imatinib	D	Sensitivity/Response	12949711	CiViC
PDGFRA	p.V561D	Gastrointestinal Stromal Tumor	Imatinib	C	Sensitivity/Response	18955451	CiViC
KIT	p.V569_L576DEL	Gastrointestinal Stromal Tumor	Sunitinib	B	Sensitivity/Response	26772734	CiViC
BRAF	p.V600	Colorectal Cancer	Panitumumab	B	Resistance	23325582	CiViC
BRAF	p.V600	Melanoma	Dabrafenib,Trametinib	B	Sensitivity/Response	23020132	CiViC
BRAF	p.V600	Melanoma	MEK Inhibitor RO4987655	B	Sensitivity/Response	24947927	CiViC
BRAF	p.V600	Melanoma	Refametinib	C	Resistance	23434733	CiViC
BRAF	p.V600	Melanoma	Dabrafenib	B	Sensitivity/Response	22608338	CiViC
BRAF	p.V600	Skin Melanoma	Trametinib,Dabrafenib	A	Sensitivity/Response	25399551	CiViC
BRAF	p.V600	Colorectal Cancer	Trametinib,Dabrafenib	B	Sensitivity/Response	26392102	CiViC
BRAF	p.V600	Melanoma	Cobimetinib,Vemurafenib	B	Sensitivity/Response	25265494	CiViC
BRAF	p.V600	Lung Non-small Cell Carcinoma	Vemurafenib	B	Sensitivity/Response	26287849	CiViC
BRAF	p.V600	Langerhans-Cell Histiocytosis	Vemurafenib	B	Sensitivity/Response	26287849	CiViC
BRAF	p.V600	Colorectal Cancer	Vemurafenib	B	Resistance	26287849	CiViC
BRAF	p.V600	Melanoma	Trametinib	B	Sensitivity/Response	22663011	CiViC
BRAF	p.V600	Cholangiocarcinoma	Vemurafenib	B	Sensitivity/Response	26287849	CiViC
BRAF	p.V600	Melanoma	Cobimetinib,Vemurafenib	A	Sensitivity/Response	27480103	CiViC
BRAF	p.V600	Colorectal Cancer	Cetuximab,Encorafenib	B	Sensitivity/Response	28363909	CiViC
BRAF	p.V600	Colorectal Cancer	Encorafenib,Cetuximab,Alpelisib	B	Sensitivity/Response	28363909	CiViC
BRAF	p.V600	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	28891408	CiViC
BRAF	p.V600	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	25265492	CiViC
BRAF	p.V600	Melanoma	Vemurafenib,Cobimetinib	B	Sensitivity/Response	25037139	CiViC
BRAF	p.V600	Melanoma	Binimetinib,Encorafenib	A	Sensitivity/Response	29573941	CiViC
BRAF	p.V600	Colorectal Cancer	Irinotecan,Vemurafenib,Cetuximab	B	Sensitivity/Response	147167	CiViC
BRAF	p.V600_K601>E	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	B	Sensitivity/Response	31580757	CiViC
BRAF	p.V600D	Melanoma	Dabrafenib	B	Sensitivity/Response	23463675	CiViC
BRAF	p.V600D	Melanoma	Vemurafenib	D	Sensitivity/Response	18287029	CiViC
BRAF	p.V600D	Melanoma	Vemurafenib	D	Sensitivity/Response	20551065	CiViC
BRAF	p.V600D	Melanoma	BRAF Inhibitor	B	Sensitivity/Response	31580757	CiViC
BRAF	p.V600D	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	B	Sensitivity/Response	31580757	CiViC
BRAF	p.V600E	Colorectal Cancer	Panitumumab,Sorafenib	D	Sensitivity/Response	19001320	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	D	Resistance	24576830	CiViC
BRAF	p.V600E	Lung Non-small Cell Carcinoma	Dabrafenib	C	Resistance	23524406	CiViC
BRAF	p.V600E	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	24583796	CiViC
BRAF	p.V600E	Colorectal Cancer	Pictilisib Bismesylate,PLX4720	D	Sensitivity/Response	23845441	CiViC
BRAF	p.V600E	Colorectal Cancer	PLX4720,Nutlin-3	D	Sensitivity/Response	23812671	CiViC
BRAF	p.V600E	Colorectal Cancer	Capecitabine,Bevacizumab,Vemurafenib	D	Sensitivity/Response	22180495	CiViC
BRAF	p.V600E	Colorectal Cancer	Vemurafenib	D	Sensitivity/Response	22180495	CiViC
BRAF	p.V600E	Colorectal Cancer	Cetuximab	B	Resistance	20619739	CiViC
BRAF	p.V600E	Melanoma	Pictilisib	C	Sensitivity/Response	25370471	CiViC
BRAF	p.V600E	Melanoma	Selumetinib,Dactolisib	D	Sensitivity/Response	26678033	CiViC
BRAF	p.V600E	Cancer	Cobimetinib	D	Sensitivity/Response	23934108	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	B	Sensitivity/Response	24508103	CiViC
BRAF	p.V600E	Colorectal Cancer	Gefitinib,Vemurafenib,Cetuximab	D	Sensitivity/Response	22281684	CiViC
BRAF	p.V600E	Skin Melanoma	Vemurafenib	A	Sensitivity/Response	21639808	CiViC
BRAF	p.V600E	Skin Melanoma	Vemurafenib	B	Sensitivity/Response	22356324	CiViC
BRAF	p.V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	C	Sensitivity/Response	24987354	CiViC
BRAF	p.V600E	Melanoma	Cobimetinib,Vemurafenib	B	Sensitivity/Response	25265494	CiViC
BRAF	p.V600E	Colorectal Cancer	GDC-0879,Dactolisib	D	Sensitivity/Response	23549875	CiViC
BRAF	p.V600E	Gastrointestinal Neuroendocrine Tumor	Trametinib,Dabrafenib,Vemurafenib	C	Sensitivity/Response	27048246	CiViC
BRAF	p.V600E	Hairy Cell Leukemia	Vemurafenib	B	Sensitivity/Response	26352686	CiViC
BRAF	p.V600E	Colorectal Cancer	Panitumumab,Vemurafenib	C	Sensitivity/Response	27325282	CiViC
BRAF	p.V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	B	Sensitivity/Response	27460442	CiViC
BRAF	p.V600E	Multiple Myeloma	Vemurafenib	C	Sensitivity/Response	24997557	CiViC
BRAF	p.V600E	Multiple Myeloma	Vemurafenib	C	Sensitivity/Response	24997557	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	B	Sensitivity/Response	20818844	CiViC
BRAF	p.V600E	Colorectal Cancer	Cetuximab,Vemurafenib,Irinotecan	B	Sensitivity/Response	27729313	CiViC
BRAF	p.V600E	Colorectal Cancer	Cetuximab,Panitumumab	B	Resistance	19001320	CiViC
BRAF	p.V600E	Colorectal Cancer	Oxaliplatin	B	Resistance	19603024	CiViC
BRAF	p.V600E	Colorectal Cancer	Irinotecan	B	Resistance	19603024	CiViC
BRAF	p.V600E	Colorectal Cancer	Bevacizumab	B	Resistance	19571295	CiViC
BRAF	p.V600E	Melanoma	Trametinib	B	Sensitivity/Response	22663011	CiViC
BRAF	p.V600E	Lung Non-small Cell Carcinoma	Dabrafenib,Trametinib	A	Sensitivity/Response	27283860	CiViC
BRAF	p.V600E	Colorectal Cancer	Cetuximab	B	Resistance	25666295	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	B	Sensitivity/Response	23569304	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	B	Sensitivity/Response	26557775	CiViC
BRAF	p.V600E	Melanoma	Vemurafenib	B	Sensitivity/Response	25524477	CiViC
BRAF	p.V600E	Skin Melanoma	Dabrafenib,Trametinib	B	Sensitivity/Response	25399551	CiViC
BRAF	p.V600E	Ganglioglioma	Vemurafenib	C	Sensitivity/Response	25524464	CiViC
BRAF	p.V600E	Ovarian Cystadenocarcinoma	Vemurafenib	C	Sensitivity/Response	26490654	CiViC
BRAF	p.V600E	Cholangiocarcinoma	Trametinib Dimethyl Sulfoxide,Dabrafenib	C	Sensitivity/Response	28480077	CiViC
BRAF	p.V600E	Cholangiocarcinoma	Trametinib Dimethyl Sulfoxide,Dabrafenib	C	Sensitivity/Response	28078132	CiViC
BRAF	p.V600E	Cholangiocarcinoma	Dabrafenib,Trametinib Dimethyl Sulfoxide	C	Sensitivity/Response	25435907	CiViC
BRAF	p.V600E	Cholangiocarcinoma	Vemurafenib,Panitumumab,Irinotecan	C	Sensitivity/Response	26687137	CiViC
BRAF	p.V600E	Lung Non-small Cell Carcinoma	Vemurafenib	B	Sensitivity/Response	29320312	CiViC
BRAF	p.V600E	Ovarian Cancer	Vemurafenib	B	Sensitivity/Response	29320312	CiViC
BRAF	p.V600E	Colorectal Cancer	Vemurafenib	C	Sensitivity/Response	29320312	CiViC
BRAF	p.V600E	Anaplastic Thyroid Carcinoma	Pertuzumab,Vemurafenib	C	Sensitivity/Response	29320312	CiViC
BRAF	p.V600E	Laryngeal Squamous Cell Carcinoma	Vemurafenib	C	Sensitivity/Response	29320312	CiViC
BRAF	p.V600E	Anaplastic Thyroid Carcinoma	Vemurafenib	B	Sensitivity/Response	26287849	CiViC
BRAF	p.V600E	Colorectal Cancer	Dabrafenib,Panitumumab,Trametinib	B	Sensitivity/Response	29431699	CiViC
BRAF	p.V600E	Melanoma	Dabrafenib,Trametinib	B	Sensitivity/Response	28891408	CiViC
BRAF	p.V600E	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	25265492	CiViC
BRAF	p.V600E	Melanoma	Dabrafenib,Trametinib	B	Sensitivity/Response	23020132	CiViC
BRAF	p.V600E	Anaplastic Thyroid Carcinoma	Trametinib,Dabrafenib	B	Sensitivity/Response	29072975	CiViC
BRAF	p.V600K	Melanoma	Vemurafenib	B	Sensitivity/Response	24508103	CiViC
BRAF	p.V600K	Melanoma	Vemurafenib	C	Sensitivity/Response	26989536	CiViC
BRAF	p.V600K	Melanoma	Dabrafenib	B	Sensitivity/Response	21343559	CiViC
BRAF	p.V600K	Melanoma	Trametinib	B	Sensitivity/Response	22663011	CiViC
BRAF	p.V600K	Melanoma	Vemurafenib	B	Sensitivity/Response	25524477	CiViC
BRAF	p.V600K	Skin Melanoma	Dabrafenib,Trametinib	B	Sensitivity/Response	25399551	CiViC
BRAF	p.V600K	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	28891408	CiViC
BRAF	p.V600K	Melanoma	Trametinib,Dabrafenib	B	Sensitivity/Response	25265494	CiViC
BRAF	p.V600M	Melanoma	Dabrafenib	C	Sensitivity/Response	23031422	CiViC
JAK2	p.V617F	Polycythemia Vera	Fedratinib	D	Sensitivity/Response	18394554	CiViC
KIT	p.V654A	Gastrointestinal Stromal Tumor	Imatinib	D	Resistance	16954519	CiViC
KIT	p.V654A	Gastrointestinal Stromal Tumor	Sunitinib	B	Sensitivity/Response	16638875	CiViC
EGFR	p.V742A	Lung Non-small Cell Carcinoma	Erlotinib	D	Sensitivity/Response	19147750	CiViC
EGFR	p.V769_770insASV	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	26773740	CiViC
ERBB2	p.V773A	Head And Neck Squamous Cell Carcinoma	Lapatinib	D	Sensitivity/Response	22046346	CiViC
EGFR	p.V774A	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	21531810	CiViC
ERBB2	p.V777L	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
ERBB2	p.V777L	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	D	Sensitivity/Response	26243863	CiViC
EGFR	p.V834I	Lung Non-small Cell Carcinoma	Gefitinib	C	Sensitivity/Response	21531810	CiViC
ERBB2	p.V842I	Breast Cancer	Neratinib	D	Sensitivity/Response	23220880	CiViC
ERBB2	p.V842I	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	D	Sensitivity/Response	26243863	CiViC
EGFR	p.V851I	Lung Non-small Cell Carcinoma	Erlotinib	C	Sensitivity/Response	21531810	CiViC
ERBB3	p.V855A	Lung Non-small Cell Carcinoma	Afatinib,Pertuzumab	D	Sensitivity/Response	26689995	CiViC
PIK3CA	p.V955I	Colorectal Cancer	Cetuximab	C	Resistance	28424201	CiViC
EGFR	VARIATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	B	Sensitivity/Response	20826716	CiViC
EGFR	VARIATION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	B	Sensitivity/Response	27664271	CiViC
BRCA1	p.W1815X	Ovarian Cancer	Olaparib	D	Sensitivity/Response	23415752	CiViC
NPM1	p.W288FS	Acute Myeloid Leukemia	NSC348884	D	Sensitivity/Response	21719597	CiViC
NPM1	p.W288FS	Acute Myeloid Leukemia	Induction Therapy	E	Sensitivity/Response	15659725	CiViC
KIT	p.W557_K558DELWK	Gastrointestinal Stromal Tumor	Sunitinib	C	Resistance	18955458	CiViC
KIT	p.W557_K558DELWK	Gastrointestinal Stromal Tumor	Ponatinib,Imatinib	D	Sensitivity/Response	25239608	CiViC
KIT	p.W557_K558DELWK	Gastrointestinal Stromal Tumor	Sunitinib,Regorafenib	D	Sensitivity/Response	25239608	CiViC
EGFR	p.W731L	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
AR	p.W742	Prostate Carcinoma	Bicalutamide	D	Resistance	12517791	CiViC
EGFR	p.WILDTYPE	Lung Non-small Cell Carcinoma	Gefitinib	C		19692680	CiViC
KIT	p.WILDTYPE	Gastrointestinal Stromal Tumor	Regorafenib	B	Sensitivity/Response	27371698	CiViC
NF2	p.Y177FS	Peritoneal Mesothelioma	Cisplatin,Carboplatin	C	Resistance	25798586	CiViC
TP53	p.Y220C	Stomach Carcinoma	Cisplatin,Mitomycin,Etoposide	C	Sensitivity/Response	14514923	CiViC
TP53	p.Y220C	Cancer	AMGMDS3	D	Resistance	25730903	CiViC
TP53	p.Y234C	Ovarian Cancer	Cisplatin,Carboplatin	C	Resistance	11595686	CiViC
ABL1	p.Y253F	Chronic Myeloid Leukemia	Imatinib	D	Resistance	19075254	CiViC
ABL1	p.Y253F	Chronic Myeloid Leukemia	Imatinib	C	Resistance	15930265	CiViC
ABL1	p.Y253F	Chronic Myeloid Leukemia	Axitinib	D	Resistance	25686603	CiViC
ABL1	p.Y253H	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	D	Resistance	16772610	CiViC
ABL1	p.Y253H	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	C	Resistance	19652056	CiViC
ABL1	p.Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	D	Resistance	16772610	CiViC
ABL1	p.Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	C	Resistance	22371878	CiViC
ABL1	p.Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	B	Resistance	17264298	CiViC
ESR1	p.Y537C	Breast Cancer	Hormone Therapy	D	Resistance	24185512	CiViC
ESR1	p.Y537C	Breast Cancer	Fulvestrant,Tamoxifen	D	Sensitivity/Response	24185510	CiViC
ESR1	p.Y537N	Breast Cancer	Hormone Therapy	D	Resistance	24185512	CiViC
ESR1	p.Y537N	Breast Cancer	Fulvestrant,Tamoxifen	D	Sensitivity/Response	24185510	CiViC
ESR1	p.Y537S	Breast Cancer	Hormone Therapy	D	Resistance	24185512	CiViC
ESR1	p.Y537S	Breast Cancer	Fulvestrant,Tamoxifen	D	Sensitivity/Response	24185510	CiViC
EZH2	p.Y646	Skin Melanoma	GSK126	D	Sensitivity/Response	26304929	CiViC
EGFR	p.Y764_V765insHH	Lung Non-small Cell Carcinoma	Erlotinib	D	Resistance	24353160	CiViC
ERBB2	p.Y772_A775DUP	Lung Non-small Cell Carcinoma	Sirolimus,Afatinib	D	Sensitivity/Response	19122144	CiViC
ERBB2	p.Y772_A775DUP	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	26559459	CiViC
ERBB2	p.Y772_A775DUP	Lung Carcinoma	Afatinib	D	Sensitivity/Response	19122144	CiViC
ERBB2	p.Y772_A775DUP	Lung Adenocarcinoma	Trastuzumab Emtansine	C	Sensitivity/Response	25789838	CiViC
ERBB2	p.Y772_A775DUP	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	22325357	CiViC
EGFR	p.Y801H	Malignant Mesothelioma	Erlotinib	D	Sensitivity/Response	20942962	CiViC
KIT	p.Y823D	Gastrointestinal Stromal Tumor	Imatinib	C	Resistance	16954519	CiViC
FGFR3	FGFR3-BAIAP2L1	Bladder Carcinoma	PD173074	D	Sensitivity/Response	23558953	CiViC
ABL1	BCR-ABL	Acute Myeloid Leukemia	Imatinib	D	Resistance	12476305	CiViC
ABL1	BCR-ABL	Acute Myeloid Leukemia	Imatinib	A	Sensitivity/Response	12476305	CiViC
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Imatinib	A	Sensitivity/Response	20537386	CiViC
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Dasatinib,Nilotinib	A	Sensitivity/Response	20537386	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib	B	Sensitivity/Response	20979473	CiViC
FGFR2	FGFR2-MGEA5	Cholangiocarcinoma	Ponatinib	C	Sensitivity/Response	24550739	CiViC
FGFR2	FGFR2-TACC3	Cholangiocarcinoma	Ponatinib,Pazopanib	C	Sensitivity/Response	24550739	CiViC
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin	B	Sensitivity/Response	8674046	CiViC
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Imatinib	A	Sensitivity/Response	20537386	CiViC
CSF1R	MEF2D-CSF1R	Acute Lymphoblastic Leukemia	GW-2580,Imatinib	D	Sensitivity/Response	24186003	CiViC
RET	KIF5B-RET	Lung Adenocarcinoma	Vandetanib	C	Sensitivity/Response	23584301	CiViC
BRAF	AGK-BRAF	Melanoma	Sorafenib	C	Sensitivity/Response	23890088	CiViC
BRAF	AGK-BRAF	Melanoma	Vemurafenib	D	Resistance	23890088	CiViC
BRAF	PAPSS1-BRAF	Melanoma	Vemurafenib	D	Resistance	24345920	CiViC
BRAF	PAPSS1-BRAF	Melanoma	Trametinib	D	Sensitivity/Response	24345920	CiViC
BRAF	TRIM24-BRAF	Melanoma	Trametinib	D	Sensitivity/Response	24345920	CiViC
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin,Arsenic Trioxide	A	Sensitivity/Response	11704842	CiViC
FGFR1	ZNF198-FGFR1	Chronic Myeloproliferative Disease	Midostaurin	C	Sensitivity/Response	15448205	CiViC
ALK	EML4-ALK	Lung Acinar Adenocarcinoma	Erlotinib	C	Resistance	23181703	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	WHI-P154	D	Sensitivity/Response	17625570	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride,Crizotinib	D	Sensitivity/Response	21258415	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Alvespimycin,Crizotinib	D	Sensitivity/Response	22912387	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib	C	Sensitivity/Response	20979469	CiViC
ALK	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib	D	Sensitivity/Response	18089725	CiViC
ALK	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib	B	Sensitivity/Response	23598171	CiViC
ALK	RANBP2-ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	C	Sensitivity/Response	20979472	CiViC
ALK	CLTC-ALK	Diffuse Large B-cell Lymphoma	TAE684	D	Sensitivity/Response	21494621	CiViC
ALK	CLTC-ALK	Diffuse Large B-cell Lymphoma	Crizotinib	C	Sensitivity/Response	26221234	CiViC
PDGFRB	EBF1-PDGFRB	Acute Lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	23835704	CiViC
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Lorlatinib	D	Sensitivity/Response	26554404	CiViC
ALK	DEL4-11	Neuroblastoma	Brigatinib	D	Sensitivity/Response	27049722	CiViC
ALK	NPM-ALK	Cancer	Crizotinib	D	Sensitivity/Response	25727400	CiViC
BRAF	TRIM24-BRAF	Skin Melanoma	Vemurafenib	D	Resistance	24345920	CiViC
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	B	Sensitivity/Response	14504092	CiViC
ROS1	TFG-ROS1	Inflammatory Myofibroblastic Tumor	Crizotinib	C	Sensitivity/Response	24875859	CiViC
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	A	Sensitivity/Response	12660384	CiViC
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin	C	Sensitivity/Response	21505136	CiViC
CTLA4	CTLA4-CD28	Sezary's Disease	Ipilimumab	C	Sensitivity/Response	25802883	CiViC
BRAF	PPFIBP2-BRAF	Skin Melanoma	Trametinib	C	Sensitivity/Response	26072686	CiViC
BRAF	KIAA1549-BRAF	Skin Melanoma	Trametinib	C	Sensitivity/Response	26072686	CiViC
RET	CCDC6-RET	Lung Non-small Cell Carcinoma	Nintedanib	C	Sensitivity/Response	26787234	CiViC
RET	KIF5B-RET	Lung Adenocarcinoma	Vandetanib,Everolimus	C	Sensitivity/Response	25982012	CiViC
BRAF	BRAF-CUL1	Ovarian Serous Carcinoma	Mitogen-Activated Protein Kinase Kinase Inhibitor	C	Sensitivity/Response	26324360	CiViC
BRAF	ZKSCAN1-BRAF	Melanoma	Trametinib	C	Sensitivity/Response	26314551	CiViC
BRAF	KIAA1549-BRAF	Sarcoma	Temsirolimus,Bevacizumab,Sorafenib	C	Sensitivity/Response	24422672	CiViC
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	C	Sensitivity/Response	24456122	CiViC
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib	D	Sensitivity/Response	24407160	CiViC
BRD4	BRD4-NUTM1	NUT Midline Carcinoma	JQ1	D	Sensitivity/Response	20871596	CiViC
PDGFRA	TNKS2-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	C	Sensitivity/Response	25658984	CiViC
FGFR2	FGFR2-BICC1	Cholangiocarcinoma	PD173074,Infigratinib	D	Sensitivity/Response	24122810	CiViC
FGFR2	FGFR2-AHCYL1	Cholangiocarcinoma	PD173074,Infigratinib	D	Sensitivity/Response	24122810	CiViC
NTRK1	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib	C	Sensitivity/Response	26565381	CiViC
NTRK3	ETV6-NTRK3	Salivary Gland Carcinoma	Entrectinib	C	Sensitivity/Response	26884591	CiViC
FGFR2	FGFR2-BICC1	Urothelial Carcinoma	Erdafitinib	C	Sensitivity/Response	26324363	CiViC
FGFR3	FGFR3-TACC3	Cancer	Erdafitinib	B	Sensitivity/Response	26324363	CiViC
FGFR2	FGFR2-BICC1	Endometrial Cancer	Erdafitinib	C	Sensitivity/Response	26324363	CiViC
NTRK1	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib	C	Sensitivity/Response	28183697	CiViC
NTRK1	LMNA-NTRK1	Sarcoma	Larotrectinib	C	Sensitivity/Response	26216294	CiViC
NTRK1	LMNA-NTRK1	Colorectal Adenocarcinoma	Entrectinib	C	Sensitivity/Response	26546295	CiViC
ABL1	BCR-ABL	Acute Lymphoblastic Leukemia	Dasatinib	C	Sensitivity/Response	16775234	CiViC
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Dasatinib	C	Sensitivity/Response	16775234	CiViC
NRG1	ATP1B1-NRG1	Cholangiocarcinoma	Afatinib	C	Sensitivity/Response	28950338	CiViC
NRG1	SDC4-NRG1	Lung Adenocarcinoma	Afatinib	C	Sensitivity/Response	28950338	CiViC
EGFR	EGFR-RAD51	Lung Adenocarcinoma	Erlotinib	C	Sensitivity/Response	29290255	CiViC
ALK	STRN-ALK	Colon Adenocarcinoma	Ceritinib	C	Sensitivity/Response	26933125	CiViC
BRAF	CUX1-BRAF	Pancreatic Cancer	Vemurafenib	C	Sensitivity/Response	29320312	CiViC
NTRK2	STRN-NTRK2	Sarcoma	Larotrectinib	C	Sensitivity/Response	29606586	CiViC
NTRK3	ETV6-NTRK3	Pediatric Fibrosarcoma	Larotrectinib	B	Sensitivity/Response	29606586	CiViC
NTRK1	LMNA-NTRK1	Sarcoma	Larotrectinib	C	Sensitivity/Response	29606586	CiViC
NTRK1	TMP3-NTRK1	Sarcoma	Larotrectinib	C	Sensitivity/Response	29606586	CiViC
NTRK1	PDE4DIP-NTRK1	Sarcoma	Larotrectinib	C	Sensitivity/Response	29606586	CiViC
NTRK1	SQSTM1-NTRK1	Pediatric Fibrosarcoma	Larotrectinib	C	Sensitivity/Response	29606586	CiViC
NTRK1	NTRK1-TRIM63	Melanoma	Larotrectinib	E	Sensitivity/Response	29683819	CiViC
NTRK1	NTRK1-DDR2	Melanoma	Larotrectinib	E	Sensitivity/Response	29683819	CiViC
NTRK1	NTRK1-GON4L	Melanoma	Larotrectinib	E	Sensitivity/Response	29683819	CiViC
NTRK2	ETV6-NTRK2	Acute Myeloid Leukemia	Larotrectinib	C	Sensitivity/Response	29920189	CiViC
FGFR3	FGFR3-TACC3	Urothelial Carcinoma	Infigratinib	B	Sensitivity/Response	29848605	CiViC
NTRK3	ETV6-NTRK3	Congenital Fibrosarcoma	Larotrectinib	C	Sensitivity/Response	27093299	CiViC
NTRK3	ETV6-NTRK3	Breast Secretory Carcinoma	Larotrectinib	C	Sensitivity/Response	29623306	CiViC
NTRK3	ETV6-NTRK3	Pediatric B-lymphoblastic Leukemia	Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate,Larotrectinib	D	Sensitivity/Response	29880614	CiViC
ABL1	ETV6-ABL1	Precursor B Lymphoblastic Lymphoma/leukemia	Dasatinib	C	Sensitivity/Response	25207766	CiViC
PDGFRB	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	24186319	CiViC
BRD4	BRD4-NUTM1	NUT Midline Carcinoma	Birabresib	C	Sensitivity/Response	26976114	CiViC
PDGFRB	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	26872634	CiViC
PDGFRB	EBF1-PDGFRB	Pediatric B-lymphoblastic Leukemia	Dasatinib,Imatinib	C	Sensitivity/Response	25207766	CiViC
ABL1	SNX2-ABL1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib	C	Resistance	24215620	CiViC
ABL1	ABL1-RCSD	Pediatric B-cell Acute Lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	25207766	CiViC
ABL1	ABL1-RCSD1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib	D	Sensitivity/Response	25207766	CiViC
JAK2	SSBP2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Ruxolitinib	C	Sensitivity/Response	25207766	CiViC
ABL1	FOXP1-ABL1	Pediatric B-lymphoblastic Leukemia	Dasatinib	C	Sensitivity/Response	30938769	CiViC
EGFR	EGFR-RAD51	Lung Adenocarcinoma	Icotinib	C	Sensitivity/Response	31064887	CiViC
PDGFRA	FIP1L1-PDGFRA	Acute Myeloid Leukemia	Sorafenib,Sunitinib	D	Sensitivity/Response	21482694	CiViC
FGFR1	FGFR1OP2-FGFR1	Acute Myeloid Leukemia	Ponatinib	D	Sensitivity/Response	21482694	CiViC
RET	CCDC6-RET	Colorectal Cancer	Agerafenib	C	Sensitivity/Response	29538669	CiViC
ALK	CAD-ALK	Colorectal Cancer	Entrectinib	C	Sensitivity/Response	26633560	CiViC
ROS1	GOPC-ROS1	Glioblastoma Multiforme	Lorlatinib	D	Sensitivity/Response	30171048	CiViC
NRG1	ATP1B1-NRG1	Pancreatic Ductal Adenocarcinoma	Afatinib	C	Sensitivity/Response	31068372	CiViC
NRG1	APP-NRG1	Pancreatic Ductal Adenocarcinoma	Afatinib	C	Sensitivity/Response	31068372	CiViC
NTRK3	ETV6-NTRK3	Cancer	Larotrectinib	B	Sensitivity/Response	30624546	CiViC
ABL1	SNX2-ABL1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib,Imatinib	D	Resistance	24367893	CiViC
BRAF	NRF1-BRAF	Urothelial Carcinoma	Trametinib	C	Sensitivity/Response	31010895	CiViC
ABL1	ABL1-RCSD1	Pediatric B-lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	27125982	CiViC
PDGFRA	BCR-PDGFRA	B-cell Acute Lymphoblastic Leukemia	Imatinib	C	Sensitivity/Response	12944919	CiViC
PDGFB	COL1A1-PDGFB	Dermatofibrosarcoma Protuberans	Sunitinib	C	Sensitivity/Response	29760553	CiViC
NTRK3	ETV6-NTRK3	B-cell Adult Acute Lymphocytic Leukemia	Larotrectinib	C	Sensitivity/Response	31905241	CiViC
NTRK3	ETV6-NTRK3	Acute Myeloid Leukemia	Entrectinib	D	Sensitivity/Response	29237803	CiViC
BRCA1	p.A1623G	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.A1708E	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
AKT3	any	BRCA	ATP-competitive AKT inhibitors	Preclinical	Sensitive	22722202	DEPO
ALK	any	DLBC	crizotinib	Clinical Trials	Sensitive	24491302	DEPO
ALK	any	IMT	crizotinib	Case Reports	Sensitive	20979472	DEPO
ALK	any	LUAD	crizotinib  ceritinib	FDA Approved	Sensitive	22954507	DEPO
ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
ALK	any	THCA	crizotinib	Case Reports	Sensitive	24687827	DEPO
ATIC-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
BCR-ABL1	any	ALL	nilotinib	FDA Approved	Sensitive	24650752	DEPO
BCR-ABL1	any	CML	imatinib  dasatinib  nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	19779040	DEPO
BCR-ABL1	any	CML	imatinib	Clinical Trials	Resistant	11423618	DEPO
BCR-JAK2	any	ALL	ruxolitinib	Preclinical	Sensitive	22897847	DEPO
BCR-PDGFRA	any	CML	Imatinib  TKIs	Case Reports	Sensitive	15034867	DEPO
BCR-RET	any	CML	sorafenib	Case Reports	Sensitive	22513837	DEPO
BRAF	any	LUAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	24727320	DEPO
BRAF	any	PRAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	20526349	DEPO
BRAF	any	SKCM	MEK inhibitors	Clinical Trials	Sensitive	24345920	DEPO
BRAF	any	SKCM	sorafenib	Preclinical	Sensitive	23890088	DEPO
BRD4	any	HNSC	BET inhibitors	Preclinical	Sensitive	20871596	DEPO
CD74-ROS1	any	---	crizotinib	Preclinical	Sensitive	23486013	DEPO
CDK5RAP2-PDGFRA	any	CML	Imatinib  TKIs	Case Reports	Sensitive	16845659	DEPO
CLTC-ALK	any	DLBC	Crizotinib	Preclinical	Sensitive	26221234	DEPO
COL1A1-PDGFRB	any	SARC	imatinib	FDA Approved	Sensitive	20194851	DEPO
CRLF2	any	ALL	mTOR inhibitors	Preclinical	Sensitive	22955920	DEPO
EGFR	any	NSCLC	erlotinib	Case Reports	Sensitive	27102076	DEPO
EML1-ABL1	any	CML	imatinib	Case Reports	Sensitive	15713800	DEPO
EML4-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
ERBB4	any	LUAD	lapatinib  afatinib	Preclinical	Sensitive	24727320	DEPO
ESR1	any	BRCA	anti-estrogens	Preclinical	Resistant	24055055	DEPO
ETS	any	PRAD	PARP inhibitors	Preclinical	Sensitive	21575865	DEPO
ETV6-ABL1	any	MPD	nilotinib	Case Reports	Sensitive	24053143	DEPO
ETV6-ABL1	any	MPD	imatinib	Case Reports	Resistant	24053143	DEPO
EWS	any	SARC	PARP inhibitors	Preclinical	Sensitive	22287547	DEPO
FGFR2	any	CHOL	FGFR inhibitors	Preclinical	Sensitive	23558953	DEPO
FGFR3	any	BLCA	FGFR inhibitors	Case Reports	Sensitive	AACR 2014 (abstr CT325)	DEPO
FGFR3	any	GBM	FGFR inhibitors	Clinical Trials	Sensitive	ASCO 2014 (abstr 2501)	DEPO
FIP1L1-PDGFRA	any	MPD	Imatinib  TKIs	FDA Approved	Sensitive	12660384	DEPO
JAK2	any	ALL	ruxolitinib	Preclinical	Sensitive	22875628  22899477	DEPO
KIF5B-RET	any	LUAD	cabozantinib	Case Reports	Sensitive	23533264	DEPO
KLC1-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
MET	any	GBM	crizotinib	Case Reports	Sensitive	27748748	DEPO
MLL	any	LAML	daunorubicin	FDA Approved	Sensitive	22417203	DEPO
NOTCH1	any	ALL	Gamma secretase inhibitors	Preclinical	Sensitive	16688224  23033986	DEPO
NOTCH1	any	BRCA	Gamma secretase inhibitors	Preclinical	Sensitive	22101766	DEPO
NOTCH2	any	BRCA	Gamma secretase inhibitors	Preclinical	Sensitive	22101766	DEPO
NPM-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
NRG1	any	LUAD	lapatinib	Preclinical	Sensitive	24727320	DEPO
NTRK1	any	COADREAD	pan-TRK inhibitor	Case Reports	Sensitive	ASCO 2015 (abstr 2517)	DEPO
NTRK1	any	LUAD	crizotinib	Case Reports	Sensitive	ASCO 2013 (abstr 8023)	DEPO
NTRK3	any	BRCA	midostaurin  IGF1R inhibitors  PI3K pathway inhibitors	Preclinical	Sensitive	21148487  23131561	DEPO
NUP214-ABL1	any	ALL	imatinib	Clinical Trials	Sensitive	16213363	DEPO
PDGFRA	any	HES	imatinib	FDA Approved	Sensitive	16089297	DEPO
PDGFRA	any	MPD	imatinib	FDA Approved	Sensitive	16089297	DEPO
PML-RARA	any	LAML	ATRA + arsenic trioxide	FDA Approved	Sensitive	15103387	DEPO
RAF1	any	PRAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	20526349	DEPO
RANBP2-ALK	any	NSCLC	Crizotinib	Case Reports	Sensitive	27494825	DEPO
RCSD1-ABL1	any	ALL	dasatinib	Case Reports	Resistant	21863287	DEPO
RET	any	LUAD	cabozantinib  vandetanib	Clinical Trials	Sensitive	23533264  23584301  25366691  ASCO 2015 (abstr 8007)	DEPO
RET-PTC1	any	THCA	RET inhibitors	Preclinical	Sensitive	23056499	DEPO
ROS1	any	IMT	crizotinib	Case Reports	Sensitive	24875859	DEPO
ROS1	any	LUAD	crizotinib	Clinical Trials	Sensitive	25264305	DEPO
ROS1	any	NSCLC	crizotinib (ALK/MET/ROS1 TKI)	FDA Approved	Sensitive	25264305	DEPO
SQSTM1-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TFG-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TMPRSS2	any	PRAD	DNA-PKc inhibitors	Preclinical	Sensitive	21575865	DEPO
TPM3-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TPM4-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TRIM33-RET	any	LUAD	cabozantinib	Case Reports	Sensitive	23533264	DEPO
AKT2	CNA	---	AKT inhibitors	Preclinical	Sensitive	ENA 2014 (abstr 373)	DEPO
ALK	CNA	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
BCL2	CNA	DLBC	BCL2 inhibitors	Preclinical	Sensitive	22649144	DEPO
CCND1	CNA	---	CDK4/6 inhibitors	Preclinical	Sensitive	22471707	DEPO
CCND1	CNA	SKCM	CDK4/6 inhibitors	Case Reports	Sensitive	ASCO 2014 (abstr 2528^)	DEPO
CCND2	CNA	---	CDK4/6 inhibitors	Preclinical	Sensitive	22471707	DEPO
CCND3	CNA	---	CDK4/6 inhibitors	Preclinical	Sensitive	22471707	DEPO
CCNE1	CNA	---	CDK2 inhibitors	Preclinical	Sensitive	22471707	DEPO
CD274	CNA	---	PDL1 inhibitors	Preclinical	Sensitive	25079317	DEPO
CDK4	CNA	SARC	CDK4 inhibitors (tumors with RB expression)	Clinical Trials	Sensitive	23569312	DEPO
CDK6	CNA	---	CDK6 inhibitors	Preclinical	Sensitive	22471707	DEPO
EGFR	CNA	COADREAD	anti-EGFR mAbs	Clinical Trials	Sensitive	18794099  17664472	DEPO
EGFR	CNA	NSCLC	erlotinib	Clinical Trials	Resistant	ASCO 2015 (abstr e19028)	DEPO
ERBB2	CNA	BRCA	trastuzumab  lapatinib  pertuzumab  ado-trastuzumab emtansine	FDA Approved	Sensitive	17208639	DEPO
ERBB2	CNA	COADREAD	trastuzumab + lapatinib (in KRAS wt)	Clinical Trials	Sensitive	ASCO 2015 (abstr 3508)	DEPO
ERBB2	CNA	COADREAD	anti-EGFR mAbs	Clinical Trials	Resistant	22586653  23348520	DEPO
ERBB2	CNA	HNSC	trastuzumab-based chemotherapy	Case Reports	Sensitive	21380780	DEPO
ERBB2	CNA	OV	trastuzumab	Clinical Trials	Sensitive	20003286  12525520	DEPO
ERBB2	CNA	STAD	trastuzumab	FDA Approved	Sensitive	20728210	DEPO
ERBB2	CNA	UCEC	trastuzumab + lapatinib	Preclinical	Sensitive	25294905	DEPO
ERBB2	CNA	UCEC	trastuzumab alone	Clinical Trials	Resistant	19840887	DEPO
FGF3	CNA	BRCA	dovitinib	Clinical Trials	Sensitive	23658459	DEPO
FGF4	CNA	BRCA	dovitinib	Clinical Trials	Sensitive	23658459	DEPO
FGFR1	CNA	BRCA	FGFR inhibitors	Clinical Trials	Sensitive	25193991	DEPO
FGFR1	CNA	HNSC	FGFR inhibitors	Preclinical	Sensitive	23418312	DEPO
FGFR1	CNA	LUSC	FGFR inhibitors	Clinical Trials	Sensitive	AACR 2012 (abstr LB-122)  AACR 2013 (abstr LB-145)	DEPO
FGFR2	CNA	BRCA	FGFR inhibitors	Case Reports	Sensitive	25193991	DEPO
FGFR2	CNA	STAD	FGFR inhibitors	Clinical Trials	Sensitive	ASCO 2015 (abstr 2508)	DEPO
FRS2	CNA	SARC	FGFR inhibitors	Preclinical	Sensitive	23393200	DEPO
HGF	CNA	BRCA	trastuzumab in HER2-ampl	Clinical Trials	Resistant	22850551	DEPO
KIT	CNA	SKCM	sunitinib	Clinical Trials	Sensitive	22261812	DEPO
KIT	CNA	SKCM	imatinib	Clinical Trials	Resistant	23775962	DEPO
KRAS	CNA	COADREAD	BRAF inhibitor + MEK inhibitor/anti-EGFR mAb	Case Reports	Resistant	ENA 2014 (abstr 428)	DEPO
MDM2	CNA	SARC	MDM2 inhibitors (tumors TP53 wt)	Clinical Trials	Sensitive	23084521  ASCO 2015 (abstr 10564)	DEPO
MDM4	CNA	SARC	MDM2/MDMX inhibitors	Preclinical	Sensitive	24336067	DEPO
MET	CNA	BRCA	trastuzumab in HER2-amplified	Clinical Trials	Resistant	22850551	DEPO
MET	CNA	GBM	crizotinib	Case Reports	Sensitive	22162573	DEPO
MET	CNA	KIRC	MET inhibitors	Clinical Trials	Sensitive	23213094	DEPO
MET	CNA	LUAD	crizotinib	Clinical Trials	Sensitive	ASCO 2014 (abstr 8001)  ASCO 2015 (abstr 2595)	DEPO
MET	CNA	LUAD	EGFR TKIs (EGFR mutant disease)	Clinical Trials	Resistant	ASCO 2015 (abstr 8089)	DEPO
MET	CNA	NSCLC	EGFR TKIs	Clinical Trials	Resistant	18093943	DEPO
MET	CNA	STAD	MET inhibitors	Case Reports	Sensitive	22042947  ASCO GI 2015 (abstr 1)	DEPO
MET	CNA	STAD	lapatinib in HER2-amplified	Preclinical	Resistant	22238368	DEPO
MITF	CNA	SKCM	BRAF inhibitors	Case Reports	Resistant	24265153	DEPO
MYC	CNA	MM	BET inhibitors	Preclinical	Sensitive	21889194	DEPO
MYC	CNA	NB	CDK7 inhibitors	Preclinical	Sensitive	25416950	DEPO
MYC	CNA	PRAD	PIM inhibitors	Preclinical	Sensitive	25505253	DEPO
MYCN	CNA	MM	BET inhibitors	Preclinical	Sensitive	21889194	DEPO
MYCN	CNA	NB	BET inhibitors	Preclinical	Sensitive	23430699	DEPO
PIK3CA	CNA	BRCA	PI3K pathway inhibitors	Preclinical	Resistant	24366379	DEPO
RET	CNA	TGCT	sunitinib	Case Reports	Sensitive	25085632	DEPO
TOP2A	CNA	BRCA	anthracyclines	Clinical Trials	Sensitive	22864769	DEPO
VEGFA	CNA	LIHC	sorafenib	Clinical Trials	Sensitive	24687604	DEPO
ATM	CNL	DLBC	DNA-PKc inhibitors	Preclinical	Sensitive	23761041	DEPO
BRCA1	CNL	OV	PARP inhibitors	FDA Approved	Sensitive	27908594	DEPO
BRCA1	CNL	OV	PARP inhibitors	Preclinical	Sensitive	22392482	DEPO
BRCA2	CNL	OV	PARP inhibitors	FDA Approved	Sensitive	27908594	DEPO
BRCA2	CNL	OV	PARP inhibitors	Preclinical	Sensitive	22392482	DEPO
CDKN2A	CNL	BRCA	Palbociclib  CDK4/6 inhibitor	Case Reports	Sensitive	26715889	DEPO
CDKN2A	CNL	GBM	CDK4/6 inhibitors	Preclinical	Sensitive	22586120  22711607	DEPO
CDKN2A	CNL	SARC	LY2835219  CDK4/6 inhibitor	Preclinical	Sensitive	25852058	DEPO
CDKN2A	CNL	SKCM	CDK4/6 inhibitors	Case Reports	Sensitive	ASCO 2013 (abstr 2500)	DEPO
CDKN2B	CNL	GBM	CDK4/6 inhibitors	Preclinical	Sensitive	22711607	DEPO
CDKN2C	CNL	GBM	CDK4/6 inhibitors	Preclinical	Sensitive	22711607	DEPO
INI1	CNL	SARC	EZH2 inhibitor	Case Reports	Sensitive	ENA 2014 (abstr 6LBA)	DEPO
MGMT	CNL	GBM	temozolomide	Clinical Trials	Sensitive	15758010	DEPO
NF1	CNL	GBM	mTOR inhibitors	Preclinical	Sensitive	19573811	DEPO
NF1	CNL	MPNST	MEK inhibitors	Preclinical	Sensitive	23221341  23858101	DEPO
NF1	CNL	SKCM	MEK inhibitors in BRAF mutant tumors	Case Reports	Resistant	23444215  23288408	DEPO
NF2	CNL	MESO	FAK inhibitors	Clinical Trials	Sensitive	ENA 2012 (abstr 610)	DEPO
NF2	CNL	MPNST	PAK inhibitors	Clinical Trials	Sensitive	23960073	DEPO
PTCH1	CNL	MB	vismodegib	Case Reports	Sensitive	26169613	DEPO
PTEN	CNL	BRCA	PI3K alpha inhibitors	Clinical Trials	Resistant	25409150	DEPO
PTEN	CNL	NSCLC	PI3K pathway inhibitors (alone or in combination)	Preclinical	Sensitive	23136191	DEPO
PTEN	CNL	PAAD	AKT inhibitors	Case Reports	Sensitive	22025163	DEPO
PTEN	CNL	PRAD	everolimus	Clinical Trials	Sensitive	23582881	DEPO
PTEN	CNL	SKCM	BRAF inhibitors in BRAF mutant tumor	Preclinical	Resistant	21317224  21725359	DEPO
PTEN	CNL	UCEC	PARP inhibitors	Case Reports	Sensitive	21468130  20944090	DEPO
RB1	CNL	SKCM	BRAF inhibitors in BRAF mutant tumor	Preclinical	Resistant	21725359	DEPO
SMARCB1	CNL	SARC	EZH inhibitors	Preclinical	Sensitive	23620515	DEPO
STK11	CNL	LUAD	phenformin	Preclinical	Sensitive	23352126	DEPO
STK11	CNL	LUAD	MEK inhibitors + docetaxel in KRAS mutant	Preclinical	Resistant	22425996	DEPO
SUZ12	CNL	---	BET inhibitors	Preclinical	Sensitive	25119042	DEPO
BRCA2	p.D3095E	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.E2663V	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.G1706E	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.G1738R	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.G1788V	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.G2748D	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.I1766S	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.I2627F	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.L1764P	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.L2653P	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.M1689R	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.M18T	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA1	mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA2	mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA2	mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
ALK	p.1151in_frame_insT	LUAD	ceritinib	FDA Approved	Sensitive	24670165	DEPO
ALK	p.1151in_frame_insT	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
KDR	p.A1065T	---	VEGFR inhibitors	Preclinical	Sensitive	24569783	DEPO
MTOR	p.A1134V	NSCLC	AZD8055	Preclinical	Resistant	23486013	DEPO
AKT2	p.A139V	COADREAD	A443654	Preclinical	Resistant	23486013	DEPO
PIK3R2	p.A171V	UCEC	mTOR inhibitors	Preclinical	Sensitive	21984976  19962665	DEPO
EGFR	p.A289V	GBM	erlotinib	Preclinical	Sensitive	17177598	DEPO
ALK	p.A348D	ALL	crizotinib	Preclinical	Sensitive	26032424	DEPO
SMO	p.A459V	BCC	Vismodegib	Case Reports	Resistant	25759019	DEPO
RET	p.A45T	COADREAD	CEP701	Preclinical	Resistant	23486013	DEPO
AR	p.A52T	COADREAD	PARP1Bical	Preclinical	Sensitive	23486013	DEPO
JAK3	p.A572V	DLBC	JAK inhibitors	Preclinical	Sensitive	22705984	DEPO
JAK3	p.A573V	DLBC	JAK inhibitors	Preclinical	Sensitive	22705984	DEPO
RPS6KA2	p.A657S	LAML	CMK	Preclinical	Sensitive	23486013	DEPO
PIK3CB	p.A686T	PRAD	NVPBEZ235	Preclinical	Resistant	23486013	DEPO
BRAF	p.A712T	COADREAD	PLX4720	Preclinical	Resistant	23486013	DEPO
IGF1R	p.A828T	COADREAD	AEW541	Preclinical	Sensitive	23486013	DEPO
KIT	p.A829P	GIST	ponatinib	Preclinical	Sensitive	25239608	DEPO
KIT	p.A829P	GIST	imatinib	Preclinical	Resistant	23582185  21689725  17259998	DEPO
ERBB2	p.A859T	NSCLC	Trastuzumab	Case Reports	Sensitive	16775247	DEPO
ALK	p.C1156Y	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
MAP2K1	p.C121S	SKCM	novel MEK inhibitors	Preclinical	Sensitive	24448821	DEPO
MAP2K1	p.C121S	SKCM	BRAF inhibitors  MEK inhibitors	Case Reports	Resistant	21383288	DEPO
MAP2K2	p.C125S	SKCM	ERK inhibitors	Preclinical	Sensitive	24265153	DEPO
MAP2K2	p.C125S	SKCM	BRAF inhibitors  MEK inhibitors	Preclinical	Resistant	24265153	DEPO
ERBB2	p.C311R	---	ERBB2 TKIs  trastuzumab	Preclinical	Sensitive	22908275	DEPO
MDM2	p.C314Y	COADREAD	Nutlin3	Preclinical	Resistant	23486013	DEPO
ERBB2	p.C334S	---	ERBB2 TKIs	Preclinical	Sensitive	22908275	DEPO
CBL	p.C384R	MPD	JAK inhibitors  dasatinib	Preclinical	Sensitive	23696637	DEPO
BTK	p.C481S	CLL	ibrutinib	Clinical Trials	Resistant	24869598	DEPO
RET	p.C634F	THCA	sorafenib	Clinical Trials	Sensitive	20368568	DEPO
RET	p.C634R	THCA	sorafenib	Clinical Trials	Sensitive	20368568	DEPO
RET	p.C634W	THCA	vandetanib	FDA Approved	Sensitive	20065189  22025146	DEPO
RET	p.C634Y	THCA	sorafenib	Clinical Trials	Sensitive	20368568	DEPO
EGFR	p.C797S	NSCLC	irreversible EGFR T790M inhibitors	Clinical Trials	Resistant	25939061	DEPO
MAPK8	p.C79Y	COADREAD	JNK9L	Preclinical	Resistant	23486013	DEPO
ALK	p.C928Y	LAML	PF2341066	Preclinical	Resistant	23486013	DEPO
IGF1R	p.D1146N	LAML	AEW541	Preclinical	Sensitive	23486013	DEPO
MET	p.D1240N	DLBC	PHA665752	Preclinical	Sensitive	23486013	DEPO
NF1	p.D1644A	HNSC	everolimus	Case Reports	Sensitive	ASCO 2015 (abstr 11010)	DEPO
PDGFRB	p.D166G	UCEC	TKI258	Preclinical	Sensitive	23486013	DEPO
STK11	p.D194E	PAAD	everolimus	Case Reports	Sensitive	21189378	DEPO
CTNNB1	p.D32V	UCEC	everolimus + letrozole	Clinical Trials	Sensitive	25624430	DEPO
KDR	p.D392N	NSCLC	Sorafenib	Preclinical	Resistant	23486013	DEPO
AKT1	p.D3N	BRCA	AKT inhibitors	Preclinical	Sensitive	23486013	DEPO
KIT	p.D419in_frame_del	GIST	Imatinib  TKIs	Case Reports	Sensitive	23599150	DEPO
SMO	p.D473H	MB	vismodegib	Case Reports	Resistant	19726788  25759019	DEPO
SMO	p.D473Y	BCC	Vismodegib	Case Reports	Resistant	25306392	DEPO
KIT	p.D52N	MPD	SCF	Case Reports	Sensitive	9168438	DEPO
PLK2	p.D560V	COADREAD	BI2536	Preclinical	Resistant	23486013	DEPO
BRAF	p.D594G	SKCM	sorafenib	Preclinical	Sensitive	18794803	DEPO
MAP2K1	p.D67N	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
ERBB2	p.D769H	BRCA	trastuzumab  lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
ERBB2	p.D769Y	BRCA	trastuzumab  lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
CSF3R	p.D771fs	CML	dasatinib	Preclinical	Sensitive	23656643	DEPO
KIT	p.D816V	LAML	dasatinib	Case Reports	Sensitive	18986703	DEPO
KIT	p.D820E	THYM	sorafenib	Case Reports	Sensitive	19461405	DEPO
KIT	p.D820Y	SKCM	nilotinib	Case Reports	Sensitive	25695690	DEPO
PDGFRA	p.D842V	GIST	dasatinib	Preclinical	Sensitive	18794084	DEPO
PDGFRA	p.D842V	GIST	imatinib  sunitinib	Preclinical	Resistant	22718859  16638875	DEPO
PDGFRA	p.D846Y	GIST	Imatinib  TKIs	Case Reports	Sensitive	15928335	DEPO
PDGFRB	p.E1069K	GBM	Sorafenib	Preclinical	Resistant	23486013	DEPO
MAP2K1	p.E120D	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
PRKCE	p.E149K	NSCLC	Bryostatin	Preclinical	Sensitive	23486013	DEPO
AKT1	p.E17K	---	AKT inhibitors	Preclinical	Sensitive	21464312  17611497  23134728	DEPO
AKT1	p.E17K	BRCA	AKT inhibitors	Preclinical	Sensitive	21464312  17611497	DEPO
AKT1	p.E17K	OV	AKT inhibitors	Clinical Trials	Sensitive	26351323	DEPO
MTOR	p.E2014K	BLCA	everolimus	Case Reports	Sensitive	24625776	DEPO
MAP2K1	p.E203K	SKCM	vemurafenib	Case Reports	Resistant	23569304	DEPO
BRAF	p.E204L	COADREAD	PLX4720	Preclinical	Resistant	23486013	DEPO
MTOR	p.E2419K	BLCA	everolimus	Case Reports	Sensitive	24625776	DEPO
PDGFRA	p.E241D	PRAD	AMG706	Preclinical	Sensitive	23486013	DEPO
BCR-ABL1	p.E255K	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.E255K	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.E25V	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.E25V	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
ERBB4	p.E317K	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
ERBB2	p.E321G	---	ERBB2 TKIs	Preclinical	Sensitive	22908275	DEPO
PRKCSH	p.E325in_frame_del	SKCM	Bryostatin	Preclinical	Sensitive	23486013	DEPO
BRAF	p.E375D	NSCLC	PLX4720	Preclinical	Resistant	23486013	DEPO
ESR1	p.E380Q	BRCA	anti-estrogens	Clinical Trials	Resistant	24185512  24185510  24398047	DEPO
ERBB4	p.E452K	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
ERBB4	p.E542K	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
PIK3CA	p.E542K	COADREAD	mTOR inhibitors	Preclinical	Sensitive	21358673	DEPO
PIK3CA	p.E545K	COADREAD	mTOR inhibitors	Preclinical	Sensitive	21358673	DEPO
FGFR2	p.E566G	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.E566G	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
KDR	p.E685G	LAML	TKI258	Preclinical	Sensitive	23486013	DEPO
EGFR	p.E690K	UCEC	lapatinib	Case Reports	Sensitive	22885469	DEPO
MAPK14	p.E71K	LAML	VX702	Preclinical	Sensitive	23486013	DEPO
HSP90B1	p.E758Q	NSCLC	17AAG	Preclinical	Resistant	23486013	DEPO
HSP90B1	p.E791in_frame_del	BLCA	17AAG	Preclinical	Resistant	23486013	DEPO
HSP90B1	p.E791in_frame_del	COADREAD	AUY922	Preclinical	Resistant	23486013	DEPO
HSP90B1	p.E791in_frame_del	LAML	17AAG	Preclinical	Resistant	23486013	DEPO
HSP90B1	p.E791in_frame_del	LIHC	17AAG	Preclinical	Resistant	23486013	DEPO
BCR-ABL1	p.E810G	DLBC	Nilotinib	Preclinical	Sensitive	23486013	DEPO
MET	p.E815D	ESCA	PF2341066	Preclinical	Resistant	23486013	DEPO
ERBB4	p.E872K	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
EGFR	p.ELR746in_frame_del	NSCLC	ZD6474	Preclinical	Sensitive	23486013	DEPO
EGFR	p.ELREA746in_frame_del	NSCLC	ZD6474	Preclinical	Sensitive	23486013	DEPO
ALK	p.F1174C	---	Crizotinib  Ceritinib	Preclinical	Resistant	24675041	DEPO
ALK	p.F1174L	GBM	crizotinib	Preclinical	Resistant	22072639	DEPO
ALK	p.F1174L	LUAD	novel ALK inhibiors	Preclinical	Sensitive	24327273	DEPO
ALK	p.F1174L	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
ALK	p.F1174V	NSCLC	Crizotinib	Case Reports	Sensitive	24736079	DEPO
ALK	p.F1245C	GBM	crizotinib	Preclinical	Sensitive	22072639	DEPO
MAP2K1	p.F129L	---	ERK inhibitors	Preclinical	Sensitive	23614898	DEPO
MAP2K1	p.F129L	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MAP2K1	p.F133L	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MTOR	p.F2108L	---	mTOR kinase inhibitors	Preclinical	Sensitive	25295501	DEPO
MTOR	p.F2108L	THCA	everolimus	Case Reports	Resistant	25295501	DEPO
BCR-ABL1	p.F317C	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317C	CML	nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317I	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317I	CML	nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317L	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317L	CML	nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317V	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F317V	CML	nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F359V	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F359V	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F35C	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F35C	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F35I	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.F35I	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
ALK	p.F856S	ALL	crizotinib	Preclinical	Sensitive	26032424	DEPO
AR	p.F876L	PRAD	enzalutamide  ARN-509	Case Reports	Resistant	23779130	DEPO
BCR-ABL1	p.G1079D	PAAD	Nilotinib	Preclinical	Sensitive	23486013	DEPO
ALK	p.G1128A	GBM	crizotinib	Preclinical	Sensitive	22072639	DEPO
KDR	p.G1145R	NSCLC	Sorafenib	Preclinical	Sensitive	23486013	DEPO
ALK	p.G1202R	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
ALK	p.G1269A	LUAD	ceritinib	FDA Approved	Sensitive	24670165	DEPO
ALK	p.G1269A	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
MAP2K1	p.G128D	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
NRAS	p.G12A	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.G12C	---	ERK inhibitors	Preclinical	Sensitive	23614898	DEPO
NRAS	p.G12C	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.G12D	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.G12S	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.G12V	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
KRAS	p.G13D	COADREAD	cetuximab	Clinical Trials	Sensitive	20978259; 22734028	DEPO
PDGFRB	p.G181V	NSCLC	TKI258	Preclinical	Sensitive	23486013	DEPO
ROS1	p.G2032R	LUAD	cabozantinib	Preclinical	Sensitive	25351743	DEPO
ROS1	p.G2032R	LUAD	crizotinib	Case Reports	Resistant	23724914  25688157	DEPO
DDR2	p.G253C	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
KDR	p.G255R	NSCLC	TKI258	Preclinical	Sensitive	23486013	DEPO
ERBB3	p.G284R	---	trastuzumab  pertuzumab  lapatinib  anti-HER3 mAbs  PI3K pathway inhibitors + MEK inhibitors	Preclinical	Sensitive	23680147	DEPO
ERBB3	p.G284R	BLCA	afatinib	Case Reports	Sensitive	ASCO 2015 (abstr e15516)	DEPO
ERBB2	p.G309A	BRCA	lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
ERBB2	p.G309E	---	ERBB2 TKIs  trastuzumab	Preclinical	Sensitive	22908275	DEPO
RAF1	p.G361A	SKCM	BRAF inhibitors in BRAF mutant tumors	Preclinical	Resistant	23737487	DEPO
EPHA2	p.G391R	LUSC	mTOR inhibitors  dasatinib	Preclinical	Sensitive	20360610	DEPO
KDR	p.G424D	COADREAD	Sorafenib	Preclinical	Resistant	23486013	DEPO
BRAF	p.G464V	BRCA	PLX4720	Preclinical	Resistant	23486013	DEPO
EGFR	p.G465R	COADREAD	cetuximab	Preclinical	Resistant	25623215	DEPO
BRAF	p.G466V	LUAD	dasatinib	Preclinical	Sensitive	22649091	DEPO
BRAF	p.G469A	LUAD	EGFR TKIs + MEK inhibitors in EGFR mutant	Preclinical	Sensitive	22773810	DEPO
BRAF	p.G469A	LUAD	EGFR TKIs	Case Reports	Resistant	22773810	DEPO
BRAF	p.G469E	SKCM	sorafenib	Preclinical	Sensitive	18794803	DEPO
SMO	p.G497W	BCC	Vismodegib	Case Reports	Resistant	25306392	DEPO
DDR2	p.G505S	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
EGFR	p.G598V	GBM	erlotinib	Preclinical	Sensitive	17177598	DEPO
EGFR	p.G719A	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.G719C	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.G719D	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.G719S	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
DDR2	p.G774V	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
ERBB2	p.G776L	LUAD	trastuzumab-based therapy	Case Reports	Sensitive	16775247	DEPO
PDGFRA	p.G853D	SKCM	imatinib  crenolanib	Preclinical	Sensitive	24132921	DEPO
PIK3CA	p.H1047R	COADREAD	PI3K/AKT/mTOR inhibitors	Clinical Trials	Sensitive	23066039	DEPO
MET	p.H1049R	---	crizotinib	Preclinical	Sensitive	17483355	DEPO
MET	p.H1094R	KIRC	MET inhibitors	Clinical Trials	Sensitive	23213094	DEPO
MET	p.H1112L	---	MET inhibitors	Preclinical	Sensitive	AACR 2012 (abstr 1786)	DEPO
MAP2K1	p.H119P	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
KDR	p.H1213Q	COADREAD	Sorafenib	Preclinical	Resistant	23486013	DEPO
AKT1	p.H238Y	SARC	everolimus	Case Reports	Sensitive	ASCO 2015 (abstr 11010)	DEPO
CTNNB1	p.H36Y	UCEC	everolimus + letrozole	Clinical Trials	Sensitive	25624430	DEPO
KIT	p.H687Y	GIST	imatinib	Preclinical	Resistant	23582185  21689725  17259998	DEPO
KIT	p.H697Y	THYM	sunitinib	Preclinical	Sensitive	19861435	DEPO
PDGFRA	p.H845Y	SKCM	imatinib  crenolanib	Preclinical	Sensitive	24132921	DEPO
MAP2K1	p.I103N	---	ERK inhibitors	Preclinical	Sensitive	23614898	DEPO
MAP2K1	p.I103N	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MAP2K1	p.I111N	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MAP2K1	p.I111S	SKCM	BRAF inhibitors in BRAF mutant tumor	Case Reports	Sensitive	22588879	DEPO
BCR-ABL1	p.I1146T	LAML	AZD0530	Preclinical	Resistant	23486013	DEPO
ALK	p.I1171N	GBM	crizotinib	Preclinical	Sensitive	22072639	DEPO
ALK	p.I1171T	LUAD	ceritinib	FDA Approved	Sensitive	25228534	DEPO
ALK	p.I1171T	LUAD	crizotinib  alectinib	Case Reports	Resistant	25228534	DEPO
MTOR	p.I1973F	SARC	everolimus	Case Reports	Sensitive	ASCO 2015 (abstr 11010)	DEPO
HSP90AB4P	p.I354in_frame_del	LAML	17AAG	Preclinical	Resistant	23486013	DEPO
EGFR	p.I491M	COADREAD	cetuximab	Preclinical	Resistant	25623215	DEPO
FGFR2	p.I548V	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.I548V	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
DDR2	p.I638F	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
JAK3	p.I87T	LAML	JAK inhibitors	Preclinical	Sensitive	18397343	DEPO
KDR	p.I915T	COADREAD	Sorafenib	Preclinical	Resistant	23486013	DEPO
MAP2K1	p.I99T	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MAP2K1	p.K104N	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
KRAS	p.K117N	COADREAD	cetuximab/panitumumab (anti-EGFR antibodies)	Clinical Trials	Resistant	26952655	DEPO
MTOR	p.K1771R	STAD	everolimus	Case Reports	Sensitive	ASCO 2015 (abstr 11010)	DEPO
EGFR	p.K209N	DLBC	Lapatinib	Preclinical	Sensitive	23486013	DEPO
HSP90B3P	p.K348fs	COADREAD	AUY922	Preclinical	Resistant	23486013	DEPO
MDM2	p.K369fs	OV	Nutlin3	Preclinical	Resistant	23486013	DEPO
EGFR	p.K467T	COADREAD	panitumumab	Preclinical	Sensitive	25623215	DEPO
EGFR	p.K467T	COADREAD	cetuximab	Case Reports	Resistant	25623215	DEPO
KIT	p.K509I	MPD	Imatinib  TKIs	Case Reports	Sensitive	16183119	DEPO
MAP2K1	p.K57E	SKCM	vemurafenib	Case Reports	Resistant	23569304	DEPO
MAP2K1	p.K57N	SKCM	MEK inhibitors	Case Reports	Resistant	23444215	DEPO
BRAF	p.K601R	SKCM	MEK inhibitors	Case Reports	Sensitive	23248257	DEPO
KIT	p.K642E	GIST	Imatinib  TKIs	Clinical Trials	Sensitive	16954519	DEPO
KIT	p.K642E	SKCM	Imatinib  TKIs	Case Reports	Sensitive	18510589	DEPO
FGFR2	p.K660E	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.K660E	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
FGFR2	p.K660N	LUSC	FGFR inhibitors	Preclinical	Sensitive	25035393	DEPO
FGFR2	p.K660N	NSCLC	FGFR inhibitors	Preclinical	Sensitive	25035393	DEPO
SF3B1	p.K700E	---	spliceosome inhibitor	Preclinical	Sensitive	ENA 2014 (abstr 456)  ENA 2014 (abstr 575)	DEPO
ALK	p.L1152R	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
ALK	p.L1196M	LUAD	ceritinib	FDA Approved	Sensitive	24670165  24327273	DEPO
ALK	p.L1196M	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
RAD50	p.L1237F	NEC	irinotecan plus CHK1/2 inhibitor in ATM deficient tumor	Case Reports	Sensitive	24934408	DEPO
PRKDC	p.L1244fs	BLCA	NU7441	Preclinical	Sensitive	23486013	DEPO
PRKDC	p.L1244fs	LAML	NU7441	Preclinical	Sensitive	23486013	DEPO
PRKDC	p.L1244fs	MPNST	NU7441	Preclinical	Sensitive	23486013	DEPO
PRKDC	p.L1244fs	NSCLC	NU7441	Preclinical	Sensitive	23486013	DEPO
PRKDC	p.L1244fs	SKCM	NU7441	Preclinical	Sensitive	23486013	DEPO
MTOR	p.L1460P	---	rapamycin	Preclinical	Sensitive	24631838	DEPO
KIT	p.L160W	LAML	Sorafenib	Preclinical	Resistant	23486013	DEPO
MAP2K1	p.L215P	---	ERK inhibitors	Preclinical	Sensitive	23614898	DEPO
MAP2K1	p.L215P	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
DDR2	p.L239R	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
MYD88	p.L265P	DLBC	JAK inhibitors	Preclinical	Sensitive	21179087	DEPO
IGF1R	p.L360F	MPNST	OSI906	Preclinical	Sensitive	23486013	DEPO
MAP2K2	p.L46F	SKCM	ERK inhibitors	Preclinical	Sensitive	24265153	DEPO
MAP2K2	p.L46F	SKCM	BRAF inhibitors  MEK inhibitors	Preclinical	Resistant	24265153	DEPO
MET	p.L530V	LAML	PHA665752	Preclinical	Resistant	23486013	DEPO
KIT	p.L576P	SKCM	KIT inhibitors	Case Reports	Sensitive	19671763	DEPO
BRAF	p.L597R	PRAD	PLX4720	Preclinical	Resistant	23486013	DEPO
BRAF	p.L597R	SKCM	BRAF inhibitors	Case Reports	Sensitive	23715574	DEPO
BRAF	p.L597V	SKCM	trametinib  MEK inhibitor	Case Reports	Sensitive	22798288	DEPO
FGFR2	p.L618M	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.L618M	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
DDR2	p.L63V	LUSC	dasatinib	Preclinical	Sensitive	22328973	DEPO
ERBB2	p.L720P	COADREAD	Lapatinib	Preclinical	Sensitive	23486013	DEPO
RET	p.L746M	PRAD	AMG706	Preclinical	Sensitive	23486013	DEPO
EGFR	p.L747S	NSCLC	erlotinib	Preclinical	Resistant	28424065	DEPO
EGFR	p.L747S	NSCLC	osimertinib	Preclinical	Sensitive	28424065	DEPO
ERBB2	p.L755S	BRCA	neratinib	Preclinical	Sensitive	23220880	DEPO
PLCG2	p.L845F	CLL	ibrutinib	Clinical Trials	Resistant	24869598	DEPO
EGFR	p.L858R	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.L861P	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.L861Q	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
EGFR	p.L861R	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
PDGFRB	p.L883M	NSCLC	TKI258	Preclinical	Sensitive	23486013	DEPO
MET	p.M1250I	---	crizotinib	Preclinical	Sensitive	17483355	DEPO
MET	p.M1268T	KIRC	MET inhibitors	Case Reports	Sensitive	23610116	DEPO
FGFR2	p.M536I	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.M536I	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
FGFR2	p.M538I	UCEC	ponatinib	Preclinical	Sensitive	23908597	DEPO
FGFR2	p.M538I	UCEC	dovitinib	Preclinical	Resistant	23908597	DEPO
KIT	p.M882V	COADREAD	Sorafenib	Preclinical	Resistant	23486013	DEPO
RET	p.M918T	THCA	vandetanib	FDA Approved	Sensitive	20065189  22025146	DEPO
MAP2K2	p.N126D	SKCM	ERK inhibitors	Preclinical	Sensitive	24265153	DEPO
MAP2K2	p.N126D	SKCM	BRAF inhibitors  MEK inhibitors	Preclinical	Resistant	24265153	DEPO
MTOR	p.N1421D	BLCA	everolimus	Case Reports	Sensitive	ASCO 2015 (abstr 11010)	DEPO
FGFR2	p.N549K	UCEC	FGFR inhibitors	Preclinical	Sensitive	18552176  22238366  23002168	DEPO
FGFR2	p.N550H	---	Dovitinib	Preclinical	Resistant	23908597	DEPO
FGFR2	p.N550K	---	Dovitinib	Preclinical	Resistant	23908597	DEPO
FGFR2	p.N550S	---	Dovitinib	Preclinical	Resistant	23908597	DEPO
PIK3R2	p.N561D	UCEC	mTOR inhibitors	Preclinical	Sensitive	21984976	DEPO
BRAF	p.N581Y	COADREAD	PLX4720	Preclinical	Resistant	23486013	DEPO
KIT	p.N655K	GIST	Imatinib  TKIs	Case Reports	Sensitive	25239608	DEPO
KIT	p.N822K	LAML	dasatinib	Preclinical	Sensitive	23149070	DEPO
KIT	p.N822K	LAML	Sorafenib	Preclinical	Resistant	23486013	DEPO
PDGFRA	p.N848I	COADREAD	Sorafenib	Preclinical	Resistant	23486013	DEPO
PDGFRA	p.N848K	GIST	Imatinib  TKIs	Case Reports	Sensitive	15928335	DEPO
ALK	p.P1218S	COADREAD	PF2341066	Preclinical	Resistant	23486013	DEPO
MAP2K1	p.P124L	SKCM	BRAF inhibitors  MEK inhibitors	Case Reports	Resistant	19915144	DEPO
MAP2K1	p.P124S	SKCM	BRAF inhibitors in BRAF mutant tumor	Case Reports	Sensitive	22588879	DEPO
ALK	p.P1543S	COADREAD	TAE684	Preclinical	Sensitive	23486013	DEPO
ALK	p.P157H	ESCA	PF2341066	Preclinical	Resistant	23486013	DEPO
HDAC3	p.P23R	LAML	Vorinostat	Preclinical	Resistant	23486013	DEPO
FGFR2	p.P253R	HNSC	pazopanib	Case Reports	Sensitive	23786770	DEPO
ERBB3	p.P262H	---	trastuzumab  pertuzumab  lapatinib  anti-HER3 mAbs  PI3K pathway inhibitors + MEK inhibitors	Preclinical	Sensitive	23680147	DEPO
RAC1	p.P29S	SKCM	BRAF inhibitors in BRAF mutant tumors	Case Reports	Resistant	25056119	DEPO
MAPK14	p.P322R	NSCLC	BIRB0796	Preclinical	Sensitive	23486013	DEPO
ALK	p.P379S	SKCM	PF2341066	Preclinical	Resistant	23486013	DEPO
MTOR	p.P453L	SKCM	AZD8055	Preclinical	Resistant	23486013	DEPO
PRKCE	p.P507A	LAML	Bryostatin	Preclinical	Sensitive	23486013	DEPO
ESR1	p.P535H	BRCA	anti-estrogens	Clinical Trials	Resistant	24185512	DEPO
EGFR	p.P546S	HNSC	cetuximab	Case Reports	Sensitive	23578570	DEPO
PDGFRA	p.P577S	SKCM	imatinib  crenolanib	Preclinical	Sensitive	24132921	DEPO
HDAC2	p.P5S	LAML	MS275	Preclinical	Resistant	23486013	DEPO
BRAF	p.P74A	BRCA	PLX4720	Preclinical	Resistant	23486013	DEPO
EGFR	p.P753S	HNSC	cetuximab + sirolimus	Case Reports	Sensitive	24934779	DEPO
PARP1	p.P850L	SKCM	AZD2281	Preclinical	Sensitive	23486013	DEPO
FLT3	p.P937H	NSCLC	Sorafenib	Preclinical	Sensitive	23486013	DEPO
GNA11	p.Q209L	SKCM	selumetinib	Clinical Trials	Sensitive	ASCO 2013 (abstr CRA9003)	DEPO
GNA11	p.Q209P	SKCM	selumetinib	Clinical Trials	Sensitive	ASCO 2013 (abstr CRA9003)	DEPO
MTOR	p.Q2223K	KIRC	everolimus	Case Reports	Sensitive	24622468	DEPO
ATM	p.Q2762R	COADREAD	KU55933	Preclinical	Sensitive	23486013	DEPO
KDR	p.Q2R	NSCLC	Sorafenib	Preclinical	Resistant	23486013	DEPO
JAK3	p.Q501H	LAML	JAK inhibitors	Preclinical	Sensitive	18397343	DEPO
MAP2K1	p.Q56P	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
MAP2K1	p.Q56P	SKCM	vemurafenib	Case Reports	Resistant	23569304	DEPO
MAP2K2	p.Q60P	SKCM	ERK inhibitors	Preclinical	Sensitive	24265154	DEPO
MAP2K2	p.Q60P	SKCM	BRAF + MEK inhibitors	Case Reports	Resistant	24265154	DEPO
NRAS	p.Q61E	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
NRAS	p.Q61H	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
NRAS	p.Q61K	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.Q61K	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
NRAS	p.Q61L	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
NRAS	p.Q61P	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
NRAS	p.Q61R	COADREAD	EGFR monoclonal antibodies	Clinical Trials	Resistant	20619739	DEPO
NRAS	p.Q61R	SKCM	MEK inhibitors	Clinical Trials	Sensitive	23414587	DEPO
CSF3R	p.Q741X	CML	dasatinib	Preclinical	Sensitive	23656643	DEPO
AKT1	p.Q79K	SKCM	BRAF inhibitors	Preclinical	Resistant	24265152	DEPO
ERBB3	p.Q809R	---	trastuzumab  lapatinib  PI3K pathway inhibitors + MEK inhibitors	Preclinical	Sensitive	23680147	DEPO
FLT3	p.Q910*	NSCLC	CEP701	Preclinical	Resistant	23486013	DEPO
ERBB3	p.R103G	BLCA	afatinib	Case Reports	Sensitive	ASCO 2015 (abstr e15516)	DEPO
EGFR	p.R108K	GBM	erlotinib	Preclinical	Sensitive	17177598	DEPO
ALK	p.R1192P	GBM	crizotinib	Preclinical	Sensitive	22072639	DEPO
MTOR	p.R1208C	GBM	AZD8055	Preclinical	Resistant	23486013	DEPO
ALK	p.R1275Q	GBM	crizotinib	Preclinical	Sensitive	22072639	DEPO
IDH1	p.R132H	GBM	IDH1 inhibitor	Preclinical	Sensitive	23558169	DEPO
IDH2	p.R140Q	LAML	IDH2 inhibitor	Clinical Trials	Sensitive	AACR 2014 (abstr CT103)	DEPO
IDH2	p.R172K	LAML	IDH2 inhibitor	Clinical Trials	Sensitive	AACR 2014 (abstr CT103)	DEPO
MTOR	p.R2152C	SKCM	Temsirolim	Preclinical	Resistant	23486013	DEPO
HDAC8	p.R223fs	PRAD	Vorinostat	Preclinical	Resistant	23486013	DEPO
CDK4	p.R24C	---	flavopiridol	Preclinical	Sensitive	23486013	DEPO
MTOR	p.R2505P	---	rapamycin	Preclinical	Sensitive	24631838	DEPO
RPS6KA6	p.R310S	COADREAD	CMK	Preclinical	Resistant	23486013	DEPO
FLT3	p.R311W	UCEC	Sorafenib	Preclinical	Sensitive	23486013	DEPO
ERBB4	p.R393W	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
EGFR	p.R451C	COADREAD	cetuximab	Case Reports	Resistant	25623215	DEPO
HSP90AA1	p.R467Q	NSCLC	AUY922	Preclinical	Resistant	23486013	DEPO
PTPN11	p.R498W	GBM	NSC87877	Preclinical	Sensitive	23486013	DEPO
MAP2K1	p.R49C	LAML	RDEA119	Preclinical	Resistant	23486013	DEPO
ERBB4	p.R544W	SKCM	lapatinib	Preclinical	Sensitive	19718025	DEPO
CTNNB1	p.R582Q	COADREAD	FH535	Preclinical	Resistant	23486013	DEPO
JAK3	p.R657Q	LAML	JAK inhibitors	Preclinical	Sensitive	18397343	DEPO
PLCG2	p.R665W	CLL	ibrutinib	Clinical Trials	Resistant	24869598	DEPO
NTRK1	p.R748W	NSCLC	CEP701	Preclinical	Resistant	23486013	DEPO
KDR	p.R791Q	NSCLC	TKI258	Preclinical	Sensitive	23486013	DEPO
PDGFRA	p.R841K	SKCM	imatinib  crenolanib	Preclinical	Sensitive	24132921	DEPO
ERBB2	p.R896C	BRCA	trastuzumab  lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
EGFR	p.R973Q	UCEC	TKI258	Preclinical	Sensitive	23486013	DEPO
MET	p.R988C	---	crizotinib	Preclinical	Sensitive	17483355	DEPO
EGFR	p.R98Q	LAML	Lapatinib	Preclinical	Resistant	23486013	DEPO
PLK1	p.S107N	COADREAD	BI2536	Preclinical	Resistant	23486013	DEPO
ALK	p.S1206Y	LUAD	ceritinib	FDA Approved	Sensitive	24670165	DEPO
ALK	p.S1206Y	LUAD	crizotinib	Case Reports	Resistant	22277784	DEPO
FLT1	p.S1277N	LAML	TKI258	Preclinical	Sensitive	23486013	DEPO
ARAF	p.S214C	LUAD	sorafenib	Case Reports	Sensitive	24569458	DEPO
MTOR	p.S2215Y	---	rapamycin	Preclinical	Sensitive	24631838	DEPO
RPS6KA4	p.S236L	BRCA	SL01011	Preclinical	Sensitive	23486013	DEPO
AR	p.S244L	LAML	PARP1Bical	Preclinical	Resistant	23486013	DEPO
FGFR2	p.S252W	UCEC	FGFR inhibitors	Preclinical	Sensitive	18552176  22238366  23002168	DEPO
RAF1	p.S257P	SKCM	BRAF inhibitors in BRAF mutant tumors	Preclinical	Resistant	23737487	DEPO
ERBB2	p.S310F	---	ERBB2 TKIs  trastuzumab	Preclinical	Sensitive	22908275	DEPO
ERBB2	p.S310Y	---	ERBB2 TKIs  trastuzumab	Preclinical	Sensitive	22908275	DEPO
FGFR2	p.S320C	LUSC	FGFR inhibitors	Preclinical	Sensitive	23786770	DEPO
CTNNB1	p.S37C	UCEC	everolimus + letrozole	Clinical Trials	Sensitive	25624430	DEPO
CTNNB1	p.S37Y	UCEC	everolimus + letrozole	Clinical Trials	Sensitive	25624430	DEPO
EGFR	p.S464L	COADREAD	cetuximab	Preclinical	Resistant	25623215	DEPO
EGFR	p.S492R	COADREAD	novel anti-EGFR mAbs	Clinical Trials	Sensitive	25962717	DEPO
EGFR	p.S492R	COADREAD	cetuximab	Case Reports	Resistant	22270724	DEPO
JAK1	p.S646F	ALL	ruxolitinib	Preclinical	Sensitive	22955920	DEPO
EGFR	p.S768I	NSCLC	erlotinib  afatinib	FDA Approved	Sensitive	18458038	DEPO
DDR2	p.S768R	LUSC	dasatinib + erlotinib	Case Reports	Sensitive	22328973	DEPO
FGFR3	p.S773F	BLCA	PD173074	Preclinical	Sensitive	23486013	DEPO
CSF3R	p.S783fs	CML	dasatinib	Preclinical	Sensitive	23656643	DEPO
MET	p.T1010I	---	crizotinib	Preclinical	Sensitive	17483355	DEPO
PDGFRA	p.T124fs	LAML	Axitinib	Preclinical	Sensitive	23486013	DEPO
PDGFRA	p.T124fs	LAML	Sorafenib	Preclinical	Resistant	23486013	DEPO
EGFR	p.T263P	GBM	erlotinib	Preclinical	Sensitive	17177598	DEPO
PDGFRA	p.T266P	UCEC	Pazopanib	Preclinical	Sensitive	23486013	DEPO
BCR-ABL1	p.T315A	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.T315A	CML	nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.T315I	---	nilotinib	Preclinical	Resistant	16772610	DEPO
BCR-ABL1	p.T315I	ALL	ponatinib	FDA Approved	Sensitive	24180494	DEPO
BCR-ABL1	p.T315I	ALL	ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.T315I	CML	ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.T315I	CML	imatinib	Clinical Trials	Resistant	11853795	DEPO
CSF3R	p.T615A	CML	ruxolitinib	Preclinical	Sensitive	23656643	DEPO
CSF3R	p.T618I	CML	ruxolitinib	Case Reports	Sensitive	23656643	DEPO
KIT	p.T670I	GIST	ponatinib	Preclinical	Sensitive	25239608	DEPO
KIT	p.T670I	GIST	imatinib	Case Reports	Resistant	24687822	DEPO
PDGFRA	p.T674I	MPD	imatinib	Case Reports	Resistant	12660384	DEPO
EGFR	p.T751I	LAML	Lapatinib	Preclinical	Resistant	23486013	DEPO
EGFR	p.T790M	NSCLC	AZD9291	FDA Approved	Sensitive	25923549	DEPO
EGFR	p.T790M	NSCLC	erlotinib  afatinib	FDA Approved	Resistant	18458038	DEPO
FGFR1	p.T79A	UCEC	TKI258	Preclinical	Sensitive	23486013	DEPO
PIK3CG	p.T827R	PAAD	NVPBEZ235	Preclinical	Resistant	23486013	DEPO
AR	p.T877A	PRAD	enzalutamide  ARN-509	Preclinical	Sensitive	23779130	DEPO
AR	p.T877A	PRAD	flutamide	Case Reports	Resistant	2260966	DEPO
PDGFRB	p.T882I	BRCA	Pazopanib	Preclinical	Sensitive	23486013	DEPO
PDGFRB	p.T88I	LAML	TKI258	Preclinical	Sensitive	23486013	DEPO
EGFR	p.V1011M	SKCM	Gefitinib	Preclinical	Sensitive	23486013	DEPO
MET	p.V1092I	---	crizotinib	Preclinical	Sensitive	17483355	DEPO
ALK	p.V1476M	COADREAD	TAE684	Preclinical	Sensitive	23486013	DEPO
MAP2K1	p.V211D	---	MEK inhibitors	Preclinical	Resistant	19915144	DEPO
BCR-ABL1	p.V299L	ALL	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.V299L	CML	nilotinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
SMO	p.V321M	BCC	Vismodegib	Case Reports	Resistant	25199678	DEPO
MAP2K2	p.V35M	SKCM	ERK inhibitors	Preclinical	Sensitive	24265153	DEPO
MAP2K2	p.V35M	SKCM	BRAF inhibitors  MEK inhibitors	Preclinical	Resistant	24265153	DEPO
SRC	p.V380M	COADREAD	AZD0530	Preclinical	Resistant	23486013	DEPO
FGFR3	p.V555M	MM	FGFR inhibitors	Preclinical	Resistant	22869148	DEPO
KIT	p.V559A	SKCM	KIT inhibitors	Case Reports	Sensitive	19718013	DEPO
KIT	p.V559I	GIST	imatinib	Preclinical	Resistant	23582185  21689725  17259998	DEPO
KIT	p.V560in_frame_del	THCA	sunitinib (KIT inhibitor)	Case Reports	Sensitive	15201427	DEPO
KIT	p.V560in_frame_del	THYM	imatinib	Case Reports	Sensitive	15201427	DEPO
PDGFRA	p.V561D	GIST	Imatinib  TKIs	Case Reports	Sensitive	17087936	DEPO
FGFR2	p.V565I	UCEC	selective FGFR inhibitor	Preclinical	Sensitive	ENA 2014 (abstr 381)	DEPO
FGFR2	p.V565I	UCEC	ponatinib	Preclinical	Resistant	23908597	DEPO
HSP90AB1	p.V575A	LIHC	17AAG	Preclinical	Resistant	23486013	DEPO
BCR-ABL1	p.V587M	LAML	Dasatinib	Preclinical	Resistant	23486013	DEPO
FLT3	p.V592A	DLBC	Sorafenib	Preclinical	Sensitive	23486013	DEPO
FLT3	p.V592A	LAML	Sunitinib	Preclinical	Sensitive	23486013	DEPO
BRAF	p.V600E	BRCA	SB590885	Preclinical	Sensitive	23486013	DEPO
BRAF	p.V600E	CLL	vemurafenib	Case Reports	Sensitive	22621641	DEPO
BRAF	p.V600E	COADREAD	BRAF inhibitors + anti-EGFR mAbs +/- PI3K pathway inhibitors	Clinical Trials	Sensitive	ENA 2014 (abstr 11LBA)	DEPO
BRAF	p.V600E	COADREAD	cetuximab  panitumumab	Clinical Trials	Resistant	20619739  21163703  23325582	DEPO
BRAF	p.V600E	GBM	BRAF inhibitors	Preclinical	Sensitive	22038996  22586120	DEPO
BRAF	p.V600E	GIST	dabrafenib	Case Reports	Sensitive	23470635  22608338	DEPO
BRAF	p.V600E	LAML	PLX4720	Preclinical	Sensitive	23486013	DEPO
BRAF	p.V600E	LUAD	dabrafenib + trametinib	Clinical Trials	Sensitive	ASCO 2015 (abstr 8006)	DEPO
BRAF	p.V600E	LUAD	EGFR TKIs	Case Reports	Resistant	22773810	DEPO
BRAF	p.V600E	MM	vemurafenib	Case Reports	Sensitive	23612012	DEPO
BRAF	p.V600E	OV	dabrafenib	Case Reports	Sensitive	22608338	DEPO
BRAF	p.V600E	SKCM	vemurafenib  dabrafenib  trametinib  dabrafenib + trametinib	FDA Approved	Sensitive	25399551	DEPO
BRAF	p.V600E	SKCM	PLX4720	Preclinical	Resistant	23486013	DEPO
BRAF	p.V600E	THCA	BRAF inhibitors + MEK inhibitors	Clinical Trials	Sensitive	ASCO 2013 (abstr 9029)	DEPO
BRAF	p.V600K	SKCM	trametinib  dabrafenib + trametinib	FDA Approved	Sensitive	25399551	DEPO
BRAF	p.V600R	SKCM	BRAF inhibitors	Clinical Trials	Sensitive	23237741	DEPO
JAK2	p.V617F	LAML	ruxolitinib	Clinical Trials	Sensitive	22422826	DEPO
JAK2	p.V617F	MPD	ruxolitinib	FDA Approved	Sensitive	26975727	DEPO
KIT	p.V654A	GIST	ponatinib	Preclinical	Sensitive	25239608	DEPO
KIT	p.V654A	GIST	imatinib	Preclinical	Resistant	23582185  21689725  17259998	DEPO
PDGFRA	p.V658A	SKCM	crenolanib	Preclinical	Sensitive	24132921	DEPO
PDGFRA	p.V658A	SKCM	imatinib	Preclinical	Resistant	24132921	DEPO
ERBB2	p.V659E	BRCA	lapatinib	Case Reports	Sensitive	23950206	DEPO
ERBB2	p.V659E	LUAD	lapatinib	Case Reports	Sensitive	23950206	DEPO
ERBB2	p.V777L	BRCA	lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
ERBB2	p.V842I	BRCA	lapatinib  neratinib	Preclinical	Sensitive	23220880	DEPO
ERBB2	p.V842I	OV	BIBW2992	Preclinical	Sensitive	23486013	DEPO
EGFR	p.V843I	HNSC	gefitinib	Case Reports	Resistant	21274259	DEPO
MET	p.V941L	NSCLC	PHA665752	Preclinical	Resistant	23486013	DEPO
EGFR	p.W1157C	LAML	Lapatinib	Preclinical	Resistant	23486013	DEPO
SMO	p.W281L	BCC	Vismodegib	Case Reports	Resistant	25199678	DEPO
FGFR2	p.W290C	LUSC	FGFR inhibitors	Preclinical	Sensitive	23786770	DEPO
MPL	p.W515F	MPD	JAK inhibitors	Preclinical	Sensitive	16834459	DEPO
KIT	p.W557R	SKCM	KIT inhibitors	Case Reports	Sensitive	19018266	DEPO
CSF3R	p.W791X	CML	dasatinib	Preclinical	Sensitive	23656643	DEPO
EGFR	p.Y1069C	COADREAD	Lapatinib	Preclinical	Sensitive	23486013	DEPO
MET	p.Y1230C	---	crizotinib	Preclinical	Resistant	17483355	DEPO
MET	p.Y1235D	---	crizotinib	Preclinical	Resistant	17483355	DEPO
MAP2K1	p.Y134C	NSCLC	CI1040	Preclinical	Resistant	23486013	DEPO
BCR-ABL1	p.Y253H	ALL	dasatinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
BCR-ABL1	p.Y253H	CML	dasatinib  bosutinib  ponatinib	FDA Approved	Sensitive	21562040	DEPO
CBL	p.Y371H	MPD	JAK inhibitors  dasatinib	Preclinical	Sensitive	23696637	DEPO
FGFR3	p.Y373C	MM	FGFR inhibitors	Preclinical	Sensitive	22869148	DEPO
FGFR3	p.Y373C	MM	bortezomib	Preclinical	Resistant	19331127  21273588	DEPO
BRAF	p.Y472C	LUAD	dasatinib	Case Reports	Sensitive	22649091	DEPO
KIT	p.Y553N	THCA	imatinib (KIT inhibitor)	Case Reports	Sensitive	21969494	DEPO
KIT	p.Y553N	THYM	sunitinib	Case Reports	Sensitive	23375402	DEPO
CSF1R	p.Y571D	MPD	imatinib	Preclinical	Sensitive	18971950	DEPO
EZH2	p.Y646F	DLBC	EZH2 inhibitor	Preclinical	Sensitive	24563539	DEPO
PIK3CG	p.Y672*	BRCA	NVPBEZ235	Preclinical	Resistant	23486013	DEPO
CSF3R	p.Y752X	CML	dasatinib	Preclinical	Sensitive	23656643	DEPO
KIT	p.Y823D	GIST	imatinib	Preclinical	Resistant	23582185  21689725  17259998	DEPO
PDGFRA	p.Y849K	GIST	Imatinib  TKIs	Case Reports	Sensitive	15928335	DEPO
PDGFRA	p.Y98*	NSCLC	Sorafenib	Preclinical	Resistant	23486013	DEPO
BRCA1	p.R1495M	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.R1699W	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.R2336H	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.R2502C	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.R2659K	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.S1715R	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.T1685A	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.T1685I	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.T2722R	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA1	p.V1688del	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
BRCA2	p.W2626C	OV	PARP inhibitors	FDA Approved	Sensitive	17924331; 27617661; 27908594	DEPO
AKT3	any	BRCA	ATP-competitive AKT inhibitors	Preclinical	Sensitive	22722202	DEPO
ALK	any	DLBC	crizotinib	Clinical Trials	Sensitive	24491302	DEPO
ALK	any	IMT	crizotinib	Case Reports	Sensitive	20979472	DEPO
ALK	any	LUAD	crizotinib  ceritinib	FDA Approved	Sensitive	22954507	DEPO
ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
ALK	any	THCA	crizotinib	Case Reports	Sensitive	24687827	DEPO
ATIC-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
BCR-ABL1	any	ALL	nilotinib	FDA Approved	Sensitive	24650752	DEPO
BCR-ABL1	any	CML	imatinib  dasatinib  nilotinib  bosutinib  ponatinib	FDA Approved	Sensitive	19779040	DEPO
BCR-ABL1	any	CML	imatinib	Clinical Trials	Resistant	11423618	DEPO
BCR-JAK2	any	ALL	ruxolitinib	Preclinical	Sensitive	22897847	DEPO
BCR-PDGFRA	any	CML	Imatinib  TKIs	Case Reports	Sensitive	15034867	DEPO
BCR-RET	any	CML	sorafenib	Case Reports	Sensitive	22513837	DEPO
BRAF	any	LUAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	24727320	DEPO
BRAF	any	PRAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	20526349	DEPO
BRAF	any	SKCM	MEK inhibitors	Clinical Trials	Sensitive	24345920	DEPO
BRAF	any	SKCM	sorafenib	Preclinical	Sensitive	23890088	DEPO
BRCA1	any frameshift mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA1	any nonsense mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA2	any frameshift mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRCA2	any nonsense mutation	OV	PARP inhibitors	FDA Approved	Sensitive	27617661; 27908594	DEPO
BRD4	any	HNSC	BET inhibitors	Preclinical	Sensitive	20871596	DEPO
CD74-ROS1	any	---	crizotinib	Preclinical	Sensitive	23486013	DEPO
CDK5RAP2-PDGFRA	any	CML	Imatinib  TKIs	Case Reports	Sensitive	16845659	DEPO
CLTC-ALK	any	DLBC	Crizotinib	Preclinical	Sensitive	26221234	DEPO
COL1A1-PDGFRB	any	SARC	imatinib	FDA Approved	Sensitive	20194851	DEPO
CRLF2	any	ALL	mTOR inhibitors	Preclinical	Sensitive	22955920	DEPO
EGFR	any	NSCLC	erlotinib	Case Reports	Sensitive	27102076	DEPO
EML1-ABL1	any	CML	imatinib	Case Reports	Sensitive	15713800	DEPO
EML4-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
ERBB4	any	LUAD	lapatinib  afatinib	Preclinical	Sensitive	24727320	DEPO
ESR1	any	BRCA	anti-estrogens	Preclinical	Resistant	24055055	DEPO
ETS	any	PRAD	PARP inhibitors	Preclinical	Sensitive	21575865	DEPO
ETV6-ABL1	any	MPD	nilotinib	Case Reports	Sensitive	24053143	DEPO
ETV6-ABL1	any	MPD	imatinib	Case Reports	Resistant	24053143	DEPO
EWS	any	SARC	PARP inhibitors	Preclinical	Sensitive	22287547	DEPO
FGFR2	any	CHOL	FGFR inhibitors	Preclinical	Sensitive	23558953	DEPO
FGFR3	any	BLCA	FGFR inhibitors	Case Reports	Sensitive	AACR 2014 (abstr CT325)	DEPO
FGFR3	any	GBM	FGFR inhibitors	Clinical Trials	Sensitive	ASCO 2014 (abstr 2501)	DEPO
FIP1L1-PDGFRA	any	MPD	Imatinib  TKIs	FDA Approved	Sensitive	12660384	DEPO
JAK2	any	ALL	ruxolitinib	Preclinical	Sensitive	22875628  22899477	DEPO
KIF5B-RET	any	LUAD	cabozantinib	Case Reports	Sensitive	23533264	DEPO
KLC1-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
MET	any	GBM	crizotinib	Case Reports	Sensitive	27748748	DEPO
MLL	any	LAML	daunorubicin	FDA Approved	Sensitive	22417203	DEPO
NOTCH1	any	ALL	Gamma secretase inhibitors	Preclinical	Sensitive	16688224  23033986	DEPO
NOTCH1	any	BRCA	Gamma secretase inhibitors	Preclinical	Sensitive	22101766	DEPO
NOTCH2	any	BRCA	Gamma secretase inhibitors	Preclinical	Sensitive	22101766	DEPO
NPM-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
NRG1	any	LUAD	lapatinib	Preclinical	Sensitive	24727320	DEPO
NTRK1	any	COADREAD	pan-TRK inhibitor	Case Reports	Sensitive	ASCO 2015 (abstr 2517)	DEPO
NTRK1	any	LUAD	crizotinib	Case Reports	Sensitive	ASCO 2013 (abstr 8023)	DEPO
NTRK3	any	BRCA	midostaurin  IGF1R inhibitors  PI3K pathway inhibitors	Preclinical	Sensitive	21148487  23131561	DEPO
NUP214-ABL1	any	ALL	imatinib	Clinical Trials	Sensitive	16213363	DEPO
PDGFRA	any	HES	imatinib	FDA Approved	Sensitive	16089297	DEPO
PDGFRA	any	MPD	imatinib	FDA Approved	Sensitive	16089297	DEPO
PDGFRB	any 	MPD	imatinib	FDA Approved	Sensitive	24687085	DEPO
PML-RARA	any	LAML	ATRA + arsenic trioxide	FDA Approved	Sensitive	15103387	DEPO
RAF1	any	PRAD	sorafenib  MEK inhibitors	Preclinical	Sensitive	20526349	DEPO
RANBP2-ALK	any	NSCLC	Crizotinib	Case Reports	Sensitive	27494825	DEPO
RCSD1-ABL1	any	ALL	dasatinib	Case Reports	Resistant	21863287	DEPO
RET	any	LUAD	cabozantinib  vandetanib	Clinical Trials	Sensitive	23533264  23584301  25366691  ASCO 2015 (abstr 8007)	DEPO
RET-PTC1	any	THCA	RET inhibitors	Preclinical	Sensitive	23056499	DEPO
ROS1	any	IMT	crizotinib	Case Reports	Sensitive	24875859	DEPO
ROS1	any	LUAD	crizotinib	Clinical Trials	Sensitive	25264305	DEPO
ROS1	any	NSCLC	crizotinib (ALK/MET/ROS1 TKI)	FDA Approved	Sensitive	25264305	DEPO
SQSTM1-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TFG-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TMPRSS2	any	PRAD	DNA-PKc inhibitors	Preclinical	Sensitive	21575865	DEPO
TPM3-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TPM4-ALK	any	NSCLC	Crizotinib  Ceritinib	FDA Approved	Sensitive	23724913	DEPO
TRIM33-RET	any	LUAD	cabozantinib	Case Reports	Sensitive	23533264	DEPO
